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ABSTRACT 
 
 Women with the highest mammographic density have a four to six-fold increased risk of 
breast cancer when compared to the ones with the least dense breasts. Mammographic breast 
density has also been associated with a wide array of factors related to the risk of breast cancer 
including age, menopausal status, age at first live birth, parity, body mass index, physical activity, 
alcohol consumption, hormone replacement therapy, endogenous levels of IGF-I and prolactin, 
family history of breast cancer, tamoxifen use and others. A question of interest is whether 
mammographic density is in the pathway by which these factors are related to breast cancer. To 
address this question, we conducted causal mediation analyses on two datasets using a newly 
developed statistical approach based on the counterfactual framework to examine the extent to 
which mammographic density acts as a mediator. The first dataset is pooled from four case-control 
studies performed in the western Washington state, contains 547 breast cancer cases (ascertained 
from a local Surveillance, Epidemiology, and End Results Program registry) and 472 controls 
(ascertained by random digit dialing) who had screening mammograms under age 50. The second 
dataset is from the Mayo Mammography Health Study (MMHS), which is a prospective cohort, 
comprised of 19,924 women (51.2% adjusted response rate) ages 35 and over, residing in the tri-
state region (Minnesota, Iowa, and Wisconsin) surrounding the Mayo Clinic in Rochester, MN, 
without a history of breast cancer, who were scheduled for a screening mammogram at the Mayo 
Clinic between October 2003 and September 2006. Previous analyses from these two datasets have 
shown associations between some breast cancer risk factors and mammographic density. Results 
showed that mammographic density partially mediated the associations for some breast cancer risk 
factors such as breast calcifications, being parous, history of breast biopsy/aspiration/lumpectomy, 
and current use of hormone replacement therapy (HRT), but not factors such as a first-degree 
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family history of breast cancer and age at first live birth, history of smoking, age at menopause. 
These results help us better understand the pathways and mechanisms whereby a risk factor may 
cause breast cancer. It also helps inform and refine clinical and public health interventions for 
breast cancer by assessing the relative importance of different pathways.  
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CHAPTER 1: INTRODUCTION 
 
High breast density is a strong and well-established risk factor for breast cancer [1, 2]. 
Currently, the best way to detect breast density is through a mammogram. Fatty tissue in the breast 
is relatively transparent to x-rays and appears dark on mammograms. Fibroglandular tissue, which 
consists of epithelial cells that line the ducts and their supporting fibrous connective tissue, is more 
radiologically dense and appears light on mammograms. The proportion of a mammogram that is 
dense is thus an indirect measure of the amount of epithelial tissue in the breast. Since, biologically, 
this is the tissue from which mammary carcinomas arise, the greater the percent mammographic 
density, the greater the number of cells available for malignant transformation. Percent dense 
volume is the proportion of fibroglandular (dense) tissue in the breast. Percent mammographic 
density (PMD), or the proportion of the breast with densities in the breast, is the ratio of the dense 
area to the total breast area that sums the dense and nondense area. Women with the densest 
mammographic patterns were estimated to have a four to six-fold increased risk of breast cancer 
when compared to women with the least dense ones [3]. PMD has been suggested to be a stronger 
risk factor than absolute dense area [4, 5], which indicates that the ratio between the two tissues is 
important, or that the nondense area, which is part of the denominator of percent density, is a 
protective factor for breast cancer risk. Although dense breast tissue may mask tumors on a 
mammogram, such a strong positive relationship between breast density and risk of breast cancer 
is regarded as causal rather than correlational [6], which has been consistently observed among 
studies after controlling for various confounding factors. 
 
 Mammographic breast density has been shown to be associated with a wide array of risk 
factors for breast cancer [1]. Higher density was found in women who were premenopausal, 
nulliparous, of low BMI (body mass index), low WHR (waist to hip ratio), greater height, had a 
late age at first birth, younger age, high alcohol consumption, taking combination postmenopausal 
hormone or with a family history of breast cancer [7-9]. Breast density tends to decrease with older 
age. Smoking and education were inversely associated with percent density among premenopausal 
but not postmenopausal women [8]. An inverse association between tissue-based assessment of 
lobular involution and breast density was also reported [10]. Although, without replication by other 
studies, some studies observed an association of dietary intake (isoflavones, fat, vitamins, etc.) and 
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physical activity with breast density [11]. Mammographic breast density can be changed by several 
exposures that are also known to influence breast cancer risk [9]. For example, tamoxifen, an anti-
estrogen, was reported to reduce mammographic breast density as well as the risk of breast cancer 
[12-15]. Current users of postmenopausal hormone replacement therapy (HRT), especially 
combined formulations, were found to have higher percent mammographic density and breast 
cancer risk [16].  
 
These observations suggest that breast density is not only an independent risk factor for 
breast cancer; it may also be on the causal pathway for many of the established breast cancer risk 
factors. That is, mammographic breast density has the potential to act as a mediating variable or 
mediator for breast cancer risk. A mediator differs from confounder in the direction of causality: 
while mediators lie on the causal pathway between exposure and outcome, confounders influence 
both the exposure of interest and the outcome [17, 18]. Thus, a mediator occurs temporally after 
the exposure — it is both caused by the exposure variable and is a cause of the outcome.  
 
Mediation can exist in both nonrandomized and randomized studies. In randomized 
controlled trials, the treatments/interventions might influence breast cancer risk through their 
effects on the intermediate marker, mammographic density. In this case, mammographic density 
as a mediator can be used as a potential surrogate endpoint. According to the National Institutes 
of Health (NIH), a surrogate endpoint is "a biomarker intended to substitute for a clinical endpoint" 
that is undesired [19]. Therefore, when the effect of an intervention on the mediator predicts the 
effect on the clinical outcome, the mediator can be used as a surrogate endpoint. A surrogate 
marker is used when the primary clinical endpoint is undesired (e.g., death), or when the number 
of events is small. Clinical trials to assess the effects of interventions on cancer risk often need to 
be large and prolonged, and as a result, are expensive. For example, the occurrence of breast cancer 
is a relatively infrequent event. When breast cancer is the primary endpoint, it is hard to measure 
and it could take a long time to occur. So it is impractical to conduct a clinical trial to gather a 
statistically significant number of breast cancer case endpoints in a short time. If mammographic 
density can serve as a surrogate marker for breast cancer as a measure of the effect of a specific 
treatment that affects the real clinical endpoint, breast cancer, then clinical trials of breast cancer 
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prevention could be smaller, shorter, and more cost-effective by just focusing on altering breast 
density.  
 
A mediator is an intermediate marker that helps explain how or why an independent factor 
influences an outcome. Several requirements, which were first laid out by Baron and Kenny [20], 
must be met for a variable to be considered as a mediator: i) the exposure variable should be 
associated with the mediator, (ii) in the model for the outcome that includes the exposure and 
mediator, the mediator should be associated with the outcome, (iii) in the model for the outcome 
that includes only the exposure, the exposure should be associated with the outcome, and (iv) when 
controlling for the mediator, the association between the exposure and outcome should be reduced, 
with the strongest demonstration of mediation occurring when the path from the exposure to the 
outcome variable, when controlling for the mediator, is zero. While requirements (iii) and (iv) have 
been criticized and challenged by many scholars, the first two requirements have generally been 
accepted as important for establishing a true mediation relationship. In the context of breast density 
and breast cancer, these two requirements are: the exposure should be associated with breast 
density and breast density should predict the risk of breast cancer.  
 
When the exposure is a treatment or intervention in a randomized controlled trial, these 
two requirements for mediation are also two of the three criteria that need to be met for a marker 
accepted as a suitable surrogate (substitute for breast cancer), proposed by Prentice [21], and 
further elaborated by Schatzkin and Gail [22], Freedman, Graubard, and Schatzkin [23], and 
others. Generally speaking, most good surrogates are expected to be on the pathway from the 
treatment to the outcome[24]. This means that most good surrogates come from mediators and 
they need to satisfy the requirements as a mediator. For PMD to be a mediator or a surrogate 
marker, an exposure or treatment should be associated with PMD and PMD should predict the risk 
of breast cancer. Boyd and colleagues [25] pointed out the third criterion that if PMD is to serve 
as a surrogate for breast cancer prevention in intervention trials, then most of the effect of such 
interventions on breast cancer risk should be mediated by PMD. This means that PMD must be a 
strong mediator in order to qualify for a good surrogate endpoint for breast cancer. are conceptually 
distinct, they share considerable statistical similarities. 
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Mediation analysis can formally assess whether a hypothesized factor mediates the effect 
of an exposure on an outcome. Mediation analyses are often employed to explore the hypothetical 
causal mechanisms by which a predictor affects an outcome through a mediator variable. In a 
mediation analysis, a mediator can be identified by decomposing the total effect of an exposure or 
treatment on an outcome into two components: an indirect effect operating through a mediator of 
interest and a direct effect operating through alternative pathways that are independent of the 
mediator. Traditional mediation analysis often applies the structural equation modeling (SEM) 
approach, first proposed by Baron and Kenny [20], to estimate the direct and indirect effects. SEM 
is a general multivariate technique widely used in the social sciences. It uses a conceptual model, 
path diagram, and a system of linked structural regression-style equations to capture complex and 
dynamic relationships within a network of observed and unobserved (latent) variables. SEM is 
fundamentally different from a regression-based approach to mediation. In a regression model, 
there exists a clear distinction between dependent and independent variables. However, these 
variables in SEM are a relative concept because a dependent variable in one model equation can 
become an independent variable in other components of the SEM system. SEM provides a more 
flexible modeling and attractive graphical modeling interface, and can easily extend to handle 
multi-level data, repeated measures data, and incomplete data. It was considered superior when 
there are latent variables and moderated mediation. However, SEMs tend to estimate more types 
of effects at the price of making additional assumptions. Many of these assumptions have often 
been ignored so they should be used principally for the purpose of exploratory analysis and 
hypothesis generation when a broad range of effects are of interest. Furthermore, SEMs generally 
make assumptions of linearity and normality. 
 
The most common regression-based approach for mediation analysis is to use the 
traditional “difference method” to estimate the “proportion mediated (PM)” as a measure of the 
mediated or indirect effect. This is based on the change in the coefficients of exposure on the risk 
of breast cancer from two regression models with and without adjustment for the mediator. This 
PM measure is equivalent to the “proportion explained (PE)” index, which was proposed by 
Freedman et al. [23] and further described by others [26, 27]. Similarly, the PE index can be 
estimated from the difference in the coefficients of treatment from two regression models with or 
without adjusting for the mediator.  
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However, structural equation models and the traditional “difference method” are often 
criticized for neither adequately accounting for the strong assumptions that need to be met nor 
addressing issues of confounding in inferring causal relationships [28-31]. The two regression 
models may not be valid simultaneously and the PM or PE index estimate can often lie outside the 
probability interval between 0 and 1. There are a few situations when using the “difference 
method” may lead to biased estimators of indirect effects and thus incorrect conclusions regarding 
mediation, especially for logistic regressions. These include when there is confounding, when a 
binary outcome is not rare, or when there is exposure-mediator interaction [24]. 
 
In the last few years, new approaches for mediation analysis have been proposed to address 
some of these limitations by using the counterfactual framework [29, 32-36]. The counterfactual 
approach emphasizes the identifiability assumptions and conceptual definitions of causal effects, 
which allows for the decomposition of a total effect into direct and indirect effects, even in models 
with interactions and nonlinearities. The mediation analysis based on the counterfactual 
framework specifies a model for the outcome and a model for the mediator and then combining 
the results of these models to obtain direct and indirect effects. A new approach has recently been 
developed to statistically assess mediation for a case-control study with a rare outcome [36, 37]. 
With some modifications, this method can also apply to other study designs. It allows us to identify 
and separate out the direct and indirect mechanisms of breast cancer development that are acting 
through or not through mammographic density. A recent study compared the traditional 
“difference method” and the natural indirect effect (NIE) based on the counterfactual framework 
and concluded that the “difference method” is always conservative for binary outcomes [38]. This 
suggests that the “difference method” could only be used to provide evidence for the presence of 
mediation but not for the absence of mediation. 
 
Increasing evidence suggests that mammographic breast density may be a potential 
mediator for breast cancer risk. Therefore, it is of interest to find out whether the effects of various 
risk factors on breast cancer are mediated by breast density. If true, then how much does breast 
density mediate the effects of these risk factors? Currently, very few studies have attempted to 
address these questions. The potential mediation role of mammographic density for breast cancer 
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has not yet been thoroughly examined. It is still uncertain whether any of the risk factors influence 
breast cancer risk through their associations with mammographic density. In this project, we aim 
to address these questions and to assess the extent to which the observed association between 
various known risk factors and breast cancer risk is mediated through mammographic density. It 
is important to utilize newly developed statistical methods to examine what role mammographic 
density may play as an intermediate marker, if any, for the association between various risk factors 
and breast cancer incidence. 
 
The results of this work would provide insights into the pathways and mechanisms involved 
in the etiology of breast cancer. It may help inform and refine clinical and public health 
interventions for breast cancer by assessing the relative importance of different pathways. This 
also adds to the current knowledge of how various factors affect breast cancer risk by applying 
new statistical methods in order to quantify mediating effects through mammographic density. 
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CHAPTER 2: LITERATURE REVIEW 
 
2.1 INTRODUCTION 
 
Mammographic breast density is a strong independent risk factor for breast cancer [1-4]. 
Breast density can be influenced by several risk factors that are known to predict breast cancer risk 
[1]. These observations have led to the hypothesis that breast density may be on the causal pathway 
for breast cancer for some of the known risk factors for breast cancer. In recent years, there has 
been an increasing interest in the potential of percent mammographic density (PMD) serving as a 
mediator or intermediate biomarker for breast cancer risk. Understanding the role of PMD in the 
pathway linking these risk factors (i.e., exposures) to breast cancer may help inform breast cancer 
screening and other prevention practices. It is essential to understand the mechanisms underlying 
the etiology of breast cancer and thus to effective prevention strategies. 
 
In order for mammographic density to be a mediator, an exposure should be associated 
with mammographic density and mammographic density should predict the risk of breast cancer 
[5]. While breast density is a well-established risk factor for breast cancer, not all breast cancer 
risk factors were found to be related to mammographic density. For example, Raloxifene, a drug 
that reduces the risk of breast cancer in postmenopausal women, appeared to neither increase nor 
decrease mammographic density [6]. This suggests that Raloxifene may affect breast cancer risk 
through alternative pathways that are independent of mammographic density. For some risk 
factors, there is no consistent evidence that the change in breast density results in a change in the 
breast cancer risk. For example, breast density generally declines as women age. However, 
Maskarinec et al. [7] found that women who developed breast cancer had 10.2% higher 
mammographic densities than controls, but the rate of change in density over a period of more than 
20 years was not significantly related to case status. These observations suggest that different risk 
factors may operate through different pathways for breast cancer development and mammographic 
density may be an intermediate mediator for some but not all of the known breast cancer risk 
factors. Today, it is not yet known whether mammographic density can serve as a mediator for 
breast cancer. 
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Mediation analysis is often used to assess the relative magnitude of different pathways and 
mechanisms by which an exposure may affect an outcome, either through a mediator or 
independent of it. The traditional approach to mediation that is commonly used is the “difference 
method”, which estimates the “proportion mediated (PM)” as a measure of mediated or indirect 
effect based on the difference in coefficients of the exposure on the outcome from two regression 
models with and without adjustment for the mediator [5]. However, the traditional approach is 
often criticized for neither adequately accounting for the strong assumptions that need to be met 
nor addressing issues of confounding in inferring causal relationships [8-11]. The two regression 
models may not be valid simultaneously and the estimate can often lie outside the proportion 
interval (not between 0 and 1).  It may lead to biased estimators of indirect effects and incorrect 
conclusions regarding mediation, especially for logistic regression. These include when there is 
confounding, when a binary outcome is not rare, or when there is an exposure-mediator interaction 
[12]. In the last few years, more advance, new approaches for mediation analysis have been 
developed to address some of these limitations by using the counterfactual framework [9, 13-17]. 
The causal inference methods for mediation analysis (“causal mediation”) emphasizes the 
identifiability assumptions and conceptual definitions of causal effects, which allows for the 
decomposition of a total effect into direct and indirect effects, even in models with interactions 
and nonlinearities. Under the counterfactual framework, the mediated effect is called natural 
indirect effect (NIE) that compares average outcomes that would be observed if we were to set the 
exposure as present and change the mediator for each individual from the level it would have been 
at in the absence of exposure to the level it would have been at in the presence of exposure. 
Therefore, the NIE captures the effect of exposure on the outcome operating through the mediator. 
A new approach has recently been developed to statistically assess mediation for a case-control 
study with a rare outcome [17, 18]. With some modifications, this method can also apply to other 
study designs. It allows us to identify and separate out the direct and indirect mechanisms of breast 
cancer development that are acting through or not through mammographic density. A recent study 
compared the traditional “difference method” and the NIE based on the counterfactual framework 
and concluded that the “difference method” is always conservative for binary outcomes [19]. It 
suggested that the “difference method” could be used to provide evidence for the presence of 
mediation but not for the absence of mediation. 
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No systematic review has yet been conducted to assess the potential role of mammographic 
density as a mediator in research on the etiology and prevention of breast cancer for the effects of 
various exposures on the risk of breast cancer. In this review, we aim to summarize existing 
scientific evidence on the relevance of mammographic density as a mediator and surrogate marker 
for breast cancer, with a focus on the statistical approaches and measures for effects of mediation 
and surrogacy. We examine the extent to which, if any, risk factors for breast cancer influence 
breast cancer risk through their effects on mammographic density and the extent to which 
mammographic density can be used as a surrogate endpoint for breast cancer in interventional 
trials. The summary of evidence helps us outline a picture of potential networks connecting various 
risk factors to the breast cancer outcome, either through or not through breast density. The results 
provide insight into the pathways through which various risk factors may affect breast cancer risk, 
and thereby draws attention to potential paths of intervention. 
 
2.2 METHODS 
2.2.1 Search Strategy 
 
A search was conducted using PubMed, Scopus, Web of Knowledge, Google Scholar, and 
ProQuest Dissertations & Theses (PQDT) from the earliest date available in each database. The 
search algorithm included all possible combinations of keywords from the following three groups: 
(i) ‘breast cancer’, ‘breast neoplasm’; (ii) ‘mediator’, ‘mediation’, ‘biomarker’; (iii) ‘breast 
density’, ‘mammographic density’. Table 2.1. lists the search terms. We restricted to studies with 
an English abstract. The most recent search was run on May 15, 2020. We also manually checked 
the bibliography of relevant articles to identify any articles not found using the above online 
databases. 
 
2.2.2 Inclusion Criteria and Data Extraction 
 
Studies that met all the following criteria were included in the review: 1) consider at least 
one potential risk factor for breast cancer; 2) examined breast density measures as a mediator for 
breast cancer risk; 3) used statistical approaches and/or measures for mediation. All relevant 
studies had their titles and abstracts screened for eligibility. The selected studies were grouped 
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according to categories of risk/protection factors, and data were extracted into a spreadsheet, which 
collected data on study characteristics (i.e., reference, program, design, subjects, measure of 
mammographic density, exposure, key results, and conclusions). Statistics including unadjusted 
odds ratio, adjusted odds ratio, measures of mediation/surrogacy, and their 95% confidence 
intervals were exacted if available.  
 
2.2.3 Data Synthesis 
 
Due to the limited number of studies selected and the heterogeneity of the exposures 
evaluated, undertaking a meta-analysis was deemed to be not appropriate. The analysis is 
descriptive. In order to evaluate the direction of mediation, the sign of the NIE for each level of 
exposure was presented based on the rule by Jiang et al. [19]. In order to quantify the mediating 
effects of breast density, we calculated the proportion explained (PE) index following the 
Freedman method [20]. Let F denotes a traditional risk factor, M mammographic density, B breast 
cancer risk, and C a set of baseline covariates. We could fit two logistic regression models for 
breast cancer on the risk factor, with or without the percentage density, and the baseline covariates: 
 
logit[𝑃(𝐵 = 1|𝐹, 𝐶)] = 𝛽0 + 𝛽1𝐹 + 𝛽2𝐶 
logit[𝑃(𝐵 = 1|𝐹,𝑀, 𝐶)] = 𝜃0 + 𝜃1𝐹 + 𝜃2𝑀 + 𝜃3𝐶 
If the coefficients β1 and θ1 differ, then some of the effects are considered to be mediated 
and the proportion explained by the mediation is calculated as using the following formula: 
𝑃𝐸 =
𝛽1 − 𝜃1
𝛽1
=
log𝑂𝑅𝑢𝑛𝑎𝑑𝑗𝑢𝑠𝑡𝑒𝑑 − log𝑂𝑅𝑎𝑑𝑗𝑢𝑠𝑡𝑒𝑑
log𝑂𝑅𝑢𝑛𝑎𝑑𝑗𝑢𝑠𝑡𝑒𝑑
 
PE index is a measure of the proportion of the association of the exposure with breast cancer 
risk that is explained by mammographic density. The PE index finds the difference between the 
logarithms of the odds ratios of a risk factor in a model that does not adjust for mammographic 
density and one that does. This difference is then divided by the log of the odds ratio in the model 
that does not adjust for mammographic density. In this way, a PE index of 1 implies perfect 
mediation in that the effect of a risk factor entirely disappears after adjusting for density, and a PE 
of 0 implies the effect is the same whether adjusting or not, indicating no mediation. Ideally, the 
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associated 95% confidence intervals (95% CI) for PE should be estimated using the Freedman [20, 
21] and the Bootstrap method. However, it is not possible to conduct such statistical tests with data 
reported in the literature. However, the statistical test results will be extracted if available in the 
article.  
 
2.3 RESULTS 
 
Characteristics of the selected studies 
A total of 895 potential references were screened and 22 studies finally met the selection 
criteria. The studies covered a wide variety of risk/protective factors for the risk of breast cancer. 
Most studies did not use a formal statistical mediation analysis. Instead, they only checked two 
important requirements for a variable to be considered as a mediator to determine the possibility 
of mammography density acting as a mediator. These two criteria, first laid out by Baron and 
Kenny [5], suggest that an exposure must be associated with both breast density and breast cancer. 
Because these studies did not take further statistical mediation analysis, they were not included in 
the current review. Finally, a total of 22 studies were selected. Among these, 20 studies were based 
on the traditional “difference method”, comparing the estimated coefficients of exposure on the 
risk of breast cancer in linear regressions before and after adjustment for mammographic density. 
Out of these, only three studies calculated the percent change in the ORs and/or estimated a 
measure of mediation [22-24], the proportion explained (PE), which is estimated from the 
difference in coefficients of an exposure from two logistic regression models with or without 
adjusting for mammographic density, as described by Freedman et al. [20]. Of these three studies, 
the 95% confidence interval for the PE was available in only one study [22]. Only two studies have 
used the counterfactual approach for analysis of mediation [25, 26], one of which was conducted 
as a secondary analysis [25]. 
 
Results based on risk factors 
Table 2.2 lists the studies examining the risk of breast cancer according to various genetic 
factors, including a family history of breast cancer in first-degree relatives [22, 25, 27, 28], genetic 
variants of single nucleotide polymorphisms (SNPs) [23, 29], and race/ethnicity [23]. A family 
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history of breast cancer is an established risk factor for breast cancer, which was confirmed in four 
of the included studies [22, 25, 27, 28]. All these studies observed attenuation of the association 
between a family history of breast cancer and the risk of breast cancer after adjusting for 
mammographic density. However, the estimated PE indexes were relatively small. The highest PE 
was reported in a study with about 75% of the women being postmenopausal, which showed that 
14% (95% CI, 4-39%) of the association of a first-degree family history of breast cancer with 
breast cancer risk was explained by PMD [22]. The upper and lower limits of the confidence 
interval for this PE were estimated by the Bootstrap method using 1,000 samples (95% CI, 4-35%). 
However, the other three studies [25, 27, 28] showed no more than 11% of the association was 
mediated by PMD. This indicates that PMD might not be in the pathway for the association 
between a family history of breast cancer and the risk of breast cancer and if yes, the mediation 
effect is likely small. Two selected studies identified genetic variants that had a reduced risk from 
breast cancer, which were also associated with lower mammographic density [30, 31]. After 
adjusting for mammographic density, the magnitude of the log ORs for the SNPs on breast cancer 
risk was reduced by 15% and 35% respectively (Table 2.2). The sign of NIE was consistently 
negative in both studies, suggesting that these two genetic variants display a negative relationship 
with breast cancer when it acts through mammographic density. That is, they might reduce breast 
cancer risk partially by decreasing breast density. However, it is unknown if these PE indexes are 
statistically significant.  
 
Table 2.3 listed studies considering a variety of clinical features of the breast as risk factors 
for breast cancer, including computerized mammographic parenchymal pattern (MPP) measure 
[32], mammographic texture resemblance (MTR) [33], breast tissue stiffness [34], history of 
benign breast disease (BBD)[25, 35], and history of previous biopsy [27, 28]. Adjustment for 
mammographic density in general attenuated the association of these risk factors with breast cancer 
(Table 2.3). However, there is a great variation on the estimated proportion explained with most 
of the PE indexes for history BBD and biopsy ranging from 12% to 73%.  
 
Among postmenopausal women, breast cancer risk increased with increasing BMI (Table 
2.4a). Adjusting for mammographic density did not attenuate the association between adult BMI 
and postmenopausal breast cancer risk. Rather, it substantially strengthened the association by at 
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least 43% using the log OR scale (Table 2.4a). Similar results were observed for body weight 
(Table 2.4b). Among premenopausal women, however, the association of anthropometric 
measures (BMI and weight) with the risk of breast cancer was not consistent, although the overall 
total effect is largely negative or insignificant (Table 2.4a-2.4b). Adjusting for mammographic 
density increased the ORs for all the selected studies. A negative association was moved toward 
the null or even become positive while a positive association was moved further away from the 
null after further adjustment for mammographic density. Results among all subjects are mixed but 
the association of anthropometric measures (BMI, weight, and height) with the risk of breast 
cancer was mostly insignificant or marginally negative before adjustment for density. The 
magnitude of the ORs generally increased after controlling for mammographic density. Regardless 
of menopausal status, adjustment for mammographic density consistently moved the odds ratios 
for the association between these anthropometric measures (BMI, weight, height) and breast 
cancer in a positive direction. Although the virtual direction of NIE is inconclusive, adding 
mammographic density to the regression with BMI or weight as a predictor for breast cancer 
yielded a large PE index. A majority of the PE indexes were much higher than zero and quite a 
few exceeded 1. Interestingly, two studies have used a 9-figure body size scale to assess body 
fatness at ages 5, 7, 10, and 20 years [36, 37] and found that greater body fatness in childhood and 
adolescence was associated with decreased risk of breast cancer (Table 2.4c). Unlike adult BMI, 
weight, and height, the inverse association between average childhood and adolescent body fatness 
and breast cancer risk was generally attenuated after adjustment for mammographic density, 
indicating a potential consistent mediation (Table 2.4c). The sign of NIE is largely negative with 
a few inconclusive and the magnitude of the PE index could be as low as 3% [36] and as high as 
41% [37].  
 
Few studies have investigated the relationship between reproductive factors (parity, age at 
first live birth, and age at menarche) with breast cancer, with and without adjustment for 
mammographic density (Table 2.5). Ever parous was associated with a lower risk of breast cancer 
and adjusting for mammographic density attenuated the association by about 14-52%, indicating 
a partial mediation. However, the results for parity were largely inconclusive because the total 
effect was not significant for some of the included studies. Age at first live birth was found in three 
studies to be a significant risk factor for breast cancer [25, 27, 28], while it is not significant in a 
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study among subjects from different ethnic groups [24]. Nevertheless, adjusting for 
mammographic density slightly attenuated the association in the three studies with significant total 
effects, yielding results of either no mediation or a PE index ranging from 13% to 17%.  
 
Whether mammographic density can serve as a mediator for the association of 
postmenopausal hormone use and breast cancer was examined by 4 studies [25-27, 38] (Table 2.6). 
Current use of hormone replacement therapy (HRT) was associated with an increased risk of breast 
cancer and the association was consistently attenuated after adjustment for breast density. The sign 
of NIE is generally positive and the PE indexes range from 10% to 37%. In two of these studies, 
combined use of estrogen and progesterone was found to have a greater association with the risk 
of breast cancer than estrogen alone [26, 27]. Further adjustment for mammographic density 
attenuated the association by 10-26%. Two studies attempted to examine the impact of adjustment 
for mammographic density on the association of circulating levels of sex hormones with breast 
cancer risk [39, 40]. In both studies, circulating levels of estradiol and testosterone and 
mammographic density were both found to be statistically significantly and independently 
associated with postmenopausal breast cancer risk. However, additional adjustment for 
mammographic density either strengthened or did not affect the association between these 
circulating sex hormones and the increased risk of breast cancer, except that in one of the two 
studies, the association was slightly attenuated for total estradiol and testosterone [39, 40]. Only 
one study examined sex hormone-binding globulin (SHBG), which was negatively associated with 
breast cancer risk and this inverse association was strengthened after adjustment for percentage 
density [40]. The effect of plasma carotenoids on breast cancer risk and its relationship with 
mammographic density were evaluated in one study [41]. Adjusting for mammographic density 
altered the association in different directions and the results are largely inconclusive about 
mediation (Table 2.6).  
 
2.4 DISCUSSION  
 
This review systematically reviewed existing evidence on the potential role of 
mammographic density plays as a mediator for the risk of breast cancer. The results of this analysis 
suggest that mammographic density might partially mediate the association between some of the 
17 
 
known risk factors and breast cancer risk. The increase in breast cancer risk due to certain 
exposures may at least in part be attributed to increases in breast density.  
 
Genetic Factors 
Breast density is a highly heritable trait while genetic and family history factors are long-
established risk factors for breast cancer. Twin studies have shown that additive genetic factors 
(heritability) were estimated to account for 53% to 63% of the variation in mammographic density 
in the population, after adjustment for other factors [42]. Results in our review suggest that breast 
density may partially mediate the genetic associations with breast cancer. All studies consistently 
observed attenuation of the association between genetic factors and the risk of breast cancer after 
adjusting for mammographic density. One of the selected studies statistically confirmed the 
presence of mediation and showed that percent mammographic density explained 14% of the 
association of family history (at least one affected first-degree relative) with breast cancer risk 
[43]. Women with a family history of breast cancer have been shown to have higher 
mammographic density than women without a family history [44, 45], as have women of 
Ashkenazi Jewish descent [46]. Although nongenetic components shared by relatives may also 
play a role, the impact of a family history on the risk of breast cancer is primarily attributed to the 
inheritance of genes. Therefore, efforts have attempted to identify common genetic variants that 
predict both breast cancer risk and breast density. Two protective genetic variants satisfying these 
criteria were found to affect breast cancer risk partially by influencing the proportion of dense 
tissue in the breast [30, 31]. These results agree with a study that suggested that the genetic 
components that determine breast density overlapped with the genetic components that influence 
other breast cancer risk factors [47]. These findings provide insights into the mechanisms 
underlying the observed gene-disease association and highlight a potential biological pathway 
involving breast density to the genetic etiology of breast cancer.  
 
Breast Characteristics 
All risk factors for breast cancer must ultimately exert their influence by an effect upon 
breast tissue [48]. Mammographic density, expressed as the percentage of the breast showing 
densities, reflects variations and changes in the tissue composition of the breast. Fat is 
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radiologically lucent and appears dark on a mammogram. Dense areas, occupied by epithelial and 
stromal tissue, are radiologically dense and appear light. Histological assessment of the dense and 
non-dense areas of the breast revealed that the dense tissue has a greater amount of epithelium and 
stroma, particularly collagen, increased nuclear occupation, lesser fat, and a higher proportion of 
proliferative disease without atypia than the non-dense breast tissue [49-51]. Breast cancer most 
commonly develops in the epithelial cells that line the milk ducts and the lobules that supply these 
ducts with milk. Therefore, the greater the percent mammographic density, the greater the number 
of cells available for cancer transformation. Mammographic density is also linked to a higher 
number of cells and an increased amount of collagen, which may exacerbate breast tissue stiffness 
[34]. Women at higher risk of breast cancer were found to have dense breasts and their 
mammographic parenchymal patterns tend to be coarser, and lower in contrast than those of the 
low-risk group [52-54]. 
 
The present review found that the association of some histology and properties of the breast 
tissue and risk of breast cancer were in general attenuated after adjustment for mammographic 
density, indicating that their effect on breast cancer risk might be partially mediated through 
mammographic density. Pathological changes in the breast, reflected by histology abnormality and 
alterations in parenmychal pattern, texture, and stiffness, are phenomena closely related to breast 
density. Simply having a history of breast biopsy examination was found to be associated with 
increased breast density [55]. Women with a previous breast biopsy had an average of 6.5% more 
density than those who had not had a biopsy, likely due to a greater area of dense tissue and smaller 
nondense area [56]. Previous studies have described a strong association between benign breast 
disease histology and mammographic density. Women with density in more than 75% of the 
mammogram, as compared to women with no density, had a 12.2-fold increased risk of hyperplasia 
without atypia and 9.7-fold increased risk of atypical hyperplasia and/or breast carcinoma in situ 
[57, 58]. Compared to women with <25% fibroglandular breast tissue density, the relative risk of 
benign proliferative breast disease for women with ≥25% density was about doubled [59]. A 
number of recent studies have identified measures of mammographic parenchymal patterns based 
on various computer-extracted texture features on mammograms as independent predictors of 
breast cancer risk [60]. Some of these computerized parenchymal pattern measures, focusing on 
characteristics of fibroglandular densities seen without taking into account the extent of densities, 
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still demonstrated a moderate correlation with mammographic density [32, 61-63]. Breast tissue 
stiffness is an important characteristic that was found to be significantly associated with breast 
cancer [34]. Greater extracellular matrix (ECM) stiffness was observed in the breast tissue of 
higher mammographic density [64, 65].  
 
These findings suggest that the association between benign breast diseases, abnormal 
parenmychal pattern, and greater stiffness and breast cancer risk may, at least in part, be 
attributable to the biological processes in the breast that give rise to elevated breast density that is 
known to be related to breast cancer risk. For example, women with benign breast disease are at 
very high risk for future breast cancer if they also have dense breast tissue than if they have less 
dense breast tissue [35, 66]. Conversely, women found on breast biopsy to have the lowest category 
of breast density, whose breast tissue is almost entirely fat, were at low risk for future breast cancer 
even with proliferative benign pathologic diagnosis [66]. This suggests the important role of breast 
density plays in the increased risk of breast cancer associated with pathological changes in the 
breast. However, the estimated PE indexes for these risk factors are mostly no more than 25%, 
indicating that a relatively small proportion was mediated. The wide range of PE may be explained 
by the fact that the risk factors covered in this category are highly heterogeneous. Nevertheless, 
since the PE measure is based on the difference method, which is conservative, we cannot rule out 
the possibility with the presence of mediation. More study is needed to evaluate this category of 
risk factors by focusing on the extent of mediation, ideally with a statistical test and alternative 
mediation analysis such as the counterfactual approach.  
 
Anthropometric Measurements 
Non-genetic factors, including environmental, lifestyle, and behavioral exposures that are 
modifiable, have been much studied in relation to breast cancer risk. Several of these are 
anthropometric measurements such as body weight, height, and adiposity. BMI in childhood and 
adolescence was inversely associated with the breast cancer risk, possibly via a mechanism 
partially mediated by mammographic density, as suggested by the consistent attenuation of the 
association after adjustment for mammographic density. Adult BMI and body weight, on the other 
hand, appear to affect the risk of breast cancer for pre- and postmenopausal women differentially. 
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Before menopause, being overweight or obese is associated with a modestly reduced risk of breast 
cancer [67-71], whereas after menopause, it increases breast cancer risk [68, 69, 72].  
 
Studies summarized in this review showed that adjustment for mammographic density 
consistently moved the odds ratio for the association between these anthropometric measures 
(BMI, weight, height) and breast cancer in a positive direction (increased the ORs). The impact of 
adding mammographic density to the regression is so strong that the overall negative association 
among premenopausal women was moved close to the null or even become positive. However, the 
overall positive association between BMI and breast cancer among postmenopausal women was 
not attenuated after controlling for mammographic density. Rather, it was substantially 
strengthened. This is in agreement with another study on postmenopausal women, which found 
that adjusting for breast density either did not change or strengthened the association of BMI with 
breast cancer overall and of large, advanced-stage, high nuclear grade, estrogen receptor (ER)-
positive and -negative invasive breast cancer [73]. This observation indicates the presence of 
suppression or inconsistent mediation. In epidemiological studies, this is called negative 
confounding [3, 74]. It was argued that the negative confounding of percent density with BMI was 
because of a strong positive correlation of BMI with absolute non-dense (fatty) area on the 
mammogram [75]. This strong correlation may cause multicollinearity but it was found that this 
was not an issue [76]. Nevertheless, although mediation, confounding, and suppression are 
conceptually distinct, they share considerable statistical similarities (statistically equivalent) [77]. 
Therefore, it is reasonable to hypothesize that the mediated effect via density and the direct effect 
have opposite signs. That is, BMI may have a negative relationship with breast cancer when it acts 
through mammographic density (the sign of NIE is generally negative), while the effect not acting 
through (independent of) mammographic density is positive. This hypothesis suggests that the 
observed negative association between adult BMI and breast cancer among premenopausal 
women, along with body fatness in childhood and adolescence and breast cancer in all women, 
may occur because BMI is acting predominantly through its negative indirect effect through breast 
density. Overweight or obese women tend to have less dense breasts and, because of this, lower 
risk or no association with premenopausal breast cancer. The mechanism by which breast density 
is associated with risk is unknown but might be explained by the combined effects of mitogens in 
younger women such as insulin-like growth factor 1 (IGF1), which leads to cell proliferation in 
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the breast and increased amounts of fibroglandular tissue where most breast cancers arise. In 
postmenopausal women, who tend to have less dense breasts than premenopausal women, BMI 
may have a more direct positive association with breast cancer. 
 
Several possible biologic mechanisms exist by which women with greater adiposity may 
have additional risk for breast tumor development in postmenopausal women [78]. One of the 
possible mechanisms through which excess adiposity is thought to favor breast tumor development 
is a change in endogenous sex hormone metabolism. The elevated breast cancer risk associated 
with adiposity (BMI, waist and hip circumferences) in postmenopausal women was substantially 
and moderately reduced by adjusting for concentrations of serum estrogen (fT, E1, E2, fE2, ) and 
sex hormone-binding globulin, respectively, especially for free estradiol [79-81]. However, 
adjustment for androgen only slightly reduced the BMI-risk relationship, except for free 
testosterone which led to a modest attenuation in excess risk with adiposity in one study [79-81]. 
These observations support the hypothesis that the increased risk of breast cancer associated with 
greater adiposity in postmenopausal women is largely mediated through estrogen levels, 
particularly bioavailable estradiol, and to a lesser extent free testosterone, but not total androgens. 
After menopause, adipose tissue becomes the main site of estrogen production by aromatization 
of androgens [82, 83]. Furthermore, increased adiposity would cause insulin resistance, which in 
turn lowers the hepatic synthesis and blood levels of SHBG, a protein that effectively binds both 
estradiol and testosterone, thereby resulting in an increased concentration of bioavailable sex 
steroid hormone in circulation [84]. This may explain why women with increased adiposity tend 
to have higher circulating levels of estrogens [85], whereas overweight and obese postmenopausal 
women with sustained weight loss showed decreases in estrogen concentrations may reduce the 
peripheral synthesis and circulating levels of estrogens but not of total androgens [80, 86, 
87].  BMI was found to be inversely associated with ER+PR+ breast cancer among premenopausal 
women but positively associated with risk among postmenopausal women, while no association 
was observed for risk of ER-PR- breast tumors [73, 88, 89]. This suggests that the effect of 
adiposity on breast cancer risk may be via an estrogen dependent pathway [90]. 
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Reproductive Factors 
 
Breast density is known to decline during a woman’s lifetime, particularly in response to 
menstrual and reproductive events [91]. Women who were nulliparous or had only one child, with 
an age at first live birth after age 30 tended to exhibit a slower rate of decline in percent 
mammographic density in comparison with those having more than one child with the first live 
birth before age 30 [7]. Percent mammographic density dropped by 2.4% (1.4–3.4) on menopausal 
transition and increased by 2.4% (1.4–3.5) with the use of hormone replacement therapy [92]. 
Studies showed that nulliparity, late age at first birth, and premenopausal status were associated 
with increased percent mammographic density [93-97]. However, there were inconsistent findings 
for age at menarche and duration of breast-feeding. While some studies found a positive 
association between mammographic density and age at menarche [97] or duration of breastfeeding 
[96, 98-100], some studies observed no significant associations [7, 94, 98].  Studies summarized 
in this review showed that the association between reproductive factors (parity, age at firth birth, 
and breast-feeding) and breast cancer was reduced (by about 12-17%, 16-37%, and 5% 
respectively) after adjustment for breast density, indicating that mammographic density might 
mediate, likely in part, the protective effects of greater parity, younger age at first birth, and a 
longer period of breastfeeding against breast cancer. This is may explain why the higher risk 
associated with low parity appeared to be stronger among women with high breast density [101]. 
The protective effect of parity from breast cancer risk was not wholly mediated by a reduction in 
mammographic density, which is in agreement with the observation that mammographic density 
was associated with the risk of both steroid receptor-positive and negative subtypes of breast 
cancer [102, 103], while parity was found to influence the risk of receptor-positive cancer only 
[104, 105]. Since no formal statistical test of the mediation effect is available, it is inconclusive 
whether the proportion mediated estimated above is significant or not. Future studies are needed 
to further address this issue.  
 
Exogenous Hormone Use 
Clinical trials have demonstrated that postmenopausal treatment with hormone 
replacement therapy (HRT), especially combined formulations of estrogen and progestin, is 
associated with increases in mammographic density and risk of breast cancer [106], whereas 
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tamoxifen, a selective anti-estrogen drug, has been shown to reduce mammographic density and 
breast cancer risk [107]. Although the mechanism of action of these exogenous hormones in 
influencing the risk of breast cancer remains to be determined, it has been hypothesized that 
circulating levels of hormones are associated with breast density and that mammographic density 
represents at least, in part, cumulative exposure to estrogens [108]. The overall effect of HRT in 
these women was found to delay breast involution and prevent loss of breast parenchyma and 
epithelial cells that typically occurs around the menopause, thus increasing the breast density in a 
proportion of the treated patients [109, 110]. Women on a combined estrogen-progestin HRT had 
2.5- and 3.7-fold higher serum estradiol and estrone levels than nonuser, while the estradiol 
concentration in nipple aspirate fluid (NAF) was estimated to 18 times higher than that in nonusers 
and seven times higher than that in premenopausal women [111]. This indicates that exogenous 
hormone use may have direct influence on local breast tissue.  
 
Published literature on the effects of using exogenous hormones on mammographic density 
and the risk of breast cancer suggests that mammographic density might be a potential surrogate 
marker for breast cancer [106, 108]. Only one study by Boyd et al. [38] directly addressed this 
question using data from three nested case-control studies and found no support for this hypothesis. 
The results showed that estimates of the risk of breast cancer associated with hormone replacement 
therapy were either unchanged or slightly reduced, by adjustment for percent density. Thus, the 
authors concluded that there was no evidence that the increased risk of breast cancer associated 
with hormone replacement therapy is a consequence of the effect of this therapy on the risk factor 
of mammographic density. In other words, the pathways that are responsible for the increase in 
mammographic density following exposure to exogenous hormones, and those that increase the 
risk of breast cancer independent of mammographic density, are separate and not related causally. 
However, this conclusion regarding mediation may be worth further consideration for several 
reasons. First, the third condition proposed in that study requires the potential surrogate marker to 
mediate the entire relation of the intervention to the disease. That means it does not allow for 
partial mediation, instead, it requires the exposure and disease to be statistically unrelated once the 
surrogate is taken into account, which is a very strong criterion. Second, that study did not formally 
use any measure of mediation to quantify the extent to which mammographic density influences 
the association between hormone replacement therapy and breast cancer. We estimated the percent 
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change in the log ORs with adjustment for mammographic density and found that the PE is about 
25% for current HRT users when data on all three nested case-control studies were combined 
(Table 2.5). This suggests the potential presence of partial mediation, although relatively small. 
Third, the study used the difference method, which is always conservative for binary outcomes 
hence the results can be used to provide evidence for the presence of mediation but not for the 
absence of mediation [19]. 
 
Endogenous Hormone 
Higher circulating levels of both estrogen and androgen are known to increase the risk of 
breast cancer in both premenopausal [112-115] and postmenopausal women [40, 80, 116-119], 
whereas SHBG, which binds estradiol and testosterone with high affinity, is associated with a 
reduced risk of breast cancer by effectively limiting their bioavailability [120, 121]. The biologic 
mechanism by which estrogens and androgens are associated with increased breast cancer risk 
remains unclear, although they are closely related. Androgens may act directly, promoting breast 
cell growth via binding to the androgen receptor, or indirectly, via conversion to estrogens in 
adipose tissue, either peripherally or locally in the breast [122, 123]. It was argued that the 
contribution of androgens to breast cancer risk might be largely through their role as estrogen 
precursors. This is because the association between androgen (testosterone) levels and breast 
cancer risk decreased substantially after adjusting for estrone sulfate and slightly after adjusting 
for total estradiol [80, 116, 124-126]. On the other hand, adjustment for androgen levels only 
mildly attenuated the relative risk of breast cancer associated with estrogens [80, 116]. Since the 
risk remained significant after adjustment, it indicates that androgens may also act through an 
independent mechanism in addition to increasing estrogen levels. 
 
The observed associations of mammographic density with menstrual and reproductive 
factors, along with exogenous sex hormone use, support that endogenous sex steroids may also 
increase breast cancer risk through their effect on breast density. However, it is unclear to what 
extent their effects on breast cancer risk are independent of the effect of mammographic density 
or to what extent density is a reflection of underlying hormone levels. In the current review, we 
identified two studies that attempted to address this question but the results were largely 
inconclusive about mediation. Adjustment for mammographic density mostly either strengthened 
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or did not affect the association between these circulating sex hormones and increased risk of 
breast cancer. On the other hand, both studies showed that the elevated risk of postmenopausal 
breast cancer associated with increased mammographic density became stronger after adjustment 
for sex hormones or SHBG, more so for those in the free available form [39, 40]. It is possible that 
endogenous hormones in the free form are acting differently or with greater bioactivity than those 
in bounded form. These observations suggest that the possible mechanism underlying the 
association between endogenous sex hormones and postmenopausal breast cancer risk is complex 
and not well understood. One potential explanation for this might be the presence of inconsistent 
mediation or suppression. This suggests that if the indirect pathway through breast density exists, 
then such intermediate partly counters the positive associations of free estradiol and testosterone, 
and the adverse association of SHBG with breast cancer risk. That is, free estradiol and testosterone 
are likely to be negatively and SHBG positively associated with mammographic density.  
 
However, previous studies on the association between sex hormone levels and breast 
density have been largely inconsistent. While some studies reported that levels of estradiol, 
prolactin, progesterone, testosterone, premenarchal DHEAS (dehydroepiandrosterone 
sulfate), and SHBG were positively associated with mammographic density among 
premenopausal women [127-131], others found either no association of plasma estradiol, 
progesterone, non-SHBG-bound testosterone, and SHBG, or negative association of androgens 
testosterone, androstenedione, and dehydroepiandrosterone sulfate with premenopausal breast 
density [127, 129, 132, 133]. Among postmenopausal women, higher blood levels of endogenous 
estrogens and androgens (estrone, estradiol, bioavailable estradiol, prolactin, and progesterone) 
were shown to be related to greater mammographic density, even after adjustment for BMI [132, 
134-138]. But in other studies, circulating levels of estrone, estradiol, free estradiol, testosterone, 
free testosterone, androstenedione, and dehydroepiandrosterone were found to be negatively [40, 
132, 135, 139-141] and sex SHBG [135, 136, 138, 142] to be positively associated with percentage 
density. In a recent study on postmenopausal women, the ratio of urinary parent estrogens (estrone 
and estradiol) to all their metabolites (methylated catechols, 2-methoxyestrone, and 4-
methoxyestrone) was found to be positively associated with percent mammographic density and 
dense area, which did not differ markedly by 2-, 4-, and 16-hydroxylation metabolic pathways. 
This suggests that increased hydroxylation of parent estrogens may protect against breast cancer 
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through a pathway involving breast density [143]. However, this association of estrogens and MD 
is maintained only among postmenopausal women with recent or sustained exposure to higher 
levels of circulating estrogens (such as occurs close to the time of menopause or among obese 
women [143]. 
 
Nevertheless, the association between sex hormone levels and mammographic density is 
strongly influenced by BMI. Most of these hormone-density associations (total/free/bioavailable 
estradiol, estrone, estrone sulfate, total/free/bioavailable testosterone, or SHBG levels, prolactin) 
were substantially weakened or eliminated with further adjustment for BMI in both premenopausal 
[127] and postmenopausal women [40, 108, 135, 138, 140, 144]. These results suggest that if the 
effect of circulating sex hormone levels to breast cancer is mediated by mammographic density, 
then they act through a pathway involving obesity. This agrees with a study that used statistical 
mediation analysis based on the difference method, which found that bodyweight mediated over 
50% of the association of progesterone, SHBG, and E2 with percent mammographic density in 
premenopausal women [131]. Meantime, this study found no support for the hypothesis that any 
of the hormones mediated the association of weight with percentage density [131]. 
 
Even if BMI mediated a large part of the association between circulating hormones with 
breast density, it is likely to mediate only a small proportion of the effect of circulating hormone 
on breast cancer risk because only part of this association is acting through breast density. 
Adjustment for BMI resulted in little change in the risk estimates of breast cancer for different 
levels of androgens, estrogens, or SHBG in postmenopausal women, suggesting a possible causal 
role of sex steroids in breast cancer is independent of postmenopausal obesity [40, 79-81, 118]. 
This is consistent with the finding that the reduced risk of breast cancer associated with greater 
hydroxylation of parent estrogens did not vary by >10% with and without adjustment for BMI, 
suggesting that adiposity is neither a confounder of the association nor is it on the causal pathway 
of estrogen metabolism to mammographic density [143]. Adjusting for both BMI and height 
simultaneously was found to reduce the ORs for postmenopausal breast cancer associated with top 
quintile of oestradiol, oestrone, and androgens by 17%, 18%, and 7–13% respectively [124].  
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While mammographic density affected risks of both estrogen- and progesterone-receptor 
positive (ER+/ PR+) and negative (ER-/PR-) breast cancers [102, 103], hormone replacement 
therapy (HRT) use and circulating levels of sex steroid hormones tended to be more strongly 
associated with risk of receptor-positive (ER+/PR+) breast tumors [88, 108, 114, 117, 119]. 
Furthermore, clinical trials showed that treatment with tamoxifen [145] or raloxifene [146] 
appeared to be effective in reducing the risk of estrogen-receptor–positive (ER+), but not receptor-
negative (ER-) breast tumors. Therefore, it was hypothesized that circulating sex hormone levels 
and mammographic density are independent risk factors for postmenopausal breast cancer and that 
they may increase breast cancer risk through different mechanisms. 
 
Limitations 
There are several limitations to the current review. First, this review is limited by the 
relatively small number of studies that have evaluated the potential role of mammographic density 
as a mediator. The risk factors for breast cancer covered were of such a great variety that it is 
impossible to conduct a meta-analysis. Therefore, the results must be interpreted with caution. 
Second, although the studies encompass a wide range of risk factors, it should be noted that the 
studies examined in this review were rarely designed to directly address the specific mediation 
question being investigated here. Third, all except two studies used the “difference method”, which 
has been criticized for lacking a causal interpretation and being conservative regarding mediation 
for binary outcomes. The proportion mediated tends to be underestimated. It can be used to provide 
evidence for the presence of mediation but not for the absence of mediation. While the “difference 
method” is commonly used, the question remains whether density mediates the effects of risk 
factors for breast cancer. Given that there are only two studies that have conducted causal 
mediation analysis, the role of mammographic density linking a risk factor and breast cancer risk 
remains unclear. 
 
Despite these limitations, the data summarized in this review do provide insights for us to 
generate important hypotheses regarding the potential mediation role of mammographic density in 
a wide range of factors known to be related to breast cancer risk. Therefore, further studies are 
needed to test the hypothesis that some risk factors may affect breast cancer risk through a pathway 
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via mammographic density. The findings can help us to better understand the biological 
mechanisms involving mammographic density to the etiology of breast cancer.  
 
2.5 CONCLUSIONS 
 
In conclusion, some evidence supported the hypothesis of mediating pathways from a risk 
factor such as HRT to breast cancer through mammographic density measures. Very few studies 
have used statistical mediation analyses to examine the effect of known risk factors on breast 
cancer risk through breast density. The available evidence is not enough to make a conclusion 
about the potential mediation effect of breast density. Despite a lack of sufficient evidence, 
available data based on the “difference method” implies that mammographic density may play a 
role in the effects of some breast cancer risk factors. The association between many of the known 
risk factors on breast cancer is likely in part, although not wholly, mediated by mammographic 
density. This is especially true for the effect of adiposity since adjustment for mammographic 
density substantially altered its association with the risk of breast cancer. Further research is 
needed to address the hypothesis generated in this review and to statistically examine the potential 
role of mammographic density as a mediator in the etiology of breast cancer, not only based on 
the traditional “difference method” but also based on the newly developed techniques such as the 
counterfactual approach. 
 
  
29 
 
TABLES 
 
Table 2.1. Search strategies 
 
Search # Search using title, abstract, and keywords 
#1 (((mammography OR mammographic) AND (density OR densities)) OR 
"breast density" OR "breast densities" OR "percent density" OR "percent 
densities”) AND (mediat* OR surrogat*) 
#2 (((mammography OR mammographic) AND (density OR densities)) OR 
"breast density" OR "breast densities" OR "percent density" OR "percent 
densities”) AND (“adjusted for" OR "adjust for" OR "adjusts for" OR 
"adjusting for" OR "adjustment for" OR "controlled for" OR "controlling for" 
OR “accounting for”) 
#3 #1 OR #2 
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Table 2.2. Changes in the OR/RRs of genetic factors by adjustment for mammographic density 
Year First 
Author 
No. 
subjects 
Subjects Exposure Unadj. 
OR/RR 
95% CI Adj. 
OR/RR 
95% CI Sign of NIE PE/ 
PM 
2011 Lindström 806/784 NHS rs10995190 in ZNF365 0.88 (0.72-1.07) 0.93 (0.76-1.14) negative 0.43 
2011 Lindström 518/742 SASBAC rs10995190 in ZNF365 0.91 (0.73-1.14) 0.93 (0.75-1.17) negative 0.23 
2011 Lindström 783/907 MCBCS rs10995190 in ZNF365 0.78 (0.65-0.95) 0.85 (0.69-1.03) negative 0.35 
2011 Lindström 2107/2433 Combined rs10995190 in ZNF365 0.85 (0.76-0.96) 0.90 (0.80-1.01) negative 0.35 
2014 Fejerman 304/809 Mexican rs140068132 0.73 (0.55-0.98) 0.77 (0.58-1.03) negative 0.15 
2014 Fejerman 304/809 Mexican Indigenous American Ancestry 0.34 (0.16-0.73) 0.34 (0.16-0.74) negative 0.01 
2014 Fejerman 304/809 Mexican African Ancestry 1.03 (0.08-13.11) 0.81 (0.06-10.59) inconclusive 8.61 
2010 Martin 926/978 ~75% 
postmenopausal 
# of 1st° relatives n=0 1.00 Referent 1.00 Referent ~ ~ 
2010 Martin 207/165 ~75% 
postmenopausal 
# of 1st° relatives n=1 1.37 (1.10-1.72) 1.31 (1.04-1.65) positive 0.14 
2010 Martin 31/15 ~75% 
postmenopausal 
# of 1st° relatives n≥2 2.45 (1.30-4.62) 2.25 (1.19-4.27) positive 0.10 
2016 Rice 559/1727 NHS/NHSII, 
premenopausal at 
mammogram 
Family history of breast cancer: Yes 
vs no 
1.47 (1.07,2.01) 1.46 (1.06,2.00) positive 2% 
2016 Rice 731/1695 NHS/NHSII, 
postmenopausal 
at mammogram 
Family history of breast cancer: Yes 
vs no 
1.45 (1.15,1.85) 1.45 (1.14,1.84) positive 1% 
2018 Rice 1083/3190 NHS/NHSII, 
premenopausal at 
mammogram 
Family history of breast cancer: Yes 
vs no 
1.59 (1.30,1.94) 1.55 (1.27,1.90) positive 5% 
2018 Rice 2188/5669 NHS/NHSII, 
postmenopausal 
at mammogram 
Family history of breast cancer: Yes 
vs no 
1.58 (1.39,1.80) 1.58 (1.39,1.80) positive 1% 
2005 Tice 81,777 diverse racial 
groups 
Age at 1st birth, # of 1st° relatives: 
<20 yrs, n=0 
1.00 Referent 1.00 Referent ~ ~ 
2005 Tice 81,777 diverse racial 
groups 
Age at 1st birth, # of 1st° relatives: 
<20 yrs, n=1 
2.89 (1.82-4.57) 2.80 (1.77-4.43) positive 0.03 
2005 Tice 81,777 diverse racial 
groups 
Age at 1st birth, # of 1st° relatives: 
<20 yrs, n=2+ 
8.33 (3.32-20.90) 7.83 (3.13-19.60) positive 0.03 
2005 Tice 81,777 diverse racial 
groups 
Age at 1st birth, # of 1st° relatives: 
20-24 yrs, n=0 
1.27 (1.09-1.48) 1.22 (1.05-1.42) positive 0.17 
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(cont.) Table 2.2. Changes in the OR/RRs of genetic factors by adjustment for mammographic density 
Year First 
Author 
No. 
subjects 
Subjects Exposure Unadj. 
OR/RR 
95% CI Adj. 
OR/RR 
95% CI Sign of NIE PE/ 
PM 
2005 Tice 81,777 diverse racial 
groups 
Age at 1st birth, # of 1st° relatives: 
20-24 yrs, n=1 
2.98 (2.11-4.21) 2.80 (1.98-3.95) positive 0.06 
2005 Tice 81,777 diverse racial 
groups 
Age at 1st birth, # of 1st° relatives: 
20-24 yrs, n=2+ 
6.99 (3.86-12.70) 6.40 (3.54-11.60) positive 0.05 
2005 Tice 81,777 diverse racial 
groups 
Age at 1st birth, # of 1st° relatives: 
25-29 yrs, n=0 
1.62 (1.20-2.18) 1.50 (1.10-2.03) positive 0.16 
2005 Tice 81,777 diverse racial 
groups 
Age at 1st birth, # of 1st° relatives: 
25-29 yrs, n=1 
3.08 (2.18-4.36) 2.80 (1.97-3.98) positive 0.08 
2005 Tice 81,777 diverse racial 
groups 
Age at 1st birth, # of 1st° relatives: 
25-29 yrs, n=2+ 
5.87 (3.60-9.57) 5.24 (3.21-8.56) positive 0.06 
2005 Tice 81,777 diverse racial 
groups 
Age at 1st birth, # of 1st° relatives: 
30+ yrs, n=0 
2.05 (1.31-3.22) 1.83 (1.16-2.89) positive 0.16 
2005 Tice 81,777 diverse racial 
groups 
Age at 1st birth, # of 1st° relatives: 
30+ yrs, n=1 
3.18 (2.00-5.07) 2.80 (1.75-4.49) positive 0.11 
2005 Tice 81,777 diverse racial 
groups 
Age at 1st birth, # of 1st° relatives: 
30+ yrs, n=2+ 
4.93 (2.43-9.99) 4.28 (2.10-8.74) positive 0.09 
Unadj.: Unadjusted; Adj.: adjusted; NIE (natural indirect effect); PE: proportion explained; PM: proportion mediated 
PE was estimated using the following formula: PE = [β(unadjusted)-β(adjusted)]/β(unadjusted) 
PM was reported in the paper, denoted as a percentage.  
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Table 2.3. Changes in the OR/RRs of clinical features of the breast by adjustment for mammographic density 
Year First 
Author 
No. 
subjects 
Subjects Exposure Unadj. 
OR/RR 
95% CI Adj. 
OR/RR 
95% CI Sign of NIE PE / 
PM 
2011 Wei 41/174 Training and test set MPP C1 1.00 Referent 1.00 Referent ~ ~ 
2011 Wei 28/50 Training and test set MPP C2 2.62 NA 2.40 (1.28-4.45) positive 0.09 
2011 Wei 67/22 Training and test set MPP C3 13.91 NA 13.38 (7.12-25.15) positive 0.01 
2011 Wei 21/87 Training set MPP C1 1.00 Referent 1.00 Referent ~ ~ 
2011 Wei 19/35 Training set MPP C2 2.65 NA 2.37 (1.04-5.36) positive 0.11 
2011 Wei 41/14 Training set MPP C3 13.91 NA 13.95 (5.93-32.85) inconclusive 0.00 
2011 Wei 20/87 Test set C3 MPP C1 1.00 Referent 1.00 Referent ~ ~ 
2011 Wei 9/15 Test set C4 MPP C2 2.87 NA 2.82 (1.04-7.64) positive 0.02 
2011 Wei 26/8 Test set C5 MPP C3 14.00 NA 13.89 (6.53-49.05) positive 0.00 
2014 Nielsen 226/442 Study S2 trained on S1 MTR T1 quartiles Q1 1.00 Referent 1.00 Referent ~ ~ 
2014 Nielsen 226/443 Study S2 trained on S1 MTR T1 quartiles Q2 1.40 (0.80-2.30) 1.04 (0.59-1.81) positive 0.88 
2014 Nielsen 226/444 Study S2 trained on S1 MTR T1 quartiles Q3 1.30 (0.70-2.20) 0.95 (0.52-1.74) inconclusive 1.20 
2014 Nielsen 226/445 Study S2 trained on S1 MTR T1 quartiles Q4 2.20 (1.40-3.60) 1.84 (1.10-3.07) positive 0.23 
2014 Nielsen 226/446 Study S2 trained on S1 MTR T1 (OR per one 
SD) 
1.39 (1.17-1.66) 1.36 (1.13-1.62) positive 0.07 
2014 Boyd 362/656 most postmenopausal Stiffness IQR 
(interquartile range) 
1.24 (1.05-1.46) 1.21 (1.03-1.43) positive 0.11 
2001 Byrne 62/94 ~85% postmenopausal Nonproliferative benign 
disease 
1.00 Referent 1.00 Referent ~ ~ 
2001 Byrne 198/223 ~85% postmenopausal Proliferative disease 
without atypia 
1.30 (0.90-1.90) 1.30 (0.90-1.90) positive 0.00 
2001 Byrne 58/41 ~85% postmenopausal Atypical hyperplasia 2.20 (1.30-3.60) 2.10 (1.30-3.60) positive 0.06 
2001 Byrne 29/52 ~85% postmenopausal Benign histology, Other 0.80 (0.50-1.40) 0.90 (0.50-1.70) negative 0.53 
2016 Rice 559/1727 NHS/NHSII, premenopausal at 
mammogram 
History of biopsy-
confirmed BBD 
Yes vs no 
2.04 (1.59,2.62) 1.81 (1.40,2.32) positive 17%** 
2016 Rice 731/1695 NHS/NHSII, postmenopausal at 
mammogram 
History of biopsy-
confirmed BBD 
Yes vs no 
1.29 (1.04,1.61) 1.19 (0.95,1.48) positive 33%* 
2016 Rice 559/1727 NHS/NHSII, premenopausal at 
mammogram 
History of unconfirmed 
BBD 
1.12 (0.89,1.41) 1.03 (0.82,1.30) positive 73% 
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(cont.) Table 2.3. Changes in the OR/RRs of clinical features of the breast by adjustment for mammographic density 
Year First 
Author 
No. 
subjects 
Subjects Exposure Unadj. 
OR/RR 
95% CI Adj. 
OR/RR 
95% CI Sign of NIE PE / 
PM 
2016 Rice 731/1695 NHS/NHSII, postmenopausal at 
mammogram 
History of unconfirmed 
BBD 
1.19 (0.95,1.48) 1.13 (0.90,1.41) positive 29% 
2018 Rice 1098/3183 NHS/NHSII, premenopausal at 
mammogram 
Previous breast biopsy 
yes versus no 
1.76 (1.48,2.10) 1.60 (1.34,1.91) positive 17%** 
2018 Rice 2202/5546 NHS/NHSII, postmenopausal at 
mammogram 
Previous breast biopsy 
yes versus no 
1.50 (1.34,1.69) 1.36 (1.21,1.53) positive 24%** 
2005 Tice 81,777 diverse racial groups Age<50 years, No 
previous biopsy 
1.00 Referent 1.00 Referent ~ ~ 
2005 Tice 81,777 diverse racial groups Age<50 years, Previous 
biopsy 
1.22 (0.82-1.82) 1.19 (0.80-1.78) positive 0.13 
2005 Tice 81,777 diverse racial groups Age<50 years, >1 
previous biopsy 
1.49 (0.67-3.31) 1.42 (0.64-3.16) positive 0.12 
2005 Tice 81,777 diverse racial groups Age≥50 years, No 
previous biopsy 
1.00 Referent 1.00 Referent ~ ~ 
2005 Tice 81,777 diverse racial groups Age≥50 years, Previous 
biopsy 
1.24 (0.99-1.56) 1.19 (0.94-1.50) positive 0.19 
2005 Tice 81,777 diverse racial groups Age≥50 years, >1 
previous biopsy 
1.54 (0.97-2.45) 1.41 (0.88-2.24) positive 0.20 
Unadj.: Unadjusted; Adj.: adjusted; NIE (natural indirect effect); PE: proportion explained; PM: proportion mediated; NA: not 
available; MPP: mammographic parenchymal pattern; MTR: mammographic texture resemblance; BBD: benign breast disease 
PE was estimated using the following formula: PE = [β(unadjusted)-β(adjusted)]/β(unadjusted) 
PM was reported in the selected studies, denoted as a percentage 
* p < 0.05, ** p < 0.01 
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Table 2.4a. Changes in the OR/RRs of BMI by adjustment for mammographic density  
Year First 
Author 
No. 
subjects 
Subjects Exposure 
BMI (kg/m2) 
Unadj. 
OR/RR 
95% CI Adj. 
OR/RR 
95% CI Sign of NIE PE 
/PM 
2004 Vacek 24006 Premenopausal <22.0 1.00 Referent 1.00 Referent ~ ~ 
2004 Vacek 24006 Premenopausal 22.0-24.9 0.66 (0.50-0.88) 0.71 (0.53-0.94) negative 0.18 
2004 Vacek 24006 Premenopausal 25.0–27.4 0.68 (0.48-0.95) 0.77 (0.55-1.09) negative 0.32 
2004 Vacek 24006 Premenopausal 27.5–29.9 0.66 (0.44-0.99) 0.79 (0.53-1.20) negative 0.43 
2004 Vacek 24006 Premenopausal ≥ 30.0 0.64 (0.47-0.88) 0.85 (0.61-1.20) negative 0.64 
2006 Boyld 86/64 Premenopausal ≤21.79 1.00 Referent 1.00 Referent ~ ~ 
2006 Boyld 54/59 Premenopausal (21.79-23.30) 0.69 (0.40-1.10) 0.88 (0.5-1.5) negative 0.66 
2006 Boyld 49/46 Premenopausal (23.30-25.02) 0.79 (0.50-1.30) 1.13 (0.60-2.00) inconclusive 1.52 
2006 Boyld 42/46 Premenopausal (25.02-27.64) 0.68 (0.40-1.20) 1.06 (0.60-1.90) inconclusive 1.15 
2006 Boyld 51/52 Premenopausal >27.64 0.76 (0.50-1.30) 1.47 (0.80-2.70) inconclusive 2.40 
2006 Boyld 162 pairs  Premenopausal BMI (continuous) 0.96 (0.91-1.02) 1.01 (0.95-1.07) inconclusive 1.14 
2011 Harris 19/46 Premenopausal  <20b 0.86 (0.47-1.58) 0.75 (0.40-1.38) inconclusive -0.91 
2011 Harris 77/151 Premenopausal 20–22.4b 1.00 Referent 1.00 Referent ~ ~ 
2011 Harris 60/146 Premenopausal 22.5–24.9b 0.85 (0.56-1.28) 1.04 (0.68-1.60) inconclusive 1.24 
2011 Harris 48/23 Premenopausal 25–27.4b 1.08 (0.68-1.71) 1.59 (0.97-2.59) inconclusive -5.03 
2011 Harris 23/26 Premenopausal 27.5–29.9b 1.75 (0.92-3.33) 2.86 (1.44-5.68) inconclusive -0.88 
2011 Harris 31/100 Premenopausal ≥30b 0.64 (0.38-1.06) 1.28 (0.72-2.30) inconclusive 1.55 
2000 Lam 298/1241 Postmenopausal <22.0 1.00 Referent 1.00 Referent ~ ~ 
2000 Lam 298/1241 Postmenopausal 22.0-24.9 1.20 (0.80-2.00) 1.40 (0.90-2.30) inconclusive -0.85 
2000 Lam 298/1241 Postmenopausal 25.0–27.4 1.30 (0.80-2.20) 1.60 (0.90-2.70) inconclusive -0.79 
2000 Lam 298/1241 Postmenopausal 27.5–29.9 1.30 (0.70-2.10) 1.60 (0.90-2.70) inconclusive -0.79 
2000 Lam 298/1241 Postmenopausal ≥ 30.0 1.90 (1.20-3.00) 2.50 (1.60-4.10) inconclusive -0.43 
2004 Vacek 36867 Postmenopausal  <22.0 1.00 Referent 1.00 Referent ~ ~ 
2004 Vacek 36867 Postmenopausal 22.0-24.9 1.09 (0.87-1.37) 1.17 (0.94-1.45) inconclusive -0.82 
2004 Vacek 36867 Postmenopausal 25.0–27.4 1.07 (0.84-1.37) 1.25 (0.99-1.57) inconclusive -2.30 
2004 Vacek 36867 Postmenopausal 27.5–29.9 1.18 (0.91-1.53) 1.43 (1.12-1.83) inconclusive -1.16 
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(cont.) Table 2.4a. Changes in the OR/RRs of BMI by adjustment for mammographic density  
Year First 
Author 
No. 
subjects 
Subjects Exposure 
BMI (kg/m2) 
Unadj. 
OR/RR 
95% CI Adj. 
OR/RR 
95% CI Sign of NIE PE 
/PM 
2004 Vacek 36867 Postmenopausal ≥ 30.0 1.19 (0.95-1.50) 1.54 (1.23-1.93) inconclusive -1.48 
2006 Boyld 159/168 Postmenopausal  ≤21.79 1.00 Referent 1.00 Referent ~ ~ 
2006 Boyld 164/158 Postmenopausal (21.79-23.30) 1.05 (0.80-1.40) 1.16 (0.80-1.60) inconclusive -2.04 
2006 Boyld 159/174 Postmenopausal (23.30-25.02) 0.95 (0.70-1.30) 1.13 (0.80-1.60) inconclusive 3.38 
2006 Boyld 170/178 Postmenopausal (25.02-27.64) 1.02 (0.80-1.40) 1.28 (0.90-1.80) inconclusive -11.47 
2006 Boyld 180/169 Postmenopausal >27.64 1.17 (0.90-1.60) 1.67 (1.20-2.30) inconclusive -2.27 
2006 Boyld 727 pairs  Postmenopausal BMI (continuous) 1.02 (0.99-1.04) 1.05 (1.02-1.03) inconclusive -1.81 
2006 Boyld 245/232 All subjects ≤21.79 1.00 Referent 1.00 Referent ~ ~ 
2006 Boyld 218/217 All subjects (21.79-23.30) 0.93 (0.70-1.20) 1.07 (0.80-1.40) inconclusive 1.93 
2006 Boyld 208/220 All subjects (23.30-25.02) 0.89 (0.70-1.20) 1.12 (0.80-1.50) inconclusive 1.97 
2006 Boyld 212/224 All subjects (25.02-27.64) 0.91 (0.70-1.20) 1.21 (0.90-1.60) inconclusive 3.02 
2006 Boyld 231/221 All subjects >27.64 1.04 (0.80-1.40) 1.60 (1.20-2.20) inconclusive -10.98 
2006 Boyld 1,114 pairs  All subjects BMI (continuous) 1.01 (0.99-1.03) 1.04 (1.02-1.06) inconclusive -3.90 
2011 Harris 185/339 All subjects BMI at Age 18: <18.5 0.97 (0.79-1.20) 0.92 (0.75-1.14) inconclusive -1.74 
2011 Harris 314/559 All subjects BMI at Age 18: 18.5–19.9 1.03 (0.87-1.23) 0.96 (0.81-1.14) inconclusive 2.38 
2011 Harris 616/1124 All subjects BMI at Age 18: 20–22.4 1.00 Referent 1.00 Referent ~ ~ 
2011 Harris 238/449 All subjects BMI at Age 18: 22.5–24.9 0.96 (0.80-1.16) 1.07 (0.89-1.30) inconclusive 2.66 
2011 Harris 99/260 All subjects BMI at Age 18: ≥25 0.68 (0.52-0.87) 0.84 (0.65-1.09) negative 0.55 
2016 Rice 559/1727 NHS/NHSII, 
premenopausal at 
mammogram 
BMI, Per 5-unit increase 1.03 (0.92,1.16) 1.22 (1.07,1.39) inconclusive NM 
2016 Rice 731/1695 NHS/NHSII, 
postmenopausal at 
mammogram 
BMI, Per 5-unit increase 1.05 (0.95,1.16) 1.17 (1.05,1.30) inconclusive NM 
2016 Rice 559/1727 NHS/NHSII, 
premenopausal at 
mammogram 
BMI at Age 18, 
Per 5-unit increase 
0.80  (0.65, 0.97) 0.96 (0.78,1.19) negative 82%* 
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(cont.) Table 2.4a. Changes in the OR/RRs of BMI by adjustment for mammographic density  
Year First 
Author 
No. 
subjects 
Subjects Exposure 
BMI (kg/m2) 
Unadj. 
OR/RR 
95% CI Adj. 
OR/RR 
95% CI Sign of NIE PE 
/PM 
2016 Rice 731/1695 NHS/NHSII, 
postmenopausal at 
mammogram 
BMI at Age 18, 
Per 5-unit increase 
0.88 (0.74,1.05) 1.00 (0.83,1.19) negative 98% 
2018 Rice 1105/3192 NHS/NHSII, 
premenopausal at 
mammogram 
BMI, Per 5-unit increase 0.98 (0.92,1.05) 1.20 (1.10,1.29) inconclusive NM 
2018 Rice 2287/5690 NHS/NHSII, 
postmenopausal at 
mammogram 
BMI, Per 5-unit increase 1.14 (1.09,1.19) 1.33 (1.26,1.40) inconclusive NM 
2014 Andersen 12640 All subjects BMI at age 7 0.91 (0.83-0.99) 0.97 (0.88-1.06) negative 0.68 
2014 Andersen 12887 All subjects BMI at age 8 0.94 (0.86-1.02) 1.01 (0.92-1.11) inconclusive 1.16 
2014 Andersen 12968 All subjects BMI at age 9 0.91 (0.83-1.00) 0.99 (0.90-1.09) negative 0.89 
2014 Andersen 13014 All subjects BMI at age 10 0.92 (0.83-1.01) 1.01 (0.92-1.10) inconclusive 1.12 
2014 Andersen 13045 All subjects BMI at age 11 0.95 (0.87-1.04) 1.05 (0.95-1.14) inconclusive 1.95 
2014 Andersen 13050 All subjects BMI at age 12 0.92 (0.85-1.01) 1.02 (0.93-1.12) inconclusive 1.24 
2014 Andersen 13002 All subjects BMI at age 13 0.92 (0.84-1.00) 1.01 (0.93-1.11) inconclusive 1.12 
2014 Fejerman 304/809 All subjects 
(Mexican) 
BMI (continuous) 0.95 (0.93-0.98) 0.97 (0.94-1.00) negative 0.40 
Unadj.: Unadjusted; Adj.: adjusted; NIE (natural indirect effect); PE: proportion explained; PM: proportion mediated; NA: not 
available; NM: not mediated 
PE was estimated using the following formula: PE = [β(unadjusted)-β(adjusted)]/β(unadjusted) 
PM was reported in the selected studies, denoted as a percentage 
* p < 0.05, ** p < 0.01 
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Table 2.4b. Changes in the OR/RRs of weight/height by adjustment for mammographic density 
Year First 
Author 
No. 
subjects 
Subjects Exposure 
Somatotype 
Unadj. 
OR/RR 
95% CI Adj. 
OR/RR 
95% CI Sign of NIE PE 
Index 
1984 Brisson 23/63 Premenopausal Body weight (kg) <55 1.00 Referent 1.00 Referent ~ ~ 
1984 Brisson 39/113 Premenopausal Body weight (kg) 55-64 0.90 (0.50-1.70) 1.10 (0.60-2.20) inconclusive 1.90 
1984 Brisson 28/49 Premenopausal Body weight (kg) 65-74 1.50 (0.70-3.10) 2.60 (1.20-5.90) inconclusive -1.36 
1984 Brisson 14/31 Premenopausal Body weight (kg) ≥75 1.20 (0.50-2.80) 2.70 (1.00-7.20) inconclusive -4.45 
2006 Boyld 162 pairs Premenopausal Weight (kg) 0.99 (0.97-1.01) 1.00 (0.98-1.03) inconclusive 1.30 
1984 Brisson 46/96 Postmenopausal Body weight (kg) <55 1.00 Referent 1.00 Referent ~ ~ 
1984 Brisson 90/172 Postmenopausal Body weight (kg) 55-64 1.10 (0.70-1.80) 1.30 (0.80-2.10) inconclusive -1.75 
1984 Brisson 64/88 Postmenopausal Body weight (kg) 65-74 1.50 (0.90-2.60) 2.10 (1.20-3.70) inconclusive -0.83 
1984 Brisson 55/73 Postmenopausal Body weight (kg) ≥75 1.60 (1.00-2.70) 2.60 (1.40-4.60) inconclusive -1.03 
2000 Lam 298/1241 Postmenopausal weight ≤63 kg 1.00 Referent 1.00 Referent ~ ~ 
2000 Lam 298/1241 Postmenopausal 63.1–70.0 kg 1.50 (1.00-2.30) 1.60 (1.10-2.50) inconclusive -0.16 
2000 Lam 298/1241 Postmenopausal 70.1–81 kg 1.60 (1.10-2.40) 1.90 (1.20-2.80) inconclusive -0.37 
2000 Lam 298/1241 Postmenopausal weight >81 kg 1.70 (1.20-2.60) 2.10 (1.30-3.20) inconclusive -0.40 
2006 Boyld 727 pairs Postmenopausal Weight (kg) 1.01 (1.00-1.02) 1.02 (1.01-1.03) inconclusive -1.20 
1984 Brisson 69/160 All subjects Body weight (kg) <55 1.00 Referent 1.00 Referent ~ ~ 
1984 Brisson 129/285 All subjects Body weight (kg) 55-64 1.10 (0.70-1.50) 1.30 (0.90-1.80) inconclusive -1.75 
1984 Brisson 94/137 All subjects Body weight (kg) 65-74 1.60 (1.10-2.40) 2.30 (1.50-3.70) inconclusive -0.77 
1984 Brisson 70/104 All subjects Body weight (kg) ≥75 1.50 (1.00-2.40) 2.70 (1.60-4.40) inconclusive -1.45 
2006 Boyld 1,114 pairs All subjects Weight (kg) 1.00 (1.00-1.01) 1.01 (1.01-1.02) inconclusive -3.34 
2014 Andersen 8,271 All subjects Birth weight (g) 0.89 (0.75-1.06) 0.88 (0.74-1.05) inconclusive -0.10 
2016 Rice 559/1727 NHS/NHSII, premenopausal 
at mammogram 
Weight change since 18, 
Per 20-lb increase 
1.03 (0.96,1.12) 1.16 (1.06,1.26) inconclusive NM 
2016 Rice 731/1695 NHS/NHSII, postmenopausal 
at mammogram 
Weight change since 18, 
Per 20-lb increase 
1.03 (0.96,1.10) 1.11 (1.03,1.19) inconclusive NM 
2016 Rice 559/1727 NHS/NHSII, premenopausal 
at mammogram 
Height 
Per 3-inch increase 
1.14 (1.01,1.28) 1.14 (1.01,1.29) inconclusive NM 
2016 Rice 731/1695 NHS/NHSII, postmenopausal 
at mammogram 
Height 
Per 3-inch increase 
0.95 (0.85,1.06) 0.96 (0.86,1.07) negative 22% 
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(cont.) Table 2.4b. Changes in the OR/RRs of weight/height by adjustment for mammographic density 
Year First 
Author 
No. 
subjects 
Subjects Exposure 
Somatotype 
Unadj. 
OR/RR 
95% CI Adj. 
OR/RR 
95% CI Sign of NIE PE 
Index 
2018 Rice 1060/3018 NHS/NHSII, premenopausal 
at mammogram 
Height 
Per 3-inch increase 
1.02 (0.94,1.11) 1.04 (0.96,1.13) inconclusive NM 
2018 Rice 2114/4938 NHS/NHSII, postmenopausal 
at mammogram 
Height 
Per 3-inch increase 
1.06 (0.99,1.12) 1.08 (1.02,1.15) inconclusive NM 
1984 Brisson 69/94 All subjects Body height (cm) <155 1.00 Referent 1.00 Referent ~ ~ 
1984 Brisson 99/208 All subjects Body height (cm) 155-159 0.60 (0.40-0.90) 0.60 (0.40-0.90) inconclusive 0.00 
1984 Brisson 90/197 All subjects Body height (cm) 160-164 0.60 (0.40-0.90) 0.50 (0.30-0.80) inconclusive -0.36 
1984 Brisson 104/187 All subjects Body height (cm) ≥165 0.80 (0.50-1.20) 0.70 (0.40-0.90) inconclusive -0.60 
2014 Fejerman 304/809 All subjects (Mexican) Height (cm)  1.03 (1.00-1.05) 1.02 (1.00-1.05) positive 0.12 
2014 Andersen 12,636 All subjects Height (cm) age 7 1.06 (0.98-1.14) 1.06 (0.99-1.15) inconclusive 0.00 
2014 Andersen 12,882 All subjects Height (cm) age 8 1.05 (0.98-1.14) 1.06 (0.98-1.14) inconclusive -0.19 
2014 Andersen 12,963 All subjects Height (cm) age 9 1.05 (0.97-1.13) 1.06 (0.98-1.14) inconclusive -0.19 
2014 Andersen 13,011 All subjects Height (cm) age 10 1.05 (0.97-1.13) 1.06 (0.98-1.14) inconclusive -0.19 
2014 Andersen 13,039 All subjects Height (cm) age 11 1.05 (0.98-1.14) 1.07 (0.99-1.15) inconclusive -0.39 
2014 Andersen 13,044 All subjects Height (cm) age 12 1.07 (0.99-1.15) 1.08 (1.01-1.16) inconclusive -0.14 
2014 Andersen 12,991 All subjects Height (cm) age 13 1.08 (1.00-1.16) 1.09 (1.01-1.17) inconclusive -0.12 
2006 Boyld 1,114 pairs All subjects Height (cm) 1.00 (0.99-1.01) 1.00 (0.99-1.01) positive 0.14 
2006 Boyld 162 pairs Premenopausal Height (cm) 1.00 (0.97-1.03) 1.01 (0.97-1.04) inconclusive -21.00 
2006 Boyld 727 pairs Postmenopausal Height (cm) 1.01 (0.99-1.03) 1.01 (0.99-1.03) positive 0.12 
Unadj.: Unadjusted; Adj.: adjusted; NIE (natural indirect effect); PE: proportion explained; PM: proportion mediated; NM: not 
mediated 
PE was estimated using the following formula: PE = [β(unadjusted)-β(adjusted)]/β(unadjusted) 
PM was reported in the paper, denoted as a percentage.  
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Table 2.4c. Changes in the OR/RRs of childhood and adolescent body fatness by adjustment for mammographic density 
Year First 
Author 
No. 
subjects 
Subjects Exposure Exposure Unadj. 
OR/RR 
95% CI Adj. 
OR/RR 
95% CI Sign of NIE PE 
Index 
2010 Jingmei 
Li 
902/862 postmenopausal, 
all 
Somatotype at age 7 Lean (1-2) 1.00 Referent 1.00 Referent ~ ~ 
2010 Jingmei 
Li 
353/428 postmenopausal, 
all 
Somatotype at age 7 Medium (3-4) 0.79 (0.66-0.94) 0.79 (0.66-0.94) inconclusive 0.00 
2010 Jingmei 
Li 
79/108 postmenopausal, 
all 
Somatotype at age 7 Large (5-9) 0.66 (0.48-0.90) 0.67 (0.49-0.92) negative 0.04 
2010 Jingmei 
Li 
510/862 postmenopausal, 
ER-positive 
Somatotype at age 7 Lean (1-2) 1.00 Referent 1.00 Referent ~ ~ 
2010 Jingmei 
Li 
200/428 postmenopausal, 
ER-positive 
Somatotype at age 7 Medium (3-4) 0.79 (0.65-0.98) 0.80 (0.65-0.98) negative 0.05 
2010 Jingmei 
Li 
49/108 postmenopausal, 
ER-positive 
Somatotype at age 7 Large (5-9) 0.73 (0.50-1.04) 0.75 (0.52-1.08) negative 0.09 
2010 Jingmei 
Li 
100/862 postmenopausal, 
ER-negative 
Somatotype at age 7 Lean (1-2) 1.00 Referent 1.00 Referent ~ ~ 
2010 Jingmei 
Li 
34/428 postmenopausal, 
ER-negative 
Somatotype at age 7 Medium (3-4) 0.66 (0.43-0.99) 0.66 (0.44-1.01) inconclusive 0.00 
2010 Jingmei 
Li 
5/108 postmenopausal, 
ER-negative 
Somatotype at age 7 Large (5-9) 0.34 (0.14-0.87) 0.36 (0.14-0.90) negative 0.05 
2010 Jingmei 
Li 
445/862 postmenopausal, 
PR-positive 
Somatotype at age 7 Lean (1-2) 1.00 Referent 1.00 Referent ~ ~ 
2010 Jingmei 
Li 
170/428 postmenopausal, 
PR-positive 
Somatotype at age 7 Medium (3-4) 0.77 (0.62-0.95) 0.77 (0.62-0.96) inconclusive 0.00 
2010 Jingmei 
Li 
44/108 postmenopausal, 
PR-positive 
Somatotype at age 7 Large (5-9) 0.73 (0.50-1.07) 0.76 (0.52-1.12) negative 0.13 
2010 Jingmei 
Li 
155/862 postmenopausal, 
PR-negative 
Somatotype at age 7 Lean (1-2) 1.00 Referent 1.00 Referent ~ ~ 
2010 Jingmei 
Li 
59/428 postmenopausal, 
PR-negative 
Somatotype at age 7 Medium (3-4) 0.77 (0.55-1.06) 0.77 (0.56-1.07) inconclusive 0.00 
2010 Jingmei 
Li 
9/108 postmenopausal, 
PR-negative 
Somatotype at age 7 Large (5-9) 0.43 (0.21-0.87) 0.44 (0.21-0.89) negative 0.03 
2016 Rice 559/1727 NHS/NHSII, 
premenopausal 
at mammogram 
Childhood somatotype Per 1-unit 
increase 
0.93 (0.86,1.01) 0.98 (0.90,1.07) negative 71 % 
2016 Rice 731/1695 NHS/NHSII, 
postmenopausal 
at mammogram 
Childhood somatotype Per 1-unit 
increase 
0.89 (0.83,0.96) 0.92 (0.85,0.99) negative 26 %** 
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(cont.) Table 2.4c. Changes in the OR/RRs of childhood and adolescent body fatness by adjustment for mammographic density 
Year First 
Author 
No. 
subjects 
Subjects Exposure Exposure Unadj. 
OR/RR 
95% CI Adj. 
OR/RR 
95% CI Sign of NIE PE 
Index 
2016 Rice 559/1727 NHS/NHSII, 
premenopausal 
at mammogram 
Adolescent somatotype Per 1-unit 
increase 
0.90 (0.82,0.99) 0.97  0.88,1.07) negative 73 %* 
2016 Rice 731/1695 NHS/NHSII, 
postmenopausal 
at mammogram 
Adolescent somatotype Per 1-unit 
increase 
0.86 (0.80,0.93) 0.90 (0.83,0.97) negative 26 %** 
2011 Harris 456/725 All subjects Body Fatness (ages 5–10) 1 1.00 Referent 1.00 Referent ~ ~ 
2011 Harris 433/758 All subjects Body Fatness (ages 5–10) 1.5–2 0.92 (0.77-1.09) 0.91 (0.77-1.08) inconclusive -0.13 
2011 Harris 294/564 All subjects Body Fatness (ages 5–10) 2.5–3 0.85 (0.70-1.02) 0.89 (0.74-1.08) negative 0.28 
2011 Harris 183/416 All subjects Body Fatness (ages 5–10) 3.5–4 0.73 (0.59-0.90) 0.83 (0.66-1.03) negative 0.41 
2011 Harris 119/290 All subjects Body Fatness (ages 5–10) ≥4.5 0.67 (0.52-0.86) 0.77 (0.60-0.99) negative 0.35 
2011 Harris 456/725 All subjects Body Fatness (ages 11–20) 1 1.00 Referent 1.00 Referent ~ ~ 
2011 Harris 433/758 All subjects Body Fatness (ages 11–20) 1.5–2 0.85 (0.67-1.07) 0.84 (0.66-1.06) inconclusive -0.07 
2011 Harris 294/564 All subjects Body Fatness (ages 11–20) 2.5–3 0.79 (0.62-0.99) 0.82 (0.64-1.03) negative 0.16 
2011 Harris 183/416 All subjects Body Fatness (ages 11–20) 3.5–4 0.73 (0.57-0.94) 0.82 (0.64-1.06) negative 0.37 
2011 Harris 119/290 All subjects Body Fatness (ages 11–20) ≥4.5 0.58 (0.44-0.78) 0.71 (0.53-0.95) negative 0.37 
Unadj.: Unadjusted; Adj.: adjusted; NIE (natural indirect effect); PE: proportion explained; PM: proportion mediated; 
PE was estimated using the following formula: PE = [β(unadjusted)-β(adjusted)]/β(unadjusted) 
PM was reported in the paper, denoted as a percentage.  
* p < 0.05, ** p < 0.01 
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Table 2.5. Changes in the OR/RRs of reproductive factors by adjustment for mammographic density 
Year First 
Author 
No. 
subjects 
Subjects Exposure Unadj. 
OR/RR 
95% CI Adj. 
OR/RR 
95% CI Sign of NIE PE 
Index 
2005 Tice 81,777 All subjects, diverse 
racial/ethnic groups 
Age at menarche, ≥14 1.00 Referent 1.00 Referent ~ ~ 
2005 Tice 81,777 All subjects, diverse 
racial/ethnic groups 
Age at menarche, 12-13 0.98 (0.83-1.15) 1.01 (0.86-1.19) inconclusive 1.49 
2005 Tice 81,777 All subjects, diverse 
racial/ethnic groups 
Age at menarche, <12 0.96 (0.69-1.33) 1.02 (0.73-1.41) inconclusive 1.49 
2016 Rice 559/1727 NHS/NHSII, premenopausal 
at mammogram 
Age at menarche 
Per 2-year increase 
0.85 (0.74-0.98) 0.83 (0.72-0.96) inconclusive NM 
2016 Rice 731/1695 NHS/NHSII, postmenopausal 
at mammogram 
Age at menarche 
Per 2-year increase 
0.92 (0.80,1.05) 0.93 (0.81,1.06) negative 11 % 
2018 Rice 573/2018 NHS/NHSII, premenopausal 
at mammogram 
Age at menarche 
Per 2-year increase 
0.86 (0.75,1.00) 0.84 (0.73,0.98) inconclusive NM 
2018 Rice 1197/3002 NHS/NHSII, postmenopausal 
at mammogram 
Age at menarche 
Per 2-year increase 
0.96 (0.87,1.07) 0.95 (0.85,1.06) inconclusive NM 
2016 Rice 559/1727 NHS/NHSII, premenopausal 
at mammogram 
Nulliparous vs parous 1.15 (0.86,1.52) 1.07 (0.80,1.42) positive 52 % 
2016 Rice 731/1695 NHS/NHSII, postmenopausal 
at mammogram 
Nulliparous vs parous 1.22 (0.88,1.69) 1.12 (0.80,1.56) positive 43 % 
2018 Rice 1095/3180 NHS/NHSII, premenopausal 
at mammogram 
Nulliparous vs parous 1.14 (0.96,1.35) 1.08 (0.91,1.29) positive 40 % 
2018 Rice 2158/5575 NHS/NHSII, postmenopausal 
at mammogram 
Nulliparous vs parous 1.23 (1.07,1.41) 1.13 (0.98,1.29) positive 43 %** 
2016 Rice 559/1727 NHS/NHSII, premenopausal 
at mammogram 
Parity (among parous) 
Per one-child increase 
1.00 (0.90,1.12) 1.03 (0.92,1.16) inconclusive NM 
2016 Rice 731/1695 NHS/NHSII, postmenopausal 
at mammogram 
Parity (among parous) 
Per one-child increase 
1.02 (0.95,1.09) 1.03 (0.96,1.11) inconclusive NM 
2018 Rice 499/1697 NHS/NHSII, premenopausal 
at mammogram 
Parity (among parous) 
Per one-child increase 
0.98 (0.87,1.09) 1.00 (0.89,1.12) inconclusive NM 
2018 Rice 1028/2713 NHS/NHSII, postmenopausal 
at mammogram 
Parity (among parous) 
Per one-child increase 
0.99 (0.93,1.06) 1.01 (0.95,1.08) inconclusive NM 
2016 Rice 559/1727 NHS/NHSII, premenopausal 
at mammogram 
Age at first birth (among 
parous) 
Per 5-year increase 
1.18 (1.03,1.36) 1.18 (1.02,1.36) positive 3% 
2016 Rice 731/1695 NHS/NHSII, postmenopausal 
at mammogram 
Age at first birth (among 
parous) 
1.23 (1.07,1.41) 1.19 (1.04,1.38) positive 13%* 
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(cont.) Table 2.5. Changes in the OR/RRs of reproductive factors by adjustment for mammographic density 
Year First 
Author 
No. 
subjects 
Subjects Exposure Unadj. 
OR/RR 
95% CI Adj. 
OR/RR 
95% CI Sign of NIE PE 
Index 
Per 5-year increase 
2018 Rice 802/2480 NHS/NHSII, premenopausal 
at mammogram 
Age at first birth ≥ 30 versus 
< 30 
1.32 (1.09,1.60) 1.30 (1.08,1.58) positive 5% 
2018 Rice 1727/4619 NHS/NHSII, postmenopausal 
at mammogram 
Age at first birth ≥ 30 versus 
< 30 
1.26 (1.08,1.47) 1.21 (1.03,1.42) positive 16% 
2016 Rice 559/1727 NHS/NHSII, premenopausal 
at mammogram 
Breastfeeding (among 
parous) 
Ever vs never 
0.99 (0.76,1.28) 1.00 (0.77,1.30) negative 89% 
2016 Rice 731/1695 NHS/NHSII, postmenopausal 
at mammogram 
Breastfeeding (among 
parous) 
Ever vs never 
0.96 (0.79,1.16) 0.97 (0.80,1.17) negative 22% 
2016 Rice 559/1727 NHS/NHSII, premenopausal 
at mammogram 
Breastfeeding (among 
parous who ever breastfed) 
Per 12-month increase 
0.95 (0.81,1.11) 0.93 (0.80,1.08) inconclusive NM 
2016 Rice 731/1695 NHS/NHSII, postmenopausal 
at mammogram 
Breastfeeding (among 
parous who ever breastfed) 
Per 12-month increase 
1.25 (1.06,1.46) 1.25 (1.06,1.47) inconclusive NM 
2016 Rice 559/1727 NHS/NHSII, premenopausal 
at mammogram 
Birth index 
Per 102-unit increase 
0.66 (0.43,1.01) 0.77 (0.50,1.19) negative 38% 
2016 Rice 731/1695 NHS/NHSII, postmenopausal 
at mammogram 
Birth index 
Per 102-unit increase 
0.96 (0.73,1.25) 1.04 (0.79,1.36) inconclusive NM 
2016 Rice 731/1695 NHS/NHSII, postmenopausal 
at mammogram 
Age at menopause 
Per 4-year increase 
1.12 (1.05,1.20) 1.12 (1.04,1.19) positive 5% 
2018 Rice 1948/4646 NHS/NHSII, postmenopausal 
at mammogram 
Age at menopause 
Per category increase 
1.07 (1.02,1.13) 1.07 (1.02,1.13) positive 1% 
2005 Tice 81,777 All subjects, diverse 
racial/ethnic groups 
Age at 1st birth, # of 1st 
degree relatives: <20 yrs, 
n=0 
1.00 Referent 1.00 Referent ~ ~ 
2005 Tice 81,777 All subjects, diverse 
racial/ethnic groups 
Age at 1st birth, # of 1st 
degree relatives: 20-24 yrs, 
n=0  
1.27 (1.09-1.48) 1.22 (1.05-1.42) positive 0.17 
2005 Tice 81,777 All subjects, diverse 
racial/ethnic groups 
Age at 1st birth, # of 1st 
degree relatives: 25-29 yrs, 
n=0 
1.62 (1.20-2.18) 1.50 (1.10-2.03) positive 0.16 
2005 Tice 81,777 All subjects, diverse 
racial/ethnic groups 
Age at 1st birth, # of 1st 
degree relatives: 30+ yrs, 
n=0 
2.05 (1.31-3.22) 1.83 (1.16-2.89) positive 0.16 
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(cont.) Table 2.5. Changes in the OR/RRs of reproductive factors by adjustment for mammographic density 
Year First 
Author 
No. 
subjects 
Subjects Exposure Unadj. 
OR/RR 
95% CI Adj. 
OR/RR 
95% CI Sign of NIE PE 
Index 
2012  Woolcott 1699/2422 All subjects, 74% 
postmenopausal, pooled 
Ethnic groups 
Age at first birth (parous), 
<26 years 
1.00 Referent 1.00 Referent ~ ~ 
2012  Woolcott 1699/2422 All subjects, 74% 
postmenopausal, pooled 
Ethnic groups 
Age at first birth (parous), ≥ 
26 
1.08 (0.93-1.26) 1.05 NA positive 0.37 
2012  Woolcott 1699/2422 All subjects, 74% 
postmenopausal, pooled 
Ethnic groups 
No. of children, 0 1.00 Referent 1.00 Referent ~ ~ 
2012  Woolcott 1699/2422 All subjects, 74% 
postmenopausal, pooled 
Ethnic groups 
No. of children, 1–2 0.76 (0.62–
0.93) 
0.79 NA negative 0.14 
2012  Woolcott 1699/2422 All subjects, 74% 
postmenopausal, pooled 
Ethnic groups 
No. of children, ≥ 3 0.65 (0.53–
0.80) 
0.70 NA negative 0.17 
2012  Woolcott 1699/2422 All subjects, 74% 
postmenopausal, pooled 
Ethnic groups 
No. of children, age at first 
birth, Nulliparous 
1.00 Referent 1.00 Referent ~ ~ 
2012  Woolcott 1699/2422 All subjects, 74% 
postmenopausal, pooled 
Ethnic groups 
1–2 children, AFB < 26 yr 0.74 (0.59-0.93) 0.78 NA negative 0.17 
2012  Woolcott 1699/2422 All subjects, 74% 
postmenopausal, pooled 
Ethnic groups 
1–2 children, AFB ≥ 26 yr 0.77 (0.62-0.97) 0.80 NA negative 0.15 
2012  Woolcott 1699/2422 All subjects, 74% 
postmenopausal, pooled 
Ethnic groups 
≥ 3 children, AFB < 26 yr 0.66 (0.53-0.81) 0.71 NA negative 0.18 
2012  Woolcott 1699/2422 All subjects, 74% 
postmenopausal, pooled 
Ethnic groups 
≥ 3 children, AFB ≥ 26 yr 0.64 (0.48-0.85) 0.69 NA negative 0.17 
2014 Fejerman 304/809 All subjects (Mexican) Parity 0.87 (0.81-0.93) 0.88 (0.82-0.95) negative 0.12 
2014 Fejerman 304/809 All subjects (Mexican) Breast feeding 0.76 (0.53-1.12) 0.77 (0.53-1.13) negative 0.04 
Unadj.: Unadjusted; Adj.: adjusted; NIE (natural indirect effect); PE: proportion explained; PM: proportion mediated; NA: not 
available; NM: not mediated 
PE was estimated using the following formula: PE = [β(unadjusted)-β(adjusted)]/β(unadjusted) 
PM was reported in the paper, denoted as a percentage.  
* p < 0.05, ** p < 0.01  
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Table 2.6. Changes in the OR/RRs of exogenous hormone use and circulating sex hormone or antioxidants by adjustment for 
mammographic density 
 
Year First 
Author 
No. 
subjects 
Subjects Exposure Unadj. 
OR/RR 
95% CI Adj. 
OR/RR 
95% CI Sign of NIE PE Index 
2006 Boyld 107/112 NBSS (n = 416) Hormone use, Never 1.00 Referent 1.00 Referent ~ ~ 
2006 Boyld 52/59 NBSS (n = 416) Hormone use, Past 0.99 (0.61-1.61) 1.04 (0.64-1.69) inconclusive 4.90 
2006 Boyld 45/41 NBSS (n = 416) Hormone use, Current 1.13 (0.68-1.88) 1.12 (0.66-1.87) positive 0.07 
2006 Boyld 190/215 OBSP (n = 708) Hormone use, Never 1.00 Referent 1.00 Referent ~ ~ 
2006 Boyld 57/44 OBSP (n = 708) Hormone use, Past 1.48 (0.95-2.32) 1.47 (0.93-2.32) positive 0.02 
2006 Boyld 103/99 OBSP (n = 708) Hormone use, Current 1.20 (0.85-1.71) 1.12 (0.78-1.60) positive 0.38 
2006 Boyld 171/191 SMPBC (n = 617) Hormone use, Never 1.00 Referent 1.00 Referent ~ ~ 
2006 Boyld 65/52 SMPBC (n = 617) Hormone use, Past 1.43 (0.93-2.22) 1.39 (0.90-2.16) positive 0.08 
2006 Boyld 75/63 SMPBC (n = 617) Hormone use, Current 1.50 (0.99-2.27) 1.44 (0.95-2.18) positive 0.10 
2006 Boyld 468/518 Combined (n = 1,741) Hormone use, Never 1.00 Referent 1.00 Referent ~ ~ 
2006 Boyld 174/155 Combined (n = 1,741) Hormone use, Past 1.27 (0.98-1.64) 1.27 (0.98-1.65) inconclusive 0.00 
2006 Boyld 223/203 Combined (n = 1,741) Hormone use, Current 1.26 (1.00-1.59) 1.19 (0.94-1.51) positive 0.25 
2016 Rice 731/1695 NHS/NHSII,  
postmenopausal at mammogram 
Hormone replacement therapy 
use 
Past vs never 
1.18 (0.91,1.53) 1.12 (0.86,1.46) positive 31% 
2016 Rice 731/1695 NHS/NHSII,  
postmenopausal at mammogram 
Hormone replacement therapy 
use 
Current vs never 
1.71 (1.37,2.13) 1.52 (1.22,1.90) positive 22%** 
2018 Rice 1993/5083 NHS/NHSII,  
postmenopausal at mammogram 
Hormone replacement therapy 
use 
Current vs never/former 
1.39 (1.24,1.55) 1.23 (1.10,1.37) positive 37% ** 
2018 Azam 299/4272 DCH (n = 4501), postmenopausal Hormone use, Never 1.00 Referent 1.00 Referent ~ ~ 
2018 Azam 299/4272 DCH (n = 4501), postmenopausal Hormone use, Ever 1.56 (1.19-2.04) 1.49 (1.13-1.95) positive 11% (4–30%) 
2018 Azam 299/4272 DCH (n = 4501), postmenopausal Hormone use, Current 1.87 (1.40-2.48) 1.76 (1.32-2.34) positive 10% (4-22%)* 
2018 Azam 299/4272 DCH (n = 4501), postmenopausal Hormone use, Never 1.00 Referent 1.00 Referent ~ ~ 
2018 Azam 299/4272 DCH (n = 4501), postmenopausal Estrogen 0.99 (0.59-1.65) 0.94 (0.56-1.57) inconclusive -5.16 
2018 Azam 299/4272 DCH (n = 4501), postmenopausal Sequential estrogen/progestin 2.09 (1.48-2.97) 1.94 (1.37-2.69) positive 0.10 
2018 Azam 299/4272 DCH (n = 4501), postmenopausal Continuous estrogen/progestin 3.39 (2.20-5.22) 3.21 (2.08-4.94) positive 0.04 
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(cont.) 
Table 2.6. Changes in the OR/RRs of exogenous hormone use and circulating sex hormone or antioxidants by adjustment for 
mammographic density 
 
Year First 
Author 
No. 
subjects 
Subjects Exposure Unadj. 
OR/RR 
95% CI Adj. 
OR/RR 
95% CI Sign of NIE PE Index 
2018 Rice 1447/4077 NHS/NHSII,  
postmenopausal at mammogram 
Hormone replacement therapy 
use 
Current E vs never/former 
1.16 (1.00,1.34) 1.05 (0.90,1.22) positive 69% 
2018 Rice 1628/4076 NHS/NHSII,  
postmenopausal at mammogram 
Hormone replacement therapy 
use 
Current E+P vs never/former 
1.66 (1.45,1.90) 1.46 (1.27,1.67) positive 26%** 
2014 Schoemaker 265/343 postmenopausal Oestradiol Q1 1.00 Referent 1.00 Referent ~ ~ 
2014 Schoemaker 265/343 postmenopausal Oestradiol Q2 1.18 (0.67-2.09) 1.21 (0.68-2.16) inconclusive -0.15 
2014 Schoemaker 265/343 postmenopausal Oestradiol Q3 1.51 (0.83-2.75) 1.49 (0.81-2.75) positive 0.03 
2014 Schoemaker 265/343 postmenopausal Oestradiol Q4 2.07 (1.11-3.84) 2.03 (1.08-3.81) positive 0.03 
2014 Schoemaker 265/343 postmenopausal Free oestradiol Q1 1.00 Referent 1.00 Referent ~ ~ 
2014 Schoemaker 265/343 postmenopausal Free oestradiol Q2 1.32 (0.74-2.36) 1.46 (0.81-2.63) inconclusive -0.36 
2014 Schoemaker 265/343 postmenopausal Free oestradiol Q3 1.72 (0.95-3.13) 1.78 (0.97-3.27) inconclusive -0.06 
2014 Schoemaker 265/343 postmenopausal Free oestradiol Q4 2.42 (1.27-4.61) 2.48 (1.29-4.78) inconclusive -0.03 
2014 Schoemaker 265/343 postmenopausal Testosterone Q1 1.00 Referent 1.00 Referent ~ ~ 
2014 Schoemaker 265/343 postmenopausal Testosterone Q2 1.34 (0.75-2.37) 1.21 (0.67-2.18) positive 0.35 
2014 Schoemaker 265/343 postmenopausal Testosterone Q3 1.42 (0.79-2.52) 1.36 (0.76-2.44) positive 0.12 
2014 Schoemaker 265/343 postmenopausal Testosterone Q4 2.11 (1.20-3.70) 2.01 (1.14-3.54) positive 0.07 
2014 Schoemaker 265/343 postmenopausal Free testosterone Q1 1.00 Referent 1.00 Referent ~ ~ 
2014 Schoemaker 265/343 postmenopausal Free testosterone Q2 1.47 (0.82-2.64) 1.53 (0.85-2.76) inconclusive -0.10 
2014 Schoemaker 265/343 postmenopausal Free testosterone Q3 1.82 (1.01-3.28) 1.87 (1.03-3.40) inconclusive -0.05 
2014 Schoemaker 265/343 postmenopausal Free testosterone Q4 2.07 (1.15-3.74) 2.15 (1.18-3.91) inconclusive -0.05 
2014 Schoemaker 265/343 postmenopausal SHBG Q1 1.00 Referent 1.00 Referent ~ ~ 
2014 Schoemaker 265/343 postmenopausal SHBG Q2 1.10 (0.63-1.90) 1.11 (0.63-1.95) inconclusive -0.09 
2014 Schoemaker 265/343 postmenopausal SHBG Q3 0.86 (0.48-1.56) 0.74 (0.40-1.37) inconclusive -1.00 
2014 Schoemaker 265/343 postmenopausal SHBG Q4 0.64 (0.35-1.20) 0.58 (0.31-1.10) inconclusive -0.22 
2007 Tamimi 253/520 postmenopausal Plasma Estradiol Q1 1.00 Referent 1.00 Referent ~ ~ 
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(cont.) 
Table 2.6. Changes in the OR/RRs of exogenous hormone use and circulating sex hormone or antioxidants by adjustment for 
mammographic density 
 
Year First 
Author 
No. 
subjects 
Subjects Exposure Unadj. 
OR/RR 
95% CI Adj. 
OR/RR 
95% CI Sign of NIE PE Index 
2007 Tamimi 253/520 postmenopausal Plasma Estradiol Q2 1.20 (0.80-2.00) 1.20 (0.80-2.00) inconclusive 0.00 
2007 Tamimi 253/520 postmenopausal Plasma Estradiol Q3 1.20 (0.80-2.00) 1.30 (0.80-2.10) inconclusive -0.44 
2007 Tamimi 253/520 postmenopausal Plasma Estradiol Q4 adj. for 
Current BMI 
2.40 (1.40-3.90) 2.40 (1.40-4.00) inconclusive 0.00 
2007 Tamimi 253/520 postmenopausal Plasma Estradiol Q4 adj. for BMI 
at age 18 
2.40 (1.50-3.80) 2.90 (1.80-4.60) inconclusive -0.22 
2007 Tamimi 253/520 postmenopausal Free Estradiol Q1 1.00 Referent 1.00 Referent ~ ~ 
2007 Tamimi 253/520 postmenopausal Free Estradiol Q2 1.10 (0.60-1.70) 1.10 (0.70-1.90) inconclusive 0.00 
2007 Tamimi 253/520 postmenopausal Free Estradiol Q3 1.30 (0.70-2.10) 1.40 (0.80-2.40) inconclusive -0.28 
2007 Tamimi 253/520 postmenopausal Free Estradiol Q4 2.20 (1.30-3.70) 2.30 (1.30-4.00) inconclusive -0.06 
2007 Tamimi 253/520 postmenopausal Testosterone Q1 1.00 Referent 1.00 Referent ~ ~ 
2007 Tamimi 253/520 postmenopausal Testosterone Q2 0.80 (0.50-1.30) 0.80 (0.50-1.40) inconclusive 0.00 
2007 Tamimi 253/520 postmenopausal Testosterone Q3 1.40 (0.90-2.20) 1.40 (0.90-2.30) inconclusive 0.00 
2007 Tamimi 253/520 postmenopausal Testosterone Q4 1.80 (1.20-2.90) 2.00 (1.20-3.10) inconclusive -0.18 
2007 Tamimi 253/520 postmenopausal Free testosterone Q1 1.00 Referent 1.00 Referent ~ ~ 
2007 Tamimi 253/520 postmenopausal Free testosterone Q2 1.50 (0.90-2.50) 1.50 (0.90-2.50) inconclusive 0.00 
2007 Tamimi 253/520 postmenopausal Free testosterone Q3 1.70 (1.00-2.80) 1.70 (1.00-2.80) inconclusive 0.00 
2007 Tamimi 253/520 postmenopausal Free testosterone Q4 2.20 (1.30-3.60) 2.20 (1.30-3.80) inconclusive 0.00 
2009 Tamimi 604/626 postmenopausal α-Carotene Quin1 1.00 Referent 1.00 Referent ~ ~ 
2009 Tamimi 604/626 postmenopausal α-Carotene Quin2 1.10 (0.80-1.60) 1.10 (0.70-1.60) inconclusive 0.00 
2009 Tamimi 604/626 postmenopausal α-Carotene Quin3 1.10 (0.80-1.60) 1.00 (0.70-1.50) positive 1.00 
2009 Tamimi 604/626 postmenopausal α-Carotene Quin4 0.80 (0.60-1.20) 0.70 (0.50-1.10) inconclusive -0.60 
2009 Tamimi 604/626 postmenopausal α-Carotene Quin5 0.70 (0.40-1.00) 0.60 (0.40-0.90) inconclusive -0.43 
2009 Tamimi 604/626 postmenopausal β-Carotene Quin1 1.00 Referent 1.00 Referent ~ ~ 
2009 Tamimi 604/626 postmenopausal β-Carotene Quin2 1.30 (0.90-1.80) 1.30 (0.90-1.80) inconclusive 0.00 
2009 Tamimi 604/626 postmenopausal β-Carotene Quin3 1.40 (1.00-2.10) 1.30 (0.90-2.00) positive 0.22 
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(cont.) 
Table 2.6. Changes in the OR/RRs of exogenous hormone use and circulating sex hormone or antioxidants by adjustment for 
mammographic density 
 
Year First 
Author 
No. 
subjects 
Subjects Exposure Unadj. 
OR/RR 
95% CI Adj. 
OR/RR 
95% CI Sign of NIE PE Index 
2009 Tamimi 604/626 postmenopausal β-Carotene Quin4 0.90 (0.60-1.40) 0.90 (0.60-1.30) inconclusive 0.00 
2009 Tamimi 604/626 postmenopausal β-Carotene Quin5 0.60 (0.40-1.00) 0.60 (0.40-0.90) inconclusive 0.00 
2009 Tamimi 604/626 postmenopausal Total carotenoids Quin1 1.00 Referent 1.00 Referent ~ ~ 
2009 Tamimi 604/626 postmenopausal Total carotenoids Quin2 1.10 (0.80-1.50) 1.00 (0.70-1.50) positive 1.00 
2009 Tamimi 604/626 postmenopausal Total carotenoids Quin3 1.20 (0.80-1.70) 1.10 (0.70-1.60) positive 0.48 
2009 Tamimi 604/626 postmenopausal Total carotenoids Quin4 0.80 (0.50-1.10) 0.70 (0.50-1.00) inconclusive -0.60 
2009 Tamimi 604/626 postmenopausal Total carotenoids Quin5 0.70 (0.50-1.00) 0.60 (0.40-0.90) inconclusive -0.43 
Unadj.: Unadjusted; Adj.: adjusted; NIE (natural indirect effect); PE: proportion explained; PM: proportion mediated; NA: not 
available; CMSP: Copenhagen mammography screening program; Q1: the first quartile; Quin1: the first quintile 
PE was estimated using the following formula: PE = [β(unadjusted)-β(adjusted)]/β(unadjusted) 
PM was reported in the paper, denoted as a percentage.  
* p < 0.05, ** p < 0.01 
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CHAPTER 3: DATA AND METHODOLOGY 
 
3.1 DATASETS AND VARIABLES 
3.1.1 Seattle Data 
 
The first data is from a combined breast cancer case-control study in which information on 
the extent of mammographic density and mammographic density patterns were ascertained from 
the results of previous mammograms. Additional details about the data set used are described in 
Thomas et al. [1].   
 
Cases (n=547) and controls (n=472) were recruited from women who had participated in 
four previous population-based case-control studies of breast cancer in the Seattle area: BCYW 
[2]; WISH [3]; HORMONE [4]; and EMF [5]. Cases from all four studies were identified through 
the Cancer Surveillance System, a population-based cancer registry sponsored by the Surveillance, 
Epidemiology, and End Results program of the National Cancer Institute that covers 13 counties 
of Western Washington State [6]. Women with an initial diagnosis of either in situ or invasive 
disease were included in all four studies.   
 
Cases eligible for the BCYW study were female residents of King, Pierce, on Snohomish 
counties who were born after 1944 and who developed breast cancer from January 1983 through 
April 1990. Cases eligible for the WISH study were those from the same three counties <45 years 
of age who were diagnosed from May 1990 through December 1992. The HORMONE study 
included the cases 50-64 years of age residing in King County, diagnosed from January 1988 to 
June 1990. Cases eligible for the EMF study were female residents of King and Snohomish 
counties diagnosed from January 1993 to June 1995. To eliminate women unlikely to have had 
access to mammographic screening before age 50 or to have had their mammograms in the too 
distant past for likely retrieval, cases diagnosed before 1985 in the BCYW studies, those >54 years 
of age in the HORMONE study, and those >59 years of age in the EMF study were not considered 
eligible for this investigation. Controls for all four studies were selected by random digit dialing, 
using a modification of the Waksberg method [7]. Controls were frequency matched to cases on 
age and county of residence.   
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Experienced interviewers had administered standardized questionnaires to all consenting 
study subjects after obtaining written informed consent. Although these questionnaires varied 
among the four prior studies, they were comparable on the standard risk factors for breast cancer 
which included information on marital, reproductive, menstrual and contraceptive history, use of 
exogenous hormones (oral contraceptives and estrogen hormone replacement therapy), lifestyle 
factors, prior breast biopsies, socioeconomic characteristics, and family history of breast cancer. 
Weight one year before the interview and the maximum height attained were also ascertained at 
the interview, except in the WISH study where height was measured; these data were used to 
calculate body mass index (weight in kilograms ÷ height in meters squared). Information on all 
potential breast cancer risk/protective factors from questionnaires and datasets of the different 
studies was combined in a systematic manner into the variables included in our dataset. 
 
A history of prior mammographic screening was also elicited from the women. The women, 
or their next of kin if the woman was deceased, were sent a questionnaire to ascertain information 
on the time and place each screening mammogram was taken and a consent form giving their 
permission for us to contact the radiologist and request a loan of the mammograms was signed.  
Telephone calls were made to women who did not respond, and in some instances, the 
questionnaire was administered during the call. 
 
The craniocaudal and mediolateral oblique or lateral radiographs were both used to classify 
each breast according to the parenchymal pattern classification of Wolfe [8, 9], including N1 
[mostly fat (radiolucent), few ducts], P1 [ductal (linear) patterns and nodular densities occupying 
>25% of the area], and DY (dense sheets, no ductal pattern discernable). The reference radiologist, 
who classified the mammograms, received training from a colleague of Wolfe (Martine Salane) to 
enhance compatibility with prior investigations.  In future analyses, women were categorized into 
having P2 and DY patterns (“high risk”) and N1 and P1 patterns (“lower risk”). 
 
The radiologist traced the outline of the dense areas on the craniocaudal view with a wax 
(China) marker. A single technician, who had also received training from Dr. Wolfe’s associate, 
then measured the areas of the breast and the dense area with a compensating polar planimeter 
(LASICO, Los Angeles, CA). In future analyses, women were categorized into the upper quartile 
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of percent breast density in controls (“high risk”: ≥70.3%) versus all other women (“lower risk”: 
≤70.2%). 
 
3.1.2 Mayo Data 
 
The second dataset is from the Mayo Mammography Health Study (MMHS), which is a 
prospective cohort, comprised of 19,924 women (51.2% adjusted response rate) ages 35 and over, 
residing in the tri-state region surrounding the Mayo Clinic in Rochester, MN. (Minnesota, Iowa, 
and Wisconsin), without a personal history of breast cancer, who were scheduled for a screening 
mammogram at the Mayo Clinic between October 2003 and September 2006 [10]. All women had 
a 4-view screening mammogram at the time of enrollment and completed a self-administered 
questionnaire. A total of 2,284 women in the cohort reported having had at least one form of cancer 
(other than breast cancer) prior to enrollment. The investigators defined a healthy cohort as the 
17,639 women who were free of a history of any cancer at baseline (excluding non-melanoma skin 
cancer). 
 
Follow-up for cancer occurrence was performed annually by linking to Mayo Clinic 
databases and the tri-state cancer registries. Active follow-up for cancer and vital status was 
conducted via mail and telephone from women who had not been back to the Mayo Clinic within 
12 months and either had moved out of the tri-state region or did not grant consent for registry 
linkage. Telephone follow-up was attempted on non-responders to the mailed contact. As of 
December 2013, the total number of incident cancers in the healthy cohort was 1601, of which 665 
were breast cancers.  
 
Percent mammographic density (dense area divided by total area, times 100%) was 
estimated using a computer-assisted thresholding program, Cumulus, on the enrollment screening 
mammogram from all participants in the case-cohort and nested case-control studies. Clinical BI-
RADS four-category tissue composition assessments corresponding to the enrollment 
mammogram were obtained from the Mayo Clinic electronic medical record. The BI-RADS tissue 
composition has been routinely estimated on all screening mammograms at the Mayo Clinic since 
mid-1996. Mayo Clinic attending radiologists classified each mammogram into one of four 
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categories as defined in the BI-RADS lexicon over this period (American College of Radiology, 
third edition): (a) the breast is almost entirely fat; (b) there are scattered fibroglandular densities; 
(c) the breast tissue is heterogeneously dense, which may lower the sensitivity of mammography; 
and (d) the breast is extremely dense, which could obscure a lesion on mammography. These 
ratings convey the relative possibility that a lesion may be obscured in mammography. All four 
mammogram views (craniocaudal and mediolateral oblique for ipsilateral and contralateral sides) 
contribute to the assessment of BI-RADS composition. In our study, we used the estimates that 
experienced radiologists assessed in the clinical setting. These radiologists did not systematically 
assess BI-RADS composition for this study, but this rating has shown adequate inter-observer 
reliability 
 
3.2 STUDY AIMS AND HYPOTHESIS 
 
Previous analyses from these two datasets have shown associations between some breast 
cancer risk factors and mammographic density. We proposed to extend the analysis of these two 
data sets for the following three specific aims:  
1) To identify the key risk/protection factors that meet the criteria 1 and 2 for a 
mediator/surrogate marker. That is, the exposures should be associated with 
mammographic density and mammographic density should predict the risk of breast 
cancer. 
2) To determine whether mammographic density accounted for any part of the association 
between any of the risk/protection factors and breast cancer risk. These would include 
a measure of direct and indirect effect as well as a formal statistical test of the 
significance of the mediation effect.  
3) To quantify the extent to which the observed association between the identified risk 
factors for breast cancer is mediated through mammographic density. These would 
include measures of mediation such as proportion mediated and test of significance as 
well as a 95% CI.  
 
The primary purpose of this project was to determine whether mammographic density was 
in the causal pathway by which traditional breast cancer risk/protective factors are related to breast 
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cancer. We hypothesized that mammographic density at least partially mediated some of the 
known factors and breast cancer associations. We further hypothesized that some risk factors may 
affect pre-menopausal and postmenopausal women differentially.  
 
3.3 METHODS 
3.3.1 Theoretical Framework 
 
The basic path diagram representation of the conceptual relationships between variables 
for the mediator analysis is illustrated in Figure 3.1 where: the coefficients represent the regression 
coefficients along the paths from the risk factors F to the mediator M (ex. BMI to mammographic 
density), b is the coefficient for the direct path from the mediator M to the outcome B (ex. 
mammographic density to breast cancer), the c coefficients represent the unmediated paths from 
the risk factors F to the outcome B (ex. BMI to cancer), and d represents the coefficient for different 
confounding covariates C in the model [11].  
 
3.3.2 Selection of Variables 
 
Two important criteria must be satisfied for a mediator: the exposures should be associated 
with breast density and breast density should predict the risk of breast cancer. Statistical analysis 
proceeded by first narrowing the set of risk factors to be those that were associated with breast 
density, using requirement 1 stated in the introduction, so as to identify which factors may act 
through breast density to increase or decrease the risk of breast cancer. Factors need not statistically 
predict the risk of breast cancer. But it would be good to check them for the direction of mediation.  
 
Variables were selected based on the literature and further confirmed by regression 
analysis. First, the relationships between potential breast cancer risk factors and the development 
of breast cancer and measures of mammographic density in the data set were examined to 
determine which variables should be included in the statistical models. Logistic regression was 
used for case-control study and Cox proportional hazards regression was used for the case-cohort 
design. Attempts were made to determine if there were additional variables that confounded the 
potential risk/protective factor – breast cancer relationship by successively adding all other non-
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identical potential confounders (other risk/protective factors) to the regression models and 
determining whether they changed the odds ratio by more than 10 percent. The same confounders 
were then added to the models investigating the relationship with these risk/protective factors with 
measures of mammographic density. We then selected variables to be used in future analyses if 
they had such a strong association with measures of mammographic density that they may indicate 
an important mediator effect in the path models. Preference was given if variables displayed a 
strong or significant relationship with breast cancer (or were a major confounder of such an 
association). Factors that did not predict breast cancer risk should also be considered because they 
may show inconsistent mediation. The Gail model and other risk assessment models incorporating 
breast density have been developed and could serve as references. The selection also depends on 
the availability of variables in the data set. Table 3.1 shows a list of potential risk factors of breast 
cancer that were likely to act through the breast density pathway. 
 
3.3.3 Model Specification and Statistical Analysis  
 
VanderWeele and colleagues have outlined the analytic approaches that are available to 
conduct mediation analysis based on the counterfactual framework [12]. Let F denote a traditional 
risk factor, M the percentage mammographic density, B breast cancer, and C a set of baseline 
covariates. The F–B pathway is independent of breast density, whereas the F–M–B pathway 
describes that the effect of the risk factor is mediated through breast density. We could fit the 
following logistic regression models: 
 
logit[𝑃(𝐵 = 1|𝐹,𝑀, 𝐶)] = 𝜃0 + 𝜃1𝐹 + 𝜃2𝑀 + 𝜃3𝐹𝑀 + 𝜃4𝐶 
𝑀 = 𝛽0 + 𝛽1𝐹 + 𝛽2𝐶 + 𝜀 
SAS and SPSS macros are available to do the above mediation analysis automatically 
(reference). It fits two regression models simultaneously: one viewing breast cancer as the outcome 
variable with breast density as a covariate, and the other viewing upper-quartile of breast density 
as the outcome variable.  
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The use of mediator models allowed us to determine the extent to which breast cancer 
risk/protective factors acted through mammographic density (indirect effect) or around it (direct 
or unmediated effect) in increasing or decreasing the risk of breast cancer. However, it is very 
important to adequately control for covariates C, namely the exposure-outcome, mediator-
outcome, and exposure-mediator confounders. 
 
3.3.4 Sensitivity Analysis 
 
It is impossible to include all the variables to the model, especially when the sample size is 
not large enough. We can only choose the most significant ones. In this case, sensitivity analysis 
is important in assessing the extent to which uncontrolled confounding may or may not 
substantially influence estimates. 
 
3.3.5 Comparison of Methods 
 
Over the past decade, studies of causal mediation have grown rapidly in different fields. 
Several mediation analysis packages in different software (SAS, R, STATA, SPSS, etc.) have been 
developed. In our project, we focus on conducting causal mediation analysis following the 
approach outlined by VanderWeele and Vansteelandt [13], implemented using a SAS macro that 
can accommodate the case-control design [14]. For comparison purposes, we also conducted 
mediation analysis based on the “difference method” when the results with and without an 
exposure × PMD interaction were comparable. The mediation analysis using the “difference 
method” is outlined by Lin et al. [15], implemented using a SAS macro developed by Spiegelman 
and colleagues [16].  Other causal mediation analyses such as the R packages “mediation” and 
“medflex” are also considered. The latter is based on the class of natural effect models (NEMs) 
originally introduced by Lange et al. [11] and Vansterlandt et al. [12] and implemented in the R 
package medflex [2].  
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TABLE AND FIGURE 
 
Table 3.1. List of potential risk factors and covariates from literature 
 
 Risk factor (F) and Covariates (C) 
Factors associated with 
breast density 
 
Age and Menopause 
 
Reproductive Variables 
• Parity: nulliparous vs parous, later age at first birth, and 
fewer live births have been associated with greater risk 
of breast cancer and with a higher proportion of dense 
breast tissue. 
Bodyweight and height 
Nutrition, alcohol, and exercise 
Family history, race 
• Family history (breast, ovarian, endometrial, and colon) 
• Age, parity, age at first live birth, age at menarche 
• HRT, menopausal status,  
• BMI, height, waist-to-hip ratio, alcohol consumption, 
smoking, education 
• Tamoxifen 
• Breast characteristics (involution, presence of atypia on 
a breast biopsy) 
Factors that have not 
been shown to be 
associated with breast 
density 
• Oral contraceptive use, Estradiol, oophorectomy, 
• Diet (low fat, polyunsaturated fat, vitamin C, E, B12, D 
supplement, folate) and physical activity (no consensus)  
• Aromatase inhibitors, raloxifene, aspirin 
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Figure 3.1. Conceptual relationships between variables illustrating mediation. Conceptual 
relationships illustrating mediation between a traditional breast cancer risk factor (F), 
mammographic density (M), and breast cancer risk (B), along with baseline confounding 
covariates (C). 
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CHAPTER 4: STUDY 1 
A Mediation Analysis of the Pooled Data from Four Population-Based Case-Control 
Studies in the Seattle Region 
 
 
Abstract 
 
Purpose: We conducted a causal mediation to examine whether and to what extent percent 
mammographic density (PMD) is in the pathway by which various breast cancer risk factors 
influence the risk of breast cancer. 
 
Methods: Data were pooled from four population-based case-control studies conducted in the 
western Washington state, containing 547 breast cancer cases and 472 controls who had screening 
mammograms under age 50. We estimated the direct effects of various risk factors on risk of breast 
cancer and their indirect effects (i.e. effects mediated through PMD), as well as the proportion 
mediated by PMD. 
 
Results: The association between breast calcifications and risk of breast cancer was partially 
mediated by PMD (proportion mediated = 29.0%), with an indirect-effect odds ratio of 1.16 (95% 
CI: 1.04-1.30; P = 0.009). PMD mediated 48.6% of the reduced risk among parous versus 
nulliparous women, which yielded an indirect-effect odds ratio of 0.76 (95% CI: 0.65-0.90; P = 
0.001). No significant mediation by PMD was observed with respect to a first-degree family 
history of breast cancer, age at first live birth, and smoking. There was inconsistent mediation for 
the effect of adult body mass index. 
 
Conclusions: Densities in mammograms from women <50 years of age partially mediated the 
effects of breast calcifications and being parous on the risk of breast cancer but appeared not to 
mediate the influence of a first-degree family history of breast cancer or age at first live birth. 
Some risk factors for breast cancer may alter risk partially by increasing mammographic densities. 
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4.1 INTRODUCTION 
 
Several independent observations support the hypothesis that some established breast 
cancer risk factors may be mediated by their intermediate effects on the mammary tissue, which is 
evaluated by mammographic densities. First, mammographic breast density has been repeatedly 
shown to be one of the strongest independent risk factors for breast cancer [1-4]. Second, 
mammographic density has also been shown to be associated with a wide array of risk factors for 
breast cancer including age, menopausal status, age at first live birth, parity, body mass index 
(BMI), physical activity, alcohol consumption, hormone replacement therapy, endogenous levels 
of insulin-like growth factor 1 (IGF1) and prolactin, and family history of breast cancer [1]. 
Furthermore, breast density can even be changed by several exposures or interventions that are 
also known to influence breast cancer risk [5]. For example, tamoxifen, an anti-estrogen, was 
reported to reduce mammographic breast density as well as the risk of breast cancer [6-9].  
 
Biologically, mammographic breast density has the potential to act as a mediator for breast 
cancer risk. Fatty tissue in the breast is relatively transparent to x-rays and appears dark on 
mammograms. Fibroglandular tissue, which consists of epithelial cells that line the ducts and their 
supporting fibrous connective tissue, is more radiologically dense and appears light on 
mammograms. Histological assessment of the dense and non-dense areas of the breast revealed 
that the dense tissue has a greater amount of epithelium and stroma, particularly collagen, increased 
nuclear occupation, lesser fat, and a higher proportion of proliferative disease without atypia than 
the non-dense breast tissue [10-12]. The proportion of a mammogram that is dense is thus an 
indirect measure of the amount of epithelial tissue in the breast. Since this is the tissue from which 
mammary carcinomas arise, the greater the percent mammographic density (PMD), the greater the 
number of cells available for malignant transformation. The increase in PMD may also reflect 
alteration of the stromal architecture and composition of the extracellular matrix such as collagen, 
which is a well-recognized component of both benign and malignant breast pathologies [13-15], 
In addition, the epithelium and stromal tissues may be a site for local inflammation, which could 
increase the risk of breast cancer [15]. Breast dense tissue has showed decreased alternatively 
activated macrophages in the stroma [15]. Both case-control studies and prospective studies have 
shown an increased risk of subsequent cancer to be correlated with PMD [4, 16, 17]. A risk factor 
for breast cancer could theoretically increase risk by altering the number of epithelial cells at risk 
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of a  malignant transformation (as measured by the PMD), in which case we would observe that 
the risk factor appears to be mediated by its effect on the observed PMD [18]. Alternatively, a risk 
factor could be independent of any effect on the number of epithelial cells, and there would not be 
evidence for mediation by PMD.   
 
Few studies have attempted to assess the role of mammographic density as a mediator for 
breast cancer risk, and the extent of mediation is rarely quantified using statistical mediation 
analyses. Seven studies have calculated the percent change in the odds ratios (ORs) and/or the 
“proportion explained (PE)” index [19-25], a measure of mediation by the traditional “difference 
method” comparing regression coefficients between models with and without the mediator [26]. 
Of these, ninety-five percent confidence intervals or p-values for the PE were available in only 
four studies [19, 22-24]. The “difference method” has been criticized for lacking a causal 
interpretation [27] and may provide biased estimators regarding mediation, especially for binary 
outcomes [28]. To address some of these limitations, the counterfactual approach has been 
proposed [29-32]. This approach emphasizes assumptions regarding confounding required for 
causal interpretation, with a formal definition of direct and indirect effects in a counterfactual 
framework, which allows for the decomposition of a total effect into direct and indirect effects, 
even in models with interactions and nonlinearities. This approach has recently been modified for 
use in analyzing data from case-control studies [32]. To date, only one study has attempted to use 
causal mediation analysis to evaluate the effect of a number of known risk factors on breast cancer 
through mammographic density [22]. 
 
Thus, the main purpose of this study was to estimate, for each breast cancer risk factor of 
interest, how much of its effect on risk is due to its influence on mammographic densities (its 
indirect effect) and how much of its effect on risk is a direct effect (not mediated through 
mammographic density). To do this, we used the analytic approaches based on the counterfactual 
framework described by Vanderweele et. al. [33] using the combined data from four population-
based case-control studies [34].  
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4.2 METHODS 
 
Study Design and Participants 
The data source, study design, and participant characteristics have been described in detail 
previously [34]. Briefly, cases (n = 547) and controls (n = 472) were recruited from women who 
had participated in four previous population-based case-control studies of breast cancer in the 
Seattle area: BCYW (Breast Cancer in Young Women) [35], WISH (Women’s Interview Study of 
Health) [36], HORMONE (Hormone Replacement Therapy and Breast Cancer in Middle-Aged 
Women) [37], and EMF (Electric Power and Risk of Breast Cancer) [38]. Women with an initial 
diagnosis of either in situ or invasive disease were included in all four studies. Controls for all four 
studies were selected by random digit dialing, using a modification of the Waksberg method [39]. 
Controls were frequency matched to cases on age and county of residence. This study has been 
approved by the Institutional Review Boards of the University of Illinois at Urbana Champaign 
and the Fred Hutchinson Cancer Research Center. 
 
Measurement of Mammographic Density and Calcification 
The earliest mammogram available on each study participant was obtained from local 
mammography facilities.  Both craniocaudal and mediolateral oblique or lateral radiographs were 
used. A single reference radiologist traced the outline of the dense areas on the craniocaudal view 
with a wax (China) marker. A single technician then measured the areas of the breast and the dense 
area with a compensating polar planimeter (LASICO, Los Angeles, CA). PMD was calculated as 
the percentage of the area of the mammogram that was mammographically dense. The mean value 
of the percent density of both breasts was used. 
 
The two views were also used to record the morphological type and distribution of all 
calcifications. This information was subsequently used to classify all mammographic 
calcifications on a scale of 1–5 in descending order of suspicion for existing carcinoma. The system 
used combined entities in the Breast Imaging Reporting and Data System (BI-RADS) of the 
American College of Radiology [40]. The BI-RADS designation of amorphous calcifications was 
not used. 
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Breast cancer risk factors and confounders 
Experienced interviewers had administered standardized questionnaires to all consenting 
study subjects after obtaining written informed consent. Although these questionnaires varied 
among the four prior studies, they were comparable on the standard risk factors for breast cancer 
which included information on marital, reproductive, menstrual and contraceptive history, use of 
exogenous hormones (oral contraceptives and postmenopausal hormone replacement therapy), 
lifestyle factors, prior breast biopsies (including, but not distinguishing, needle aspiration, a biopsy 
of a lesion, and lumpectomy), socioeconomic characteristics, and family history of breast cancer. 
Weight at 1 year before the interview, weight at 18 years of age, and maximum height attained 
were also ascertained at the interview, except in the WISH study, in which height was measured; 
and these data were used to calculate the BMI. 
 
Statistical Methods 
We conducted a causal mediation analysis following the approach outlined by 
VanderWeele and Vansteelandt [32], implemented using a SAS macro that can accommodate the 
case-control design [41]. The analysis proceeded by first fitting an unconditional logistic 
regression model for breast cancer on the potential risk factor and PMD, adjusting for matching 
variables (study and age) and the baseline covariates. Second, a linear regression was fit for PMD 
on the potential risk factor and covariates using the controls. The regression for PMD and the 
regression for breast cancer risk were combined to obtain the ORs and 95% CIs for the following 
effects: (a) the natural direct effect (NDE) (i.e., the effect of the exposure on breast cancer risk not 
through PMD if PMD was fixed at the level that it would have been without the exposure), (b) the 
natural indirect effect (NIE) (i.e., the effect of the exposure on breast cancer risk through PMD), 
and (c) the total association between the exposure and breast cancer risk. Despite a lack of 
statistical significance on all exposure–PMD interaction terms, we compared the results with and 
without an exposure × PMD interaction term. We used both the delta method and bootstrap 
sampling (1000 samples) to obtain 95% confidence intervals (CIs). The proportion mediated was 
estimated by the equation of ORNDE × (ORNIE -1)/(ORNDE × ORNIE -1), where ORNDE is the direct-
effect odds ratio and ORNIE is the indirect-effect odds ratio [32]. All the p-values used were two-
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sided. Type I errors were set at 0.10. All statistical analyses were performed using SAS version 
9.3 (SAS Institute, Inc., Cary, North Carolina, USA). 
 
Sensitivity Analysis 
To assess the robustness of our results, we repeated the analyses by restricting the data to 
premenopausal women at mammography date. Analyses were also performed by excluding 
women who had stopped bleeding at least four years by mammography date and similar results 
were obtained (not shown). Since the results with and without an exposure × PMD interaction 
were comparable, we also conducted a mediation analysis using the “difference method” outlined 
by Lin et al. [42], implemented using the SAS macro developed by Spiegelman and colleagues 
[43]. To determine the causal direction of the relationship between mammographic density and the 
risk factors of calcification and breast biopsy history, we also conducted mediation analyses using 
these two risk factors as potential mediators for the effect of PMD by assuming the mediation path 
in a way that PMD preceded these two risk factors.  
 
4.3 RESULTS 
 
The characteristics of the study population and the set of potential risk factors and selected 
confounders are shown in Table 4.1. We identified a total of 547 cases and 472 controls who had 
a screening mammogram before 50 years of age and 1 year or more prior to the date of diagnosis 
(for the cases) or reference date (for the controls). The participants were largely white women 
(97%) and less than 5% were aged 55 or older. More than 70% of women had their screening 
mammograms between the age of 35 and 45 years old.  
 
Having had calcifications (OR = 1.263; 95% CI: 1.164, 1.371), first degree family history 
of breast cancer (OR = 2.066; 95% CI: 1.456, 2.960), ever having had a live birth (OR = 0.671; 
95% CI: 0.480, 0.935) and per year increase in age at first live birth among parous women (OR = 
1.042, 95% CI: 1.010, 1.075) were significantly associated with risk of breast cancer (Table 4.2). 
BMI at 1 year before the interview, BMI at 18 years old, history of breast 
biopsy/aspiration/lumpectomy, smoking, and the number of live births (among parous women) 
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were not significantly associated with breast cancer risk. Mediation analyses using the “difference 
method” showed that a first-degree family history of breast cancer, smoking, and age at the first 
live birth were not mediated by PMD, whereas having had calcifications and ever having had a 
live birth were partially mediated by PMD (PE = 16.5% and 42.5% respectively, p = 0.0001 for 
both).  
 
The results of the causal mediation analyses for the whole data set were shown in Table 4.3 
and Supplementary Table 4.1. Having had calcifications was directly associated with breast cancer 
risk (ORNDE, 1.66; 95% CI, 1.26-2.19; P < 0.001), but it was also indirectly associated with breast 
cancer risk through its effect on mammographic density (ORNIE, 1.16; 95% CI, 1.04-1.30; P = 
0.009), with a proportion of 29.0% mediated by PMD. Although a first-degree family history of 
breast cancer was a significant breast cancer risk factor (ORtotal effect, 1.893; 95% CI, 1.26858, 
2.82474; P = 0.002), no significant mediation by PMD was observed (ORNIE 0.891, 95% CI: 
0.75642, 1.04965; P = 0.168). Ever having had a live birth exhibited a significant negative 
association with breast cancer (ORtotal effect, 0.61; 95% CI, 0.42-0.89; P = 0.010), which was 
decomposed into a significant indirect-effect odds ratio of 0.76 (95% CI, 0.65-0.90; P = 0.001) 
through PMD and a direct-effect odds ratio of 0.80 (95% CI, 0.57-1.13; P = 0.207). Overall, 48.6% 
of the reduced risk of breast cancer related to being parous was attributable to lower PMD. Among 
parous women, per year increase in age at first live birth had a significant total effect (ORtotal effect, 
1.04; 95% CI, 1.00-1.07; P = 0.043) on the risk of breast cancer. However, the association was not 
mediated through PMD (ORNIE, 0.999; 95% CI, 95% CI, 0.98-1.01; P = 0.88). 
 
Although the BMI measures were not significantly associated with risk of breast cancer in 
our data, results from casual mediation analyses suggested the presence of inconsistent mediation 
or suppression, in which the direct and indirect effects had opposite directions while the total effect 
was not significant. BMI at 1 year before interview displayed a highly significant negative indirect 
association with breast cancer risk through PMD (ORNIE, 0.940; 95% CI, 0.92-0.96; P=0.000), 
while it displayed a significant positive relationship with breast cancer risk (ORNDE, 1.048; 95% 
CI, 1.02-1.08; P=0.003) independent of PMD. The opposing direct and indirect effects resulted in 
an overall non-significant total effect of BMI (ORtotal effect, 0.98; 95% CI, 0.96-1.01; P = 0.274). 
Similarly, BMI at 18 years old was not associated with the risk of breast cancer (ORtotal effect, 0.970; 
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95% CI, 0.92-1.02; P = 0.256). It had a significant negative indirect association with breast cancer 
risk through PMD (ORNIE, 0.931; 95% CI, 0.91-0.96; P = 0.000). However, the direct association 
acting independently of PMD was not significant, although positive (ORNDE, 1.04; 95% CI, 0.99-
1.10; P = 0.121). This indicates that BMI at a younger age might act predominantly through its 
negative association through breast density, whereas BMI at an older age may also act positively 
through pathways independent of breast density. 
 
At the 10% significance level, smoking (ORtotal effect, 1.28; 95% CI, 0.96-1.71; P = 0.092) 
and history of breast biopsy/aspiration/lumpectomy (ORtotal effect, 1.36; 95% CI, 0.96-1.93; P = 
0.083) were associated with increased risk of breast cancer. PMD mediated the association with 
history of breast biopsy/aspiration/lumpectomy (ORNIE, 1.28; 95% CI, 1.11-1.49; P = 0.001) but 
not smoking (ORNIE, 1.02; 95% CI, 0.92-1.14; P = 0.676). The proportion mediated was estimated 
to be 83.1%, which is higher than the PE index (64.4%) from the difference method. Note that the 
PE has a wide range of 95% CI, indicating that the PE estimate is very imprecise.   
 
Including versus excluding the exposure-mediator interaction terms did not change the 
estimates of the direct and indirect effects much (Table 4.3). When analyses were restricted to 
premenopausal women, results were similar to that seen for all women (Supplementary Table 4.2).  
 
4.4 DISCUSSION  
 
Our results showed that PMD partially mediated the association between breast 
calcifications and ever having had a live birth with the risk of breast cancer. The associations of 
other factors with breast cancer risk, including a family history of breast cancer, age at first live 
birth, and smoking, were not mediated by PMD. Furthermore, we observed the presence of 
inconsistent mediation for adult BMI.  
 
Calcifications are tiny mineral deposits within the breast tissue, which may show up as 
high-density white spots on a mammogram. It is well known that certain calcifications on a 
mammogram, particularly if small, multiple, and clustered, are predictive of a future diagnosis of 
breast tumors [44]. A third of breast cancers show calcifications as the only mammographically 
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suspicious feature [45]. Our results showed that about 29% of the increased risk of breast cancer 
in relation to having breast calcifications was mediated through PMD, while it also increased breast 
cancer risk through pathways independent of PMD. However, since calcifications and PMD were 
measured using the same mammogram, we cannot disentangle the direction of causality between 
calcifications and PMD. To further test our hypothesis, we conducted a sensitivity analysis by 
assuming the mediation path in a way that PMD precedes calcifications and that the effect of PMD 
on the risk of breast cancer is mediated by calcifications. Results showed that adjustment for 
calcifications led to only a minimal attenuation in the association between PMD and breast cancer 
risk, with less than 10% mediated by calcification (Supplementary Table 4.3). The results provided 
no support for the hypothesis that calcifications mediated the association of PMD with breast 
cancer risk even if we assume calcification precedes mammographic density. Therefore, it is more 
likely that PMD mediated the association between having breast calcifications and the risk of 
breast cancer. Biologically, microcalcification is an important feature in breast lesions and early 
signs of breast cancer. Of the breast cancers detected on mammography due to calcifications, about 
two-thirds represent ductal carcinoma in situ and the remainder are invasive ductal carcinoma [45]. 
It is thought to be a result of abnormal calcium deposition and mineralization of necrotic debris 
that is caused by rapidly proliferating tumor cells that use up the blood supply, resulting in cell 
death and subsequently increased acidosis in the microenvironment [46]. However, given that it is 
difficult to determine the temporality between these two breast cancer risk factors, this result 
should be interpreted cautiously. 
 
Our results showed that PMD mediated 48.6% of the association between ever having had 
a live birth and breast cancer risk, which is supported by two previous studies[22, 23]. Although 
the calculated proportion mediated by PMD in these studies was only significant among 
postmenopausal women [23], the estimates (40-52%) were very similar to our observation, 
regardless of menopausal status. A potential mechanism for this finding of mediation might be a 
reduction in mammographic density after pregnancy [47]. Studies have consistently shown that 
nulliparous women had a greater percent density than parous women [48-52], and there is a 
negative association between increasing parity and mammographic density [48-51, 53-55]. 
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A family history of breast cancer in first-degree relatives is an established risk factor for 
breast cancer. In our study, the increased risk of breast cancer in relation to a first-degree family 
history of breast cancer was found to be independent of PMD. This result of no mediation is 
consistent with two recent studies which showed that the association with a family history of breast 
cancer was not mediated by PMD in both premenopausal and postmenopausal women [22, 23]. 
However, in another study, PMD was found to explain 14% (95% CI, 4-39%) of the association 
of family history (at least one affected first-degree relative) with breast cancer risk [19]. Note that 
about 75% of the participants in that study were postmenopausal women, whereas most of our 
study population is premenopausal. This evidence suggests that a small portion of the association 
between family history of breast cancer and the risk of breast cancer is mediated by PMD, if any. 
 
In analyses restricted to parous women, later age at first live birth was found to be 
associated with a higher risk of breast cancer but there was no evidence of mediation by PMD. 
These results were in line with the findings in premenopausal women in two previous studies [22, 
23]. Although these two studies found significant mediation by PMD for the associations between 
later age at first birth and all invasive breast cancer among postmenopausal women, the proportion 
mediated (13-16%) is small. In another study by Tice et al. (2005), later age at first live birth was 
also found to be a significant breast cancer risk factor among women without a first-degree family 
history of breast cancer [56]. Adjusting for BI-RADS mammographic density categories 
attenuated the relative risk by about 16%. These results suggest that the association between age 
at first live birth and breast cancer risk is not likely to be mediated by PMD, at least among 
premenopausal women. The portion of mediation would be small if there is any. 
 
The presence of inconsistent mediation for adult BMI was also observed in several studies 
that compared the association between BMI and breast cancer risk before and after further 
adjustment for breast density [16, 22, 23, 57-61]. The overall association between BMI and breast 
cancer risk was not significant in all these studies except for one, which showed a significantly 
lower risk of breast cancer risk among premenopausal women with higher BMI [16]. Further 
adjustment for mammographic density consistently strengthened the overall positive associations, 
whereas the overall negative associations largely became positive. Our results showed that BMI at 
age 18 had a significant negative indirect association with breast cancer risk through PMD, 
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although the overall association was not significant. This finding is partially supported by Rice et 
al. (2016) [22], who found that PMD mediated a substantial portion of the significant association 
between BMI at age 18 and breast cancer risk among premenopausal women. While the overall 
association was significant among premenopausal women, the association in postmenopausal 
women was not significant. Similar results were found in another study that included both pre- and 
post-menopausal women, which showed that the association between BMI at age 18 and breast 
cancer risk was only significant when comparing overweight or obese women to those with a BMI 
between 20 and 22.4 [61]. This significant association was substantially attenuated after 
adjustment for mammographic density. These results suggest that BMI at a younger age might act 
predominantly through its negative association through breast density, whereas BMI at an older 
age may also act positively through pathways independent of breast density, resulting in an 
inconsistent mediation. 
 
Our study has several limitations. In order to establish a causal interpretation of the direct 
and indirect effects, it is important to make the no-unmeasured-confounding assumptions. 
Although we have checked confounding for a large number of participant characteristics, there 
may be other unmeasured factors (such as physical activity) that were not ascertained in our study. 
Our study has a relatively small sample size (547 cases and 472 controls), which may be the reason 
why we did not have sufficient statistical power to detect a significant association for some risk 
factors such as a history of breast biopsy and number of live births.  
 
The temporal relationship, that the exposure preceded the mediator and that the mediator 
preceded the outcome, is also necessary. With a case-control design, our study was not able to 
make sure all the risk factors occurred before mammographic measurement, although screening 
mammograms were taken before the diagnosis of breast cancer. Since a majority of our study 
participants had their mammograms at age 35 years old or older, it is reasonable to assume that the 
reproductive factors and lifestyle habits considered in our study were established before the 
measurement of breast density. However, this assumption does not apply to the presence of 
calcifications and history of breast biopsy, because calcifications and mammographic density were 
measured using the same mammogram, while a biopsy may be performed after detecting a high-
density pattern in the mammogram. Therefore, we conducted a sensitivity analysis by assuming 
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the mediation path in a way that calcifications or breast biopsies were the potential mediators for 
the effect of PMD. The results provided no support for the hypothesis that calcifications or breast 
biopsies mediated the association of PMD with breast cancer risk (Supplementary Table 4.3). 
However, given that women with denser breasts are more likely to undergo breast biopsy and they 
likely had a high PMD at the time their calcification was detected, it is difficult to determine the 
temporality between these two breast cancer risk factors and PMD. Therefore, the results must be 
interpreted with caution. Further studies are warranted to determine the causal direction of the 
relationships. The assumption of temporality may have a better application to cohort studies or 
nested case-control studies, where risk factors are ascertained before the measurement of 
mammographic density, both of which may have occurred prior to the development of the disease. 
In addition, note that the mediator we studied is percent mammographic density. We did not use 
“Wolfe’s classification” because PMD was found to provide more information on breast cancer 
risk than Wolfe’s parenchymal patterns and the parenchymal patterns appeared to be redundant 
once PMD is taken into account [62]. However, it is possible that other aspects of mammographic 
patterns, such as texture, coarseness, stiffness, etc., could potentially be responsible for part of the 
effect of these different exposures on the risk of breast cancer. These characteristics may be 
important but would not be captured simply by a percent mammographic density measure.  
 
4.5 CONCLUSIONS 
 
In summary, using data from four population-based case-control studies of women having 
screening mammograms under age 50, we demonstrated that breast calcifications, being parous, 
and higher BMI affect the risk of breast cancer partially through their effect on PMD. On the other 
hand, first-degree family history of breast cancer, age at first live birth, and cigarette smoking 
affect breast cancer risk mainly through pathways independent of PMD. These findings may 
provide insights into the mechanisms involved in the development of breast cancer and highlight 
a potential biological pathway from breast density to the etiology of breast cancer. 
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TABLES 
 
Table 4.1. Characteristics of cases vs. controls by selected risk factors 
Variables 
Case 
(n=547) 
Control 
(n=472) 
STUDY     
    EMF 231 (42.2%) 213 (45.1%) 
    OB 37 (6.8%) 31 (6.6%) 
    BCIA 87 (15.9%) 77 (16.3%) 
    WISH 192 (35.1%) 151 (32.0%) 
Age at diagnosis or reference date (y)     
    <40 101 (18.5%) 73 (15.5%) 
    40-44 254 (46.4%) 222 (47.0%) 
    45-49 78 (14.3%) 72 (15.3%) 
    50-54 89 (16.3%) 90 (19.1%) 
    55-59 25 (4.6%) 15 (3.2%) 
Age at mammogram (y)     
    <35 75 (13.7%) 42 (8.9%) 
    35-39 215 (39.3%) 185 (39.2%) 
    40-44 166 (30.3%) 173 (36.7%) 
    45-49 91 (16.6%) 72 (15.3%) 
Age at menopause (y)     
    Pre-menopausal 453 (82.8%) 387 (82.0%) 
    <35 41 (7.5%) 43 (9.1%) 
    35+ 53 (9.7%) 42 (8.9%) 
Race: White 531 (97.4%) 458 (97.0%) 
Marital status     
    Single, never married 33 (6.2%) 19 (4.1%) 
    Married/living as married 428 (80.3%) 370 (79.9%) 
    Separated/Divorced/Widowed 72 (13.5%) 74 (16.0%) 
Education level     
    Attended or completed HS/GED or less 120 (22.0%) 127 (26.9%) 
    Technical school/2-year college 55 (10.1%) 48 (10.2%) 
    Attended or completed college 294 (53.8%) 243 (51.5%) 
    Attended or completed graduate school 77 (14.1%) 54 (11.4%) 
Income     
    Less than median income category 153 (28.3%) 149 (32.3%) 
    Median income category 146 (27.0%) 121 (26.2%) 
    Greater than median income category 241 (44.6%) 192 (41.6%) 
Drinks per week, 6 to 2 years before     
    No drinking 131 (23.9%) 131 (27.8%) 
    <1.0 drink per week 136 (24.9%) 104 (22.0%) 
    1.0-2.99 drinks per week 93 (17.0%) 74 (15.7%) 
    3.0-6.99 drinks per week 81 (14.8%) 62 (13.1%) 
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Table 4.1. Characteristics of cases vs. controls by selected risk factors 
Variables 
Case 
(n=547) 
Control 
(n=472) 
    7.0+ drinks per week 106 (19.4%) 101 (21.4%) 
Ever smoked cigarettes 296 (54.1%) 222 (47.0%) 
First degree family had BC 120 (21.9%) 60 (12.7%) 
Parity: Nulliparous 132 (24.1%) 82 (17.4%) 
Ever breastfed (among parous) 284 (68.6%) 268(68.7%) 
Total duration of BCPs (months)     
    Never used 50 (9.3%) 50 (10.6%) 
    >0 - 60 months 284 (52.9%) 239 (50.7%) 
    >60 months 203 (37.8%) 182 (38.6%) 
Estrogen use history     
    Never 486 (88.8%) 414 (87.7%) 
    Past 9 (1.6%) 13 (2.8%) 
    Current 52 (9.5%) 45 (9.5%) 
Progesterone ever     
    No 512 (93.6%) 431 (91.3%) 
    Yes 35 (6.4%) 41 (8.7%) 
Wolfe classification     
    N1 2 (0.4%) 11 (2.3%) 
    P1 62 (11.3%) 135 (28.6%) 
    P2 420 (76.8%) 302 (64.0%) 
    DY 63 (11.5%) 24 (5.1%) 
Calcification class     
    No calcifications 192 (35.1%) 229 (48.5%) 
    Lowest (non-epithelial) 6 (1.1%) 11 (2.3%) 
    Low suspicion 138 (25.2%) 109 (23.1%) 
    Intermediate 77 (14.1%) 63 (13.3%) 
    High 100 (18.3%) 52 (11.0%) 
    Highest 34 (6.2%) 8 (1.7%) 
Breast biopsy/aspiration/lumpectomy ever 142 (26.0%) 101 (21.4%) 
Type of mammogram film     
    X-ray 485 (88.7%) 429 (90.9%) 
    Xeroradiograph 62 (11.3%) 43 (9.1%) 
Age at menarche (y)  12.49 (1.5) 12.45 (1.4)  
Age at first live birth (y) (among parous)  24.4 (5.2)  23.8 (5.1) 
Number of live births (among parous) 2.2 (0.9) 2.2 (1.0) 
Months breastfed (among parous)  8.9 (13.9)  8.2 (11.6) 
Total duration of BCPs (months)  54.0 (50.2)  56.1 (53.7) 
Body Mass Index (kg/m2)  24.5 (5.0)  25.2 (5.8) 
BMI at age 18 (kg/m2) 20.5 (2.6)   20.6 (2.9) 
Percent mammographic density (%) 61.3 (21.2)   48.6 (25.1) 
Time since mammogram (y) 4.8 (3.1)  4.5 (3.2)  
(cont.) 
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Table 4.2. Odds ratios (ORs) and 95% CI for risk of breast cancer, adjusted or not adjusted for percent mammographic 
density (PMD), the difference method 
 
  Unadjusted for PMD Adjusted for PMD Proportion Explained§ 
  OR* 95%CI p-value ORadj† 95%CI p-value PE (95%CI) 
p-
value 
Full dataset         
 BMI (continuous, kg/m2) 0.98 0.96, 1.00 0.090 1.04 1.01, 1.07 0.015 ~ ~ 
 Normal/Underweight (BMI <25) 1.00 Reference  1.00 Reference  Reference  
 Overweight/obese (BMI 25+ vs <25) 0.92 0.70, 1.20 0.530 1.57 1.15, 2.16 0.005 ~ ~ 
 BMI at age 18 (continuous, kg/m2) 0.98 0.93, 1.03 0.350 1.03 0.98, 1.09 0.196 ~ ~ 
 Normal/Underweight (BMI at age 18y <25) 1.00 Reference  1.00 Reference  Reference  
 Overweight/obese at age 18 (BMI 25+ vs <25) 0.85 0.49, 1.45 0.540 1.29 0.73, 2.31 0.387 ~ ~ 
 Breast biopsy/aspiration/lumpectomy never 1.00 Reference  1.00 Reference  Reference  
 Breast biopsy/aspiration/lumpectomy ever 1.26 0.92, 1.72 0.152 1.06 0.77, 1.47 0.720 64.4% (3.9% - 98.8%) <.001 
 Calcification class (continuous score) 1.26 1.16, 1.37 <.001 1.22 1.12, 1.32 <.001 16.5% (8.7% - 29.0%) <.001 
 Calcification (no) 1.00 Reference  1.00 Reference  Reference  
 Calcification (yes vs no) 1.86 1.43, 2.43 <.001  1.66 1.26, 2.19 <.001 18.5% (8.5% - 35.7%) 0.001 
 First degree family history of BC no 1.00 Reference  1.00 Reference  Reference  
 First degree family history of BC yes 2.07 1.46, 2.96 <.001  2.12 1.48, 3.08 <.001 -3.8% (~) ~ 
 Nulliparous 1.00 Reference  1.00 Reference  Reference  
 Parous vs nulliparous 0.67 0.48, 0.94 0.019 0.80 0.57, 1.13 0.207 
42.5% (11.4% - 
81.0%) 
<.001 
 Smoking never 1.00 Reference  1.00 Reference  Reference  
 Smoking ever 1.26 0.97, 1.63 0.082 1.25 0.96, 1.63 0.099 2.4% (0.0% - 100.0%) 0.437 
Parous women only‡         
 Number of live births (continuous) 1.04 0.88, 1.23 0.636 1.12 0.94, 1.34 0.215 ~ ~ 
 Number of live births (1-2) 1.00 Reference  1.00 Reference  Reference  
 Number of live births (3+ vs 1-2) 1.08 0.77, 1.52 0.664 1.25 0.87, 1.80 0.220 ~ ~ 
 Age at first live birth (continuous) 1.04 1.01, 1.08 0.011 1.04 1.01, 1.07 0.023 11.0% (0.8% - 66.4%) 0.200 
81 
 
(cont.) 
Table 4.2. Odds ratios (ORs) and 95% CI for risk of breast cancer, adjusted or not adjusted for percent mammographic 
density (PMD), the difference method 
 
  Unadjusted for PMD Adjusted for PMD Proportion Explained§ 
  OR* 95%CI p-value ORadj† 95%CI p-value PE (95%CI) 
p-
value 
 Age at first live birth (15-29) 1.00 Reference  1.00 Reference  Reference  
 Age at first live birth (30+ vs <30) 1.36 0.90, 2.06 0.150 1.31 0.85, 2.03 0.216 15.0% (0.4% - 89.7%) 0.255 
*Multivariate analyses adjusted for study (EMF, OB, BCIA, WISH), age at mammogram (<35 y, 35-39 y, 40-44 y, 45-49 y), BMI (<20, 20 to <24, 24 to <28, 28 to 32 kg/m2), calcification (yes or no), first 
degree family history of breast cancer (yes or no), parity (yes or no), breast biopsy/aspiration/lumpectomy ever (yes or no), smoking (ever or never), mammogram film type (X-ray or Xeroradiograph); 
†In addition to risk factors listed in footnote *, odds ratios were further adjusted for continuous percent mammographic density; 
‡Multivariate analyses restricted to parous women. In addition to risk factors listed in footnote †, replaced number of live births (1, 2, or 3+) for parity and further adjusted for age at first live birth (continuous, 
years); 
§Proportion Explained (PE) index, percent of the total association (on the log odds scale) between the exposure and breast cancer risk that was mediated by PMD, was calculated using the following 
equation: PE= 1 - (lnORadjusted/lnORunadjusted); It was not calculated (notated using symbol ~) if the absolute value of PE is outside the range of [0, 1].   
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Table 4.3. Total, direct and indirect effects of exposure on risk of breast cancer, mediated by percent mammographic density 
(PMD), among all women or parous women* 
 Natural Direct Effect (NDE) Natural Indirect Effect (NIE) Total Effect (TE) 
Proportion 
Mediated§ 
 OR 95%CI p-val OR 95%CI p-val OR 95%CI p-val  
Without exposure × MD interaction           
 Full dataset†           
  BMI (continuous, kg/m2)** 1.05 1.02, 1.08 0.003 0.94 0.92, 0.96 <.001 0.98 0.96, 1.01 0.274 > 
  BMI (25+ vs <25) 1.57 1.15, 2.15 0.005 0.57 0.48, 0.69 <.001 0.90 0.66, 1.23 0.514 > 
  BMI at age 18 (continuous, kg/m2)** 1.04 0.99, 1.10 0.121 0.93 0.91, 0.96 <.001 0.97 0.92, 1.02 0.256 > 
  BMI at age 18 (25+ vs <25) 1.29 0.73, 2.29 0.386 0.60 0.47, 0.77 <.001 0.78 0.42, 1.42 0.413 > 
  Breast biopsy/aspiration/lumpectomy 1.06 0.77, 1.47 0.720 1.28 1.11, 1.49 0.001 1.36 0.96, 1.93 0.083 83.1% 
  Calcification (yes vs no) 1.66 1.26, 2.19 <.001 1.16 1.04, 1.30 0.009 1.93 1.44, 2.59 <.001 29.0% 
  Calcification class (continuous score) 1.22 1.12, 1.32 <.001 1.05 1.01, 1.08 0.015 1.27 1.16, 1.39 <.001 20.5% 
  First degree family history of BC 2.12 1.47, 3.07 <.001 0.89 0.76, 1.05 0.168 1.89 1.27, 2.82 0.002 Not mediated 
  Parous vs nulliparous 0.80 0.57, 1.13 0.207 0.76 0.65, 0.90 0.001 0.61 0.42, 0.89 0.010 48.6% 
  Smoking ever 1.25 0.96, 1.63 0.099 1.02 0.92, 1.14 0.676 1.28 0.96, 1.71 0.092 Not mediated 
 Parous women only‡           
  Number of live births (continuous) 1.12 0.94, 1.34 0.215 0.90 0.83, 0.97 0.007 1.01 0.83, 1.22 0.949 < 
  Age at first live birth (continuous) 1.04 1.01, 1.07 0.023 1.00 0.98, 1.01 0.876 1.04 1.00, 1.07 0.043 Not mediated 
With exposure × MD interaction           
 Full dataset†           
  Overweight/obese (BMI 25+) 1.54 1.04, 2.29 0.033 0.58 0.46, 0.73 <.001 0.90 0.65, 1.23 0.499 > 
  Overweight/obese at age 18 (BMI 25+) 1.70 0.70, 4.15 0.245 0.49 0.29, 0.85 0.011 0.84 0.42, 1.67 0.612 > 
  Breast biopsy/aspiration/lumpectomy 1.08 0.77, 1.49 0.665 1.20 1.02, 1.39 0.023 1.29 0.91, 1.81 0.152 73.6% 
  Calcification (yes vs no) 1.63 1.23, 2.16 0.001 1.15 1.03, 1.28 0.012 1.87 1.37, 2.54 <.001 28.0% 
  Calcification class (continuous score) 1.21 1.11, 1.32 <.001 1.05 1.01, 1.09 0.016 1.27 1.16, 1.39 <.001 21.3% 
  First degree family history of BC 2.46 1.56, 3.88 <.001 0.86 0.68, 1.08 0.181 2.10 1.31, 3.37 0.002 Not mediated 
  Parous vs nulliparous 0.87 0.60, 1.25 0.439 0.75 0.64, 0.89 0.001 0.65 0.45, 0.94 0.024 61.2% 
  Smoking ever 1.25 0.95, 1.65 0.114 1.02 0.92, 1.14 0.677 1.28 0.95, 1.72 0.106 Not mediated 
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(cont.) 
Table 4.3. Total, direct and indirect effects of exposure on risk of breast cancer, mediated by percent mammographic density 
(PMD), among all women or parous women* 
 Natural Direct Effect (NDE) Natural Indirect Effect (NIE) Total Effect (TE) 
Proportion 
Mediated§ 
 OR 95%CI p-val OR 95%CI p-val OR 95%CI p-val  
 Parous women only‡           
  Number of live births (continuous) 1.17 0.95, 1.44 0.144 0.91 0.84, 0.98 0.014 1.06 0.85, 1.33 0.606 < 
  Age at first live birth (continuous) 1.04 1.01, 1.07 0.023 1.00 0.99, 1.01 0.876 1.04 1.00, 1.08 0.038 Not mediated 
*Mediation analysis using the SAS macro by Valeri, L., & VanderWeele, T. J. (2013) and the 95% CIs were estimated using the delta method; 
†Multivariate analyses adjusted for study (EMF, OB, BCIA, WISH), age at mammogram (<35 y, 35-39 y, 40-44 y, 45-49 y), percent mammographic density (continuous, %), BMI (<20, 20 to <24, 24 to <28, 28 to 32 kg/m2), 
calcification (yes or no), family history of breast cancer in a first-degree relative (yes or no), parity (yes or no), breast biopsy/aspiration/lumpectomy (ever or never), smoking (ever or never), mammogram film type (X-ray or 
Xeroradiograph); 
‡Multivariate analyses restricted to parous women. In addition to risk factors listed in footnote †, replaced number of live births (1, 2, or 3+) for parity and further adjusted for age at first live birth (continuous, years);  
§Proportion mediated (PM) was calculated using the following formula if NIE is significant: PM = ORNDE (ORNIE - 1)/(ORNDE × ORNIE - 1); PM calculated to be < 0% and > 100% were denoted by “<” and “>” respectively; 
**Mediation analysis with exposure-mediator interaction for continuous BMI and BMI at age 18 was not reported due to high multicollinearity detected for the interaction term; 
Abbreviations: CI, confidence interval; OR, odds ratio; NDE, natural direct effect; NIE, natural indirect effect; PM, proportion mediated. 
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SUPPLEMENTAL MATERIAL 
 
Supplementary Table 4.1. Total, direct and indirect effects and their 95% CI (by bootstrapping) of exposure on risk of breast 
cancer, mediated by percent mammographic density (MD), among all women or parous women* 
  Natural Direct Effect (NDE) Natural Indirect Effect (NIE) Total Effect (TE) 
Proportion  
Mediated§ 
  OR 95%CI OR 95%CI OR 95%CI   
Without exposure × MD interaction         
 Full dataset†        
  BMI (continuous, kg/m2)** 1.04 1.01, 1.08 0.94 0.93, 0.96 0.98 0.96, 1.01 > 
  Overweight/obese (BMI 25+) 1.60 1.14, 2.20 0.57 0.46, 0.67 0.91 0.67, 1.19 > 
  BMI at age 18 (continuous, kg/m2)** 1.04 0.99, 1.10 0.93 0.91, 0.95 0.97 0.92, 1.02 > 
  Overweight/obese at age 18 (BMI 25+) 1.38 0.73, 2.49 0.60 0.45, 0.78 0.82 0.43, 1.42 > 
  Breast biopsy/aspiration/lumpectomy 1.08 0.76, 1.50 1.29 1.12, 1.51 1.39 0.99, 1.91 80.1% 
  Calcification (yes vs no) 1.69 1.24, 2.22 1.17 1.05, 1.31 1.98 1.45, 2.62 29.7% 
  Calcification class (continuous score) 1.22 1.12, 1.33 1.05 1.01, 1.09 1.28 1.17, 1.40 20.3% 
  First degree family history of BC 2.18 1.51, 3.11 0.89 0.75, 1.03 1.94 1.32, 2.76 Not mediated 
  Parous vs nulliparous 0.81 0.55, 1.13 0.76 0.66, 0.88 0.62 0.41, 0.86 49.6% 
  Smoking ever 1.27 0.97, 1.64 1.02 0.91, 1.15 1.30 0.98, 1.68 Not mediated 
 Parous women only‡        
  Number of live births (3+ vs 1-2) 1.29 0.88, 1.89 0.80 0.68, 0.93 1.03 0.70, 1.50 < 
  Number of live births (continuous) 1.13 0.93, 1.38 0.90 0.82, 0.96 1.01 0.83, 1.21 < 
  Age at first live birth (30+ vs <30) 1.36 0.86, 2.09 1.01 0.84, 1.20 1.37 0.86, 2.11 Not mediated 
  Age at first live birth (continuous) 1.04 1.00, 1.08 1.00 0.99, 1.01 1.04 1.00, 1.08 Not mediated 
With exposure × MD interaction         
 Full dataset†        
  Overweight/obese (BMI 25+) 1.61 1.02, 2.49 0.58 0.42, 0.74 0.91 0.66, 1.22 > 
  Overweight/obese at age 18 (BMI 25+) 2.29 0.82, 6.27 0.48 0.17, 0.83 0.90 0.48, 1.58 < 
  Breast biopsy/aspiration/lumpectomy 1.10 0.80, 1.53 1.19 1.05, 1.36 1.31 0.94, 1.78 66.8% 
  Calcification (yes vs no) 1.65 1.22, 2.21 1.15 1.05, 1.27 1.89 1.42, 2.49 27.6% 
  Calcification class (continuous score) 1.22 1.12, 1.34 1.05 1.01, 1.09 1.28 1.17, 1.40 21.8% 
  First degree family history of BC 2.66 1.67, 4.17 0.84 0.60, 1.03 2.20 1.49, 3.20 Not mediated 
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(cont.) 
Supplementary Table 4.1. Total, direct and indirect effects and their 95% CI (by bootstrapping) of exposure on risk of breast 
cancer, mediated by percent mammographic density (MD), among all women or parous women* 
  Natural Direct Effect (NDE) Natural Indirect Effect (NIE) Total Effect (TE) 
Proportion  
Mediated§ 
  OR 95%CI OR 95%CI OR 95%CI   
  Parous vs nulliparous 0.87 0.60, 1.26 0.75 0.61, 0.88 0.65 0.46, 0.89 63.0% 
  Smoking ever 1.27 0.94, 1.67 1.02 0.90, 1.13 1.29 0.97, 1.67 Not mediated 
 Parous women only‡        
  Number of live births (continuous) 1.18 0.92, 1.54 0.91 0.84, 0.97 1.07 0.85, 1.35 < 
  Number of live births (3+ vs 1-2) 1.44 0.92, 2.20 0.77 0.58, 0.93 1.09 0.75, 1.53 < 
  
Age at first live birth (continuous) 1.04 1.00, 1.08 1.00 0.99, 1.02 1.04 1.00, 1.08 Not mediated 
  Age at first live birth (30+ vs <30) 1.39 0.87, 2.14 0.99 0.81, 1.15 1.37 0.85, 2.10 Not mediated 
*Mediation analysis using the SAS macro by Valeri, L., & VanderWeele, T. J. (2013) and the 95% CIs were estimated using 1000 bootstrapping; 
†Multivariate analyses adjusted for study (EMF, OB, BCIA, WISH), age at mammogram (<35 y, 35-39 y, 40-44 y, 45-49 y), percent mammographic density (continuous, %), BMI (<20, 20 to <24, 24 to <28, 28 to 32 kg/m2), 
calcification (yes or no), family history of breast cancer in a first-degree relative (yes or no), parity (yes or no), breast biopsy/aspiration/lumpectomy (ever or never), smoking (ever or never), mammogram film type (X-ray or 
Xeroradiograph); 
‡Multivariate analyses restricted to parous women. In addition to risk factors listed in footnote †, replaced number of live births (1, 2, or 3+) for parity and further adjusted for age at first live birth (continuous, years);  
§Proportion mediated (PM) was calculated using the following formula if NIE is significant: PM = ORNDE (ORNIE - 1)/(ORNDE × ORNIE - 1); PM calculated to be < 0% and > 100% were denoted by “<” and “>” respectively; 
**Mediation analysis with exposure-mediator interaction for continuous BMI and BMI at age 18 was not reported due to high multicollinearity detected for the interaction term; 
Abbreviations: CI, confidence interval; OR, odds ratio; NDE, natural direct effect; NIE, natural indirect effect; PM, proportion mediated. 
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Supplementary Table 4.2. Direct and indirect effects of exposure on risk of breast cancer, mediated by percent mammographic 
density (MD), excluding postmenopausal women at mammogram date* 
  Natural Direct Effect (NDE) Natural Indirect Effect (NIE) Total Effect (TE) 
Proportion 
Mediated§ 
  OR 95%CI p-val OR 95%CI p-val OR 95%CI p-val   
Without exposure × MD interaction            
 Full dataset†           
  BMI (continuous, kg/m2)** 1.04 1.00, 1.08 0.016 0.94 0.92, 0.96 0.000 0.98 0.95, 1.01 0.279 > 
  Overweight/obese (BMI 25+) 1.62 1.15, 2.30 0.006 0.58 0.48, 0.71 0.000 0.95 0.67, 1.33 0.762 > 
  BMI at age 18 (continuous, kg/m2)** 1.04 0.98, 1.10 0.192 0.93 0.90, 0.95 0.000 0.96 0.91, 1.02 0.192 > 
  Overweight/obese at age 18 (BMI 25+) 1.21 0.66, 2.24 0.536 0.56 0.43, 0.74 0.000 0.68 0.36, 1.29 0.240 > 
  Breast biopsy/aspiration/lumpectomy 1.21 0.85, 1.74 0.294 1.22 1.04, 1.43 0.016 1.48 1.00, 2.18 0.050 55.3% 
  Calcification (yes vs no) 1.85 1.36, 2.51 0.000 1.22 1.07, 1.38 0.003 2.24 1.61, 3.11 0.000 31.9% 
  Calcification class (continuous score) 1.24 1.13, 1.36 0.000 1.05 1.01, 1.10 0.015 1.30 1.18, 1.44 0.000 21.2% 
  First degree family history of BC 2.24 1.50, 3.36 0.000 0.88 0.73, 1.05 0.151 1.97 1.27, 3.05 0.003 Not mediated 
  Parous vs nulliparous 0.79 0.54, 1.16 0.225 0.78 0.66, 0.93 0.005 0.62 0.41, 0.93 0.022 45.1% 
  Smoking ever 1.30 0.97, 1.75 0.082 1.00 0.89, 1.13 0.992 1.30 0.94, 1.79 0.107 Not mediated 
 Parous women only‡           
  Number of live births (continuous) 1.05 0.86, 1.29 0.626 0.89 0.81, 0.97 0.010 0.94 0.75, 1.16 0.552 > 
  Age at first live birth (continuous) 1.03 1.00, 1.07 0.083 1.00 0.98, 1.01 0.841 1.03 0.99, 1.07 0.132 Not mediated 
With exposure × MD interaction            
 Full dataset†           
  Overweight/obese (BMI 25+) 1.64 1.05, 2.57 0.031 0.58 0.45, 0.75 0.000 0.95 0.66, 1.37 0.790 > 
  Overweight/obese at age 18 (BMI 25+) 1.82 0.66, 5.03 0.251 0.41 0.21, 0.79 0.008 0.74 0.35, 1.58 0.437 > 
  Breast biopsy/aspiration/lumpectomy 1.21 0.84, 1.74 0.297 1.178 1.00, 1.39 0.053 1.43 0.97, 2.11 0.073 50.5% 
  Calcification (yes vs no) 1.78 1.29, 2.45 0.000 1.176 1.04, 1.32 0.008 2.09 1.48, 2.95 0.000 28.6% 
  Calcification class (continuous score) 1.23 1.11, 1.35 0.000 1.055 1.01, 1.10 0.015 1.30 1.17, 1.44 0.000 23.1% 
  First degree family history of BC 2.78 1.63, 4.73 0.000 0.821 0.62, 1.08 0.165 2.28 1.32, 3.93 0.003 Not mediated 
  Parous vs nulliparous 0.864 0.58, 1.29 0.477 0.770 0.64, 0.93 0.005 0.665 0.44, 1.00 0.049 59.3% 
  Smoking ever 1.280 0.94, 1.74 0.117 0.999 0.89, 1.12 0.992 1.279 0.92, 1.78 0.145 Not mediated 
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(cont.) 
Supplementary Table 4.2. Direct and indirect effects of exposure on risk of breast cancer, mediated by percent mammographic 
density (MD), excluding postmenopausal women at mammogram date* 
  Natural Direct Effect (NDE) Natural Indirect Effect (NIE) Total Effect (TE) 
Proportion 
Mediated§ 
  OR 95%CI p-val OR 95%CI p-val OR 95%CI p-val   
 Parous women only‡           
  Number of live births (continuous) 1.17 0.93, 1.47 0.176 0.92 0.85, 1.00 0.039 1.08 0.86, 1.36 0.515 < 
  Age at first live birth (continuous) 1.03 0.99, 1.07 0.167 1.00 0.98, 1.02 0.842 1.03 0.98, 1.08 0.264 Not mediated 
*Mediation analysis using the method and SAS macro by Valeri, L., & VanderWeele, T. J. (2013) and the 95% CIs were estimated using the delta method; 
†Multivariate analyses adjusted for study (EMF, OB, BCIA, WISH), age at mammogram (<35 y, 35-39 y, 40-44 y, 45-49 y), percent mammographic density (continuous, %), BMI (<20, 20 to <24, 24 to <28, 28 to 32 kg/m2), 
calcification (yes or no), family history of breast cancer in a first-degree relative (yes or no), parity (yes or no), breast biopsy/aspiration/lumpectomy (ever or never), smoking (ever or never), mammogram film type (X-ray or 
Xeroradiograph); 
‡Multivariate analyses restricted to parous women. In addition to risk factors listed in footnote †, replaced number of live births (1, 2, or 3+) for parity and further adjusted for age at first live birth (continuous, years); 
§Proportion mediated (PM) was calculated using the following formula if NIE is significant: PM = ORNDE (ORNIE - 1)/(ORNDE × ORNIE - 1); PM calculated to be < 0% and > 100% were denoted by “<” and “>” respectively; 
**Mediation analysis with exposure-mediator interaction for continuous BMI and BMI at age 18 was not reported due to high multicollinearity detected for the interaction term; 
Abbreviations: CI, confidence interval; OR, odds ratio; NDE, natural direct effect; NIE, natural indirect effect; PM, proportion mediated. 
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Supplementary Table 4.3. Total, direct and indirect effects of percent mammographic density (PMD) on the risk of breast cancer, 
mediated by breast biopsy or calcification, among all women* 
 Natural Direct Effect (NDE) Natural Indirect Effect (NIE) Total Effect (TE) 
Proportion 
Mediated§ 
 OR 95%CI p-val OR 95%CI p-val OR 95%CI p-val  
Without exposure × MD interaction           
 Full dataset†           
  Breast biopsy/aspiration/lumpectomy 1.03 1.02, 1.03 0.000 1.00 1.00, 1.00 0.727 1.03 1.02, 1.03 0.000 Not mediated 
  Calcification (yes vs no) 1.03 1.02, 1.03 0.000 1.00 1.00, 1.00 0.021 1.03 1.02, 1.04 0.000 5.6% 
With exposure × MD interaction 
          
 Full dataset† 
          
  Breast biopsy/aspiration/lumpectomy 1.03 1.02,1.04 0.000 1.00 1.00,1.00 0.278 1.03 1.02, 1.04 0.000 Not mediated 
  
Calcification (yes vs no) 1.03 1.02, 1.03 0.000 1.00 1.00, 1.00 0.081 1.03 1.02, 1.04 0.000 Not mediated 
*Mediation analysis using the method and SAS macro by Valeri, L., & VanderWeele, T. J. (2013) and the 95% CIs were estimated using the delta method; 
†Multivariate analyses adjusted for study (EMF, OB, BCIA, WISH), age at mammogram (<35 y, 35-39 y, 40-44 y, 45-49 y), percent mammographic density (continuous, %), BMI (<20, 20 to <24, 24 to <28, 28 to 32 kg/m2), 
calcification (yes or no), family history of breast cancer in a first-degree relative (yes or no), parity (yes or no), breast biopsy/aspiration/lumpectomy (ever or never), smoking (ever or never), mammogram film type (X-ray or 
Xeroradiograph); 
‡Multivariate analyses restricted to parous women. In addition to risk factors listed in footnote †, replaced number of live births (1, 2, or 3+) for parity and further adjusted for age at first live birth (continuous, years);  
§Proportion mediated (PM) was calculated using the following formula if NIE is significant: PM = ORNDE (ORNIE - 1)/(ORNDE × ORNIE - 1); 
**Mediation analysis with exposure-mediator interaction for continuous BMI and BMI at age 18 was not reported due to high multicollinearity detected for the interaction term; 
Abbreviations: CI, confidence interval; OR, odds ratio; NDE, natural direct effect; NIE, natural indirect effect; PM, proportion mediated. 
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CHAPTER 5: STUDY 2 
A Mediation Analysis of the Mayo Mammography Health Study Data 
 
 
Abstract 
 
Background: Percent mammographic density (PMD) is a strong risk factor for breast cancer. 
Less is known about the role of PMD as an intermediate marker for breast cancer risk.  
 
Methods: Data from a nested case-control study of breast cancer, including 677 cases and 1284 
matched controls, was analyzed using mediation analysis. We estimated the direct effects of 
various risk factors on risk of breast cancer and their indirect effects (i.e. effects mediated 
through PMD), as well as the proportion mediated by PMD. 
 
Results: The association between prior breast biopsy and risk of breast cancer was partially 
mediated by PMD (proportion mediated = 19.12%) in postmenopausal women, with an indirect-
effect odds ratio of 1.09 (95% CI: 1.02-1.17; P = 0.016). PMD mediated 32.13% and 14.97% of 
the increased risks associated with combined current use of estrogen and progesterone and the 
number of alcoholic drinks per month, which yielded an indirect-effect odds ratio of 1.17 (95% 
CI: 1.02-1.33; P = 0.021) and (ORNIE, 1.00; 95% CI, 1.00-1.01; P = 0.096), respectively. No 
significant mediation by PMD was observed with respect to a first-degree family history of 
breast cancer and age at menopause. There was inconsistent mediation for the effect of adult 
body mass index. 
 
Conclusions: PMD partially mediated the associations between prior breast biopsy and hormone 
replacement therapy of combined estrogen and progestin with the risk of breast cancer among 
postmenopausal women, suggesting that these risk factors at least partially influence breast 
cancer risk through changes in breast tissue composition. 
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5.1 INTRODUCTION 
 
Several independent observations suggest that mammographic breast density may be a 
potential mediator for breast cancer risk. First, high breast density on a mammogram has been 
repeatedly shown to be one of the strongest independent risk factors for breast cancer [1-4]. 
Second, mammographic density has also been shown to be associated with a wide array of risk 
factors for breast cancer such as age, menopausal status, family history of breast cancer, parity, 
age at first live birth, body mass index, physical activity, alcohol consumption, and hormone 
replacement therapy [1]. Furthermore, breast density can even be changed by several exposures or 
interventions that are also known to influence breast cancer risk [5]. For example, tamoxifen, an 
anti-estrogen, has been reported to reduce mammographic density as well as the risk of breast 
cancer [6-9]. In this context, it was proposed that some established breast cancer risk factors may 
be mediated by their intermediate effects on the mammary tissue, which is evaluated by 
mammographic densities. 
 
To test this hypothesis, several studies have attempted to assess the potential role of 
mammographic density as a mediator for breast cancer risk [10-16]. Results showed that 
mammographic density partially mediated the associations for some breast cancer risk factors such 
as childhood somatotype, being parous, history of benign breast disease, and hormone replacement 
therapy (HRT) use, but not risk factors such as a family history of breast cancer. While these 
studies have examined whether mammographic density mediates the associations with breast 
cancer risk for some risk factors, the extent of mediation was not estimated using statistical 
mediation analyses based on a counterfactual framework. Most of the studies regarding the role of 
mammographic density as a mediator were based on analysis using the traditional “difference 
method” [10, 13-15]. To our knowledge, only two studies [13, 15] used causal mediation analysis 
to evaluate the effect of a number of known risk factors for breast cancer through mammographic 
density and one of which was conducted as a secondary analysis [13].   
 
In the present study, we conducted a causal mediation analysis [17] using data from the 
Mayo Mammographic Health Study, aiming to evaluate and quantify the extent to which 
mammographic density mediated the association between various risk factors of interest, each 
factor at a time, with the risk of breast cancer risk.  
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5.2 METHODS 
 
Study Design and Participants 
We included data from a nested case-control study of breast cancer, the Mayo 
Mammography Health Study (MMHS). The data source, study design, and participant 
characteristics have been described in detail previously [18]. The MMHS prospectively enrolled 
patients scheduled for a screening mammogram from October 2003 through September 2006 at 
the Mayo Clinic in Rochester, MN. Women were invited to participate if they were at least 35 
years old, residents of Minnesota, Iowa, or Wisconsin (tri-state), and had no personal history of 
breast cancer. Women scheduled for a diagnostic mammogram (known or suspected breast cancer) 
were not eligible. Eligible women were mailed an invitation packet consisting of a study brochure, 
a consent form, a baseline questionnaire, and a permission form to link to state tumor registries. 
This study included 677 cases of women with an initial diagnosis of either in situ or invasive 
disease and 1284 matched controls. Controls were randomly sampled from the underlying cohort 
and were matched to cases on age, year of examination, and state of residence. This study was 
approved by the Institutional Review Boards at Mayo Clinic (Rochester, MN). 
 
Measurement of Mammographic Density 
For all cases and women in the sub-cohort, we obtained and digitized one view from the 
enrollment screen-film mammogram (2003-2006). Screen-film mammograms were digitized on 
the Array 2905 laser digitizer. Absolute dense area, absolute non-dense area (the total area minus 
the dense area), and percent mammographic density (PMD, the dense area divided by the total 
area, times 100%) were measured from digitized images of the craniocaudal mammogram view 
using the Cumulus software for computer-assisted thresholding (Canto Software, San Francisco, 
CA, USA). PMD was estimated from the contralateral breast for cases and the corresponding side 
for matched controls. All images had identifying information removed and re-oriented so that all 
images were presented consistently despite the side evaluated. Thus, the reader was blinded to 
cancer status.  
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In addition, the clinical BI-RADS four-category tissue composition assessment, 
corresponding to the enrollment mammogram, was obtained from the Mayo Clinic electronic 
medical record. Mayo Clinic attending radiologists classified each mammogram into one of four 
categories as defined in the BI-RADS lexicon during this period (American College of Radiology, 
3rd edition): a) the breast is almost entirely fat; b) there are scattered fibro glandular densities; c) 
the breast tissue is heterogeneously dense, which may lower the sensitivity of mammography; and 
d) the breast is extremely dense, which could obscure a lesion on mammography. All four 
mammogram views (craniocaudal and mediolateral oblique for ipsilateral and contralateral sides) 
contributed to the assessment of BI-RADS composition.   
 
Breast cancer risk factors and confounders 
All women were asked to complete a written questionnaire that covered mammogram 
screening behaviors; menstrual and reproductive factors; surgeries of the breast, ovaries, and/or 
uterus; use of hormone replacement therapies; medical history; family size and cancer history; use 
of non-steroidal anti-inflammatory medications; use of vitamins and complementary medicines; 
alcohol and cigarette use; physical activity; current weight and weight history; race; and education. 
Height and weight were also abstracted from the Mayo Clinic medical record at the medical visit 
closest in time to when each mammogram was collected for the study. Information on the selected 
risk factors and covariates were obtained from both medical record review and self-administered 
questionnaires at the time of mammography.  
 
Statistical Methods 
The mean and standard deviation (SD) were presented for continuous variables while 
numbers and percentages were presented for categorical variables. A causal mediation analysis 
was conducted following the approach outlined by VanderWeele and Vansteelandt [19], 
implemented by using a SAS macro that can accommodate the case-control design [20]. First, an 
unconditional logistic regression model for breast cancer was fitted on the potential risk factor and 
PMD, adjusting for matching variables and the baseline covariates. Second, a linear regression 
was fit for PMD on the potential risk factor and covariates using the controls. The regression for 
PMD and the regression for breast cancer risk were combined to obtain the ORs and 95% CIs for 
the following effects: (a) the natural direct effect (NDE) (i.e., the effect of the exposure on breast 
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cancer risk not through PMD if PMD was fixed at the level that it would have been without the 
exposure), (b) the natural indirect effect (NIE) (i.e., the effect of the exposure on breast cancer risk 
through PMD), and (c) the total association between the exposure and breast cancer risk. Despite 
a lack of statistical significance on all exposure–PMD interaction terms, we compared the results 
with and without an exposure × PMD interaction term. We used both the delta method and 
bootstrap sampling (1000 samples) to obtain 95% confidence intervals (CIs). The proportion 
mediated was estimated by the equation of ORNDE × (ORNIE -1)/(ORNDE × ORNIE -1), where ORNDE 
is the direct-effect odds ratio and ORNIE is the indirect-effect odds ratio [19]. For all analyses, PMD 
measures were square-root transformed to improve normality. The analyses were conducted on 
post- and pre-menopausal women separately. All the p-values used were two-sided. Type I errors 
were set at 0.05. All statistical analyses were performed using SAS version 9.3 (SAS Institute, 
Inc., Cary, North Carolina, USA). 
 
Sensitivity Analysis 
To assess the robustness of our results, we repeated the analyses by restricting the data 
based on menopausal status at the enrollment date. This increased the sample size of 
premenopausal women and gave the analysis a greater power. Analyses were also conducted based 
on both models with and without an exposure × PMD interaction.  
 
5.3 RESULTS 
 
The characteristics of the study population and the set of potential risk factors and selected 
confounders are shown in Table 5.1. We identified a total of 537 cases and 1021 controls who 
were postmenopausal at the time of screening mammograms. Only 20.6% of the subjects (140/263 
cases/controls) were premenopausal. The participants were largely white women (98%).  
 
Among postmenopausal women, several risk factors were found to be significantly 
associated with increased risk of breast cancer (Table 5.2). These include those women with a first-
degree family history of breast cancer (OR = 1.451; 95% CI: 1.132, 1.858), history of breast 
biopsy/lumpectomy (OR = 1.815; 95% CI: 1.410, 2.335), per year increase in age at menopause 
(OR = 1.126, 95% CI: 1.011, 1.256), combined estrogen and progesterone hormone replacement 
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therapy (HRT) use (OR = 1.932, 95% CI: 1.212, 3.070), an increasing number of alcoholic drinks 
(OR = 1.010; 95% CI: 1.000, 1.020), and higher BMI (OR = 1.032; 95% CI: 1.014, 1.051). Further 
adjustment for PMD attenuated the associations for a history of breast biopsy/lumpectomy, 
combined estrogen and progesterone HRT use, and the number of alcoholic drinks (Table 5.2). 
Among premenopausal women, no risk factor was significant. This is likely due to low power for 
the small sample size with only 140 cases and 263 controls. Therefore, a sensitivity analysis 
including subjects who were premenopausal at enrollment (191 cases and 356 controls) was 
conducted, which was able to detect a significant effect for having a first-degree family history of 
breast cancer (OR = 1.751; 95% CI: 1.097, 2.789) (Table 5.3). Further adjustment for PMD did 
not attenuate the association between first-degree family history and risk of breast cancer. 
 
The results of mediation analyses for postmenopausal women are summarized in Table 5.4 
and Supplementary Table 5.1. Women with a first-degree family history of breast cancer were 
found to have a significantly higher risk of breast cancer (ORtotal effect, 1.40; 95% CI, 1.082-1.810; 
P = 0.010). However, no significant mediation by PMD was observed for this variable (ORNIE 0.95, 
95% CI: 0.902-1.011; P = 0.170). Having a history of breast biopsy/lumpectomy was indirectly 
associated with increased risk of breast cancer through its effect on PMD (ORNIE, 1.09; 95% CI, 
1.025-1.166; P = 0.007), with a proportion of 18.7% mediated by PMD. It was also directly 
associated with breast cancer risk (ORNDE, 1.64; 95% CI, 1.269-2.120; P < 0.001) via a pathway 
independent of PMD. Women who reported usage of combined estrogen and progesterone HRT 
had a significantly increased risk of breast cancer (ORtotal effect, 1.95; 95% CI, 1.203-3.160; P = 
0.007). This association was decomposed into a significant indirect-effect odds ratio of 1.19 (95% 
CI, 1.048-1.340; P = 0.007) through PMD and a direct-effect odds ratio of 1.65 (95% CI, 1.026-
2.637; P = 0.039) independent of PMD. Overall, 32.5% of the increased risk of breast cancer 
related to using combined estrogen and progesterone HRT was attributable to higher PMD. PMD 
partially mediated the association with number of alcoholic drinks (ORNIE, 1.00; 95% CI, 1.00-
1.01; P = 0.096) but not age at menopause (ORNIE, 1.02; 95% CI, 0.92-1.14; P = 0.676).  
 
BMI at enrollment before a questionnaire was provided displayed a highly significant 
negative indirect association with breast cancer risk through PMD (ORNIE, 0.940; 95% CI, 0.92-
0.96; P=0.000), while it displayed a significant positive relationship with breast cancer risk 
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(ORNDE, 1.048; 95% CI, 1.02-1.08; P=0.003) independent of PMD. The opposing direct and 
indirect effects resulted in an overall non-significant total effect of BMI (ORtotal effect, 0.98; 95% 
CI, 0.96-1.01; P = 0.274). 
 
BMI at time of mammogram (enrollment) was associated with risk of breast cancer (ORtotal 
effect, 1.03; 95% CI, 1.009-1.046; P = 0.004). It had a significant negative indirect association with 
breast cancer risk through PMD (ORNIE, 0.931; 95% CI, 0.91-0.96; P = 0.000). However, the direct 
association acting independently of PMD was not significant, although positive (ORNDE, 1.04; 95% 
CI, 0.99-1.10; P = 0.121).  
 
The results of mediation analyses for premenopausal women are summarized in Table 5.5. 
Similarly, a first-degree family history of breast cancer was found to be a significant risk factor 
for breast cancer (ORtotal effect, 1.72; 95% CI, 1.065-2.784; P = 0.027). However, the association 
was not mediated through PMD (ORNIE, 0.98; 95% CI, 0.910-1.062; P = 0.664). 
 
Including versus excluding the exposure-mediator interaction terms did not change the 
estimates of the direct and indirect effects dramatically (Table 5.4-5.5). When the analyses for 
postmenopausal women excluding those who became postmenopausal between enrollment and the 
time of mammograms, results were similar to that seen for all women at the time of enrollment 
(Supplementary Table 5.1).  
 
5.4 DISCUSSION  
 
Our results showed that PMD partially mediated the association between prior history of a 
breast biopsy and current combined hormone replacement therapy (E+P) with the risk of breast 
cancer among postmenopausal women. However, it did not mediate the observed association 
between first-degree family history of breast cancer and the risk of breast cancer in both pre- and 
post-menopausal women.  
 
The present study estimated that about 19% of the increased risk associated with a history 
of breast biopsy is mediated through PMD among postmenopausal women. This observation of 
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significant mediation by PMD for the association between prior breast biopsy and breast cancer 
risk in postmenopausal is consistent with a previous study that included the MMHS as part of the 
data source [14]. In the study, a significant mediation by PMD of the association between prior 
breast biopsy and invasive breast cancer risk was found in both pre- and postmenopausal women, 
with mediation proportions of 17% and 24% respectively. In another study using data from the 
Nurses’ Health Study (NHS), PMD was also found to mediate the association between history of 
biopsy-confirmed benign breast disease and breast cancer risk, with 17% and 33% mediated in 
pre- and postmenopausal women respectively [13]. The observed partial mediation is also 
supported by an earlier study [21] that compared the relative risks of Gail model risk factors before 
and after adjusting for BI-RADS mammographic density categories, which showed that the 
association of having a previous biopsy with breast cancer was reduced by 13% and 19% for 
women under age 50 and those aged 50 or above respectively. Although significant mediation by 
PMD of the association between prior breast biopsy and breast cancer risk was consistently 
observed in these studies, this result should be cautiously interpreted. This is because it is difficult 
to determine the temporality between breast biopsy and PMD and a biopsy may be requested after 
detecting a high-density pattern in the mammogram. However, in our study, breast biopsy was 
assessed prior to PMD measurements. 
 
PMD was found to partially mediate the association between current use of combined 
estrogen and progestin HRT and the risk of breast cancer in postmenopausal women, with a 
mediated proportion of 32%. This result is in agreement with that of Rice et al., who analyzed data 
by pooling MMHS data with the other three case-control studies and found that 26% of the 
increased risk associated with current estrogen plus progestin HRT use was mediated by PMD. A 
study by Byrne et al. even found that the increase in breast cancer risk among postmenopausal 
women using estrogen plus progestin HRT regimen was completely mediated by the increase in 
PMD after a year of HRT treatment [16]. In our study, the total effects for the current use of any 
HRT and current estrogen-only HRT use were not significant. Thus, we did not present the 
mediated proportion. These results are supported by previous clinical trials that have demonstrated 
that postmenopausal treatment with formulations of estrogen plus progestin, is associated with an 
increase in mammographic density and risk of breast cancer [22], whereas estrogen therapy alone 
is not [23].  
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A family history of breast cancer in first-degree relatives is an established risk factor for 
breast cancer. In our study, the increased risk of breast cancer in relation to a first-degree family 
history of breast cancer was found to be independent of PMD. This result of no mediation is 
consistent with two recent studies which showed that the association with a family history of breast 
cancer was not mediated by PMD in both premenopausal and postmenopausal women [13, 14]. 
However, in another study, PMD was found to explain 14% (95% CI, 4-39%) of the association 
of family history (at least one affected first-degree relative) with breast cancer risk [10]. This 
evidence suggests that only a small portion of the association between family history of breast 
cancer and the risk of breast cancer may be mediated by PMD if any. 
 
We hypothesize that BMI at a younger age might act predominantly through its negative 
association through breast density, whereas BMI at an older age may also act positively through 
pathways independent of breast density. Thus, for young women, BMI is a protective factor acting 
mainly through reducing breast density. However, for older women (postmenopausal), other 
pathways may play a more important role, thus BMI is a risk factor for postmenopausal women. 
Although the BMI measures were not significantly associated with risk of breast cancer in our 
data, results from casual mediation analyses suggested the presence of inconsistent mediation or 
suppression, in which the direct and indirect effects had opposite directions while the total effect 
was not significant. 
 
Limitations of the study recognized by the authors include the small number of 
premenopausal women, the uncertain temporality for breast biopsy and mammograms, and the 
representativeness of the controls which are a random sample of the population in a nested case-
control design. In addition, the mediation results are based on PMD but not on other 
mammographic measures available in the study, including absolute dense area and absolute non-
dense area by the Cumulus software and the clinical BI-RADS four-category tissue composition 
assessment. We used PMD as the potential mediator because it was found to be a stronger breast 
cancer risk factor than the absolute dense area and non-dense area [3, 24]. Another reason is that 
previous studies found that Tamoxifen can reduce PMD and breast cancer risk, however, it is 
unknown whether a decrease in the dense area, an increase in the nondense area, or both were 
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responsible for the change in PMD (Norman F Boyd 2011). Therefore, it makes sense to examine 
if PMD serves as a mediator for breast cancer risk before conducting further mediation analysis 
on other potential mediators.  
 
 
5.5 CONCLUSIONS 
 
In summary, the present study demonstrated that prior breast biopsy and current combined 
hormone replacement therapy (E+P) may affect the risk of breast cancer partially through their 
effect on PMD among postmenopausal women. On the other hand, a first-degree family history of 
breast cancer and the number of alcoholic drinks per month affect breast cancer risk mainly 
through pathways independent of PMD. These findings may provide insights into the mechanisms 
involved in the development of breast cancer and highlight a potential biological pathway through 
breast density to the etiology of breast cancer.  
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TABLES 
 
Table 5.1. Selected risk factors at the time of mammography by case/control status and menopausal 
status 
 Postmenopausal Premenopausal 
 
Cases 
(N=537) 
Controls 
(N=1021) 
Cases 
(N=140) 
Controls 
(N=263) 
Mean (SD)         
    Age (years) 63.8 (9.1) 63.5 (9.5) 46.8 (5.6) 46.5 (5.1) 
    Percent mammography density (%) 16.2 (11.2) 13.8 (10.9) 25.6 (12.8) 22.4 (15.5) 
    Dense area (cm2) 23.7 (16.9) 19.5 (16.5) 31.5 (16.3) 27.2 (17.1) 
    Non-dense area (cm2) 141.7 (65.9) 141.5 (67.9) 106.3 (62.5) 119.5 (71.9) 
    Weight (LBS) 167.6 (36.1) 161.6 (36.4) 161.0 (36.8) 166.7 (43.3) 
    Height (Inches) 64.8 (2.4) 64.5 (2.4) 65.4 (2.8) 65.2 (2.6) 
    BMI (kg/m2) 29.2 (6.4) 28.1 (6.1) 27.0 (6.1) 28.0 (7.2) 
    Number of alcoholic drinks (# per month) 6.6 (12.3) 5.7 (10.3) 5.8 (9.1) 5.9 (9.2) 
    Godin Scale Score 22.0 (17.7) 22.7 (18.7) 28.7 (22.9) 27.7 (21.0) 
N (percent)     
Race or ethnicity         
    White 494 (99.2%) 948 (98.6%) 127 (98.4%) 245 (98.0%) 
    Other 4 (0.8%) 13 (1.4%) 2 (1.6%) 5 (2.0%) 
Education         
    Grade school or junior high 5 (1.0%) 10 (1.0%) 1 (0.8%) 2 (0.8%) 
    High school 132 (26.9%) 291 (30.5%) 11 (8.5%) 33 (13.2%) 
    College 253 (51.5%) 478 (50.1%) 96 (74.4%) 169 (67.6%) 
    Professional (after college) 101 (20.6%) 175 (18.3%) 21 (16.3%) 46 (18.4%) 
State         
    Minnesota 421 (78.4%) 799 (78.3%) 122 (87.1%) 236 (89.7%) 
    Wisconsin 34 (6.3%) 50 (4.9%) 4 (2.9%) 6 (2.3%) 
    Iowa 42 (7.8%) 107 (10.5%) 4 (2.9%) 8 (3.0%) 
    Unspecified 40 (7.4%) 65 (6.4%) 10 (7.1%) 13 (4.9%) 
BIRADS         
    1 96 (17.9%) 273 (26.7%) 13 (9.3%) 42 (16.0%) 
    2 243 (45.3%) 427 (41.8%) 34 (24.3%) 89 (33.8%) 
    3 171 (31.8%) 280 (27.4%) 67 (47.9%) 101 (38.4%) 
    4 27 (5.0%) 41 (4.0%) 26 (18.6%) 31 (11.8%) 
Previous breast biopsy         
    No breast surgery 372 (69.5%) 816 (80.1%) 122 (89.7%) 238 (91.5%) 
    Breast biopsy or lumpectomy 159 (29.7%) 191 (18.7%) 14 (10.3%) 19 (7.3%) 
    Other breast surgery including mastectomy 4 (0.7%) 12 (1.2%) 0 (0.0%) 3 (1.2%) 
Family history of breast cancer         
    No 383 (71.3%) 798 (78.2%) 111 (79.3%) 227 (86.3%) 
    Yes 154 (28.7%) 223 (21.8%) 29 (20.7%) 36 (13.7%) 
Age at menarche         
    9 or younger 7 (1.3%) 6 (0.6%) 2 (1.5%) 1 (0.4%) 
    10 22 (4.1%) 33 (3.2%) 4 (2.9%) 5 (1.9%) 
    11 66 (12.3%) 117 (11.5%) 11 (8.1%) 37 (14.2%) 
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Table 5.1. Selected risk factors at the time of mammography by case/control status and menopausal 
status 
 Postmenopausal Premenopausal 
 
Cases 
(N=537) 
Controls 
(N=1021) 
Cases 
(N=140) 
Controls 
(N=263) 
    12 139 (26.0%) 265 (26.0%) 29 (21.3%) 76 (29.2%) 
    13 156 (29.2%) 295 (28.9%) 52 (38.2%) 70 (26.9%) 
    14 64 (12.0%) 136 (13.3%) 16 (11.8%) 30 (11.5%) 
    15 or older 46 (8.6%) 103 (10.1%) 12 (8.8%) 28 (10.8%) 
    Unknown 35 (6.5%) 64 (6.3%) 10 (7.4%) 13 (5.0%) 
Nulliparous         
    No 466 (88.6%) 879 (87.8%) 120 (87.0%) 227 (87.0%) 
    Yes 60 (11.4%) 122 (12.2%) 18 (13.0%) 34 (13.0%) 
Parity (among parous)         
    1 45 (9.7%) 88 (10.0%) 14 (11.7%) 31 (13.7%) 
    2 159 (34.1%) 295 (33.6%) 56 (46.7%) 119 (52.4%) 
    3 131 (28.1%) 256 (29.1%) 35 (29.2%) 49 (21.6%) 
    4 67 (14.4%) 130 (14.8%) 13 (10.8%) 23 (10.1%) 
    5 64 (13.7%) 110 (12.5%) 2 (1.7%) 5 (2.2%) 
Age at first birth (among parous)         
    <30 392 (89.7%) 763 (91.6%) 82 (73.2%) 166 (77.2%) 
    30+ 45 (10.3%) 70 (8.4%) 30 (26.8%) 49 (22.8%) 
Number of children breastfed for at least a 
month (among parous) 
        
    Did not breastfeed any 221 (50.7%) 417 (50.0%) 33 (29.7%) 70 (32.7%) 
    1 to 2 children 137 (31.4%) 261 (31.3%) 46 (41.4%) 106 (49.5%) 
    3 to 5 children 71 (16.3%) 140 (16.8%) 31 (27.9%) 36 (16.8%) 
    6 to 11 children or more 7 (1.6%) 14 (1.7%) 0 (0.0%) 1 (0.5%) 
    Unknown 0 (0.0%) 2 (0.2%) 1 (0.9%) 1 (0.5%) 
Postmenopausal at enrollment         
    No 56 (10.4%) 96 (9.4%) 140 (100.0%) 263 (100.0%) 
    Yes 481 (89.6%) 925 (90.6%) 0 (0.0%) 0 (0.0%) 
Age at menopause         
    <30 3 (0.7%) 16 (2.0%) - - 
    30-39 33 (8.2%) 92 (11.7%) - - 
    40-44 49 (12.2%) 101 (12.8%) - - 
    45-49 106 (26.3%) 194 (24.7%) - - 
    50-54 163 (40.4%) 289 (36.7%) - - 
    55+ 49 (12.2%) 95 (12.1%) - - 
Birth control pill use         
    Never 189 (35.3%) 346 (34.0%) 18 (13.2%) 23 (8.8%) 
    Yes, Past 333 (62.2%) 651 (63.9%) 96 (70.6%) 190 (73.1%) 
    Yes, Current 12 (2.2%) 15 (1.5%) 21 (15.4%) 47 (18.1%) 
    Yes, Unknown 1 (0.2%) 7 (0.7%) 1 (0.7%) 0 (0.0%) 
Hormone replacement therapy use         
    Never 162 (30.3%) 310 (30.4%) 126 (92.6%) 231 (88.8%) 
    Past 238 (44.5%) 450 (44.2%) 5 (3.7%) 15 (5.8%) 
(cont.) 
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Table 5.1. Selected risk factors at the time of mammography by case/control status and menopausal 
status 
 Postmenopausal Premenopausal 
 
Cases 
(N=537) 
Controls 
(N=1021) 
Cases 
(N=140) 
Controls 
(N=263) 
    Current, E only 79 (14.8%) 168 (16.5%) 0 (0.0%) 2 (0.8%) 
    Current, P only 0 (0.0%) 1 (0.1%) 2 (1.5%) 1 (0.4%) 
    Current, E+P 40 (7.5%) 44 (4.3%) 1 (0.7%) 9 (3.5%) 
    Current, other 4 (0.7%) 21 (2.1%) 1 (0.7%) 0 (0.0%) 
    Current, unknown 12 (2.2%) 25 (2.5%) 1 (0.7%) 2 (0.8%) 
Regular alcohol use         
    No 167 (31.2%) 348 (34.2%) 30 (22.1%) 61 (23.5%) 
    Yes 368 (68.8%) 671 (65.8%) 106 (77.9%) 199 (76.5%) 
Smoking history         
    Never 327 (61.1%) 626 (61.4%) 84 (61.8%) 173 (66.5%) 
    Yes, Past 188 (35.1%) 334 (32.8%) 42 (30.9%) 68 (26.2%) 
    Yes, Current 20 (3.7%) 59 (5.8%) 10 (7.4%) 19 (7.3%) 
Frequency to work up a sweat         
    Often 73 (14.9%) 164 (17.2%) 28 (21.5%) 55 (22.3%) 
    Sometimes 271 (55.2%) 503 (52.9%) 64 (49.2%) 124 (50.2%) 
    Never/Rarely 147 (29.9%) 284 (29.9%) 38 (29.2%) 68 (27.5%) 
Godin Scale         
    Score <14 Sedentary 168 (33.9%) 334 (34.9%) 36 (27.7%) 69 (27.8%) 
    Score 14-23 Moderate 131 (26.5%) 221 (23.1%) 28 (21.5%) 51 (20.6%) 
    Score ≥24 Active 196 (39.6%) 402 (42.0%) 66 (50.8%) 128 (51.6%) 
BMI: body mass index, E: estrogen, E + P: estrogen plus progestin 
a Among parous 
 
 
  
(cont.) 
105 
 
Table 5.2. Odds ratios (ORs) for breast cancer risk unadjusted and adjusted for PMD in 
women who were postmenopausal at the time of mammogram 
Selected risk factor Cases / 
controls 
OR (95% CI) Unadjusted 
for PMD 
OR (95% CI) Adjusted 
for PMD 
BMI (kg/m2)  524/999 1.032 (1.014, 1.051) 1.063 (1.042, 1.085) 
Height (inch) (adjust for BMI) 524/999 1.039 (0.992, 1.088) 1.043 (0.995, 1.093) 
Height (inch) (adjust for weight) 525/997 1.019 (0.971, 1.069) 1.000 (0.953, 1.051) 
Weight (lbs) (adjust for height) 525/997 1.005 (1.002, 1.008) 1.010 (1.007, 1.014) 
BMI (kg/m2), current 535/1017 1.029 (1.010, 1.049) 1.062 (1.040, 1.085) 
BMI (kg/m2), 5 years ago 530/1008 1.012 (0.993, 1.031) 1.036 (1.015, 1.058) 
BMI (kg/m2), 10 years ago 525/1004 1.019 (0.998, 1.040) 1.046 (1.022, 1.070) 
Age at menarche ≤10 vs 11-14 years 524/999 1.353 (0.802, 2.256) 1.387 (0.817, 2.328) 
Age at menarche ≥15 vs 11-14 years 524/999 0.828 (0.562, 1.204) 0.824 (0.557, 1.202) 
Nulliparous versus parous a 524/999 0.925 (0.656, 1.293) 0.814 (0.573, 1.144) 
Parity per 1 child increase b 464/877 0.973 (0.897, 1.055) 0.993 (0.915, 1.077) 
Age at first birth ≥30 vs <30 years b 437/883 1.278 (0.846, 1.915) 1.189 (0.782, 1.791) 
Family history of breast cancer yes vs 
no 
524/999 1.451 (1.132, 1.858) 1.465 (1.138, 1.883) 
Previous breast biopsy yes vs no 524/999 1.815 (1.410, 2.335) 1.641 (1.269, 2.122) 
Age at menopause c 393/771 1.126 (1.011, 1.256) 1.127 (1.011, 1.259) 
HRT current vs never/former use 524/999 1.054 (0.817, 1.356) 0.931 (0.717, 1.204) 
    HRT current vs never use 524/999 1.064 (0.790, 1.433) 0.924 (0.681, 1.252) 
    HRT former vs never use 524/999 1.016 (0.785, 1.316) 0.987 (0.760, 1.284) 
HRT current E vs never/former use 524/999 0.934 (0.685, 1.264) 0.838 (0.611, 1.140) 
HRT E+P vs never/former use 524/999 1.932 (1.212, 3.070) 1.645 (1.023, 2.636) 
Number of alcoholic drinks per month, 
per drink increase 
524/999 1.010 (1.000, 1.020) 1.008 (0.998, 1.018) 
Adjusted for age (continuous), state (Minnesota, Wisconsin, Iowa, unspecified), current BMI (continuous), 
parity/age at first birth (nulliparous, parous age at first birth <30, parous age at first birth ≥30 years), previous biopsy 
(no, yes, other), and family history of breast cancer (no, yes), any HT use (current, past, never), and alcoholic drinks 
per month (continuous) 
PMD was square-root transformed 
Nulliparous versus parous a: not adjusted for parity/age at first birth 
Parity per 1 child increase b: Among parous 
Age at first birth ≥ 30 versus < 30 years b: Among parous 
Age at menopause c: categories <30, 30-39, 40-44, 45-49, 50-54, ≥55 years 
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Table 5.3. Odds ratios (ORs) for breast cancer risk unadjusted and adjusted for PMD in 
women who were premenopausal at the time of enrollment 
Selected risk factor Cases/controls OR (95% CI) 
Unadjusted for PMD 
OR (95% CI)  
Adjusted for PMD 
BMI (kg/m2)  191/356 0.985 (0.958, 1.011) 1.010 (0.978, 1.044) 
Height (inch) (adjust for BMI) 191/356 1.015 (0.946, 1.090) 1.013 (0.944, 1.089) 
Height (inch) (adjust for weight) 191/356 1.028 (0.956, 1.107) 1.005 (0.933, 1.084) 
Weight (lbs) (adjust for height) 191/356 0.998 (0.993, 1.002) 1.002 (0.997, 1.008) 
BMI (kg/m2), current 135/259 0.974 (0.941, 1.006) 1.002 (0.962, 1.043) 
BMI (kg/m2), 5 years ago 135/257 0.973 (0.938, 1.006) 1.000 (0.959, 1.042) 
BMI (kg/m2), 10 years ago 135/256 0.976 (0.936, 1.015) 1.011 (0.963, 1.059) 
Age at menarche ≤10 vs 11-14 years 191/356 2.571 (0.908, 7.569) 2.734 (0.950, 8.156) 
Age at menarche ≥15 vs 11-14 years 191/356 0.894 (0.471, 1.636) 0.838 (0.440, 1.543) 
Nulliparous vs parous a 191/356 1.157 (0.813, 1.665) 1.331 (0.928, 1.932) 
Parity per 1 child increase b 162/307 0.922 (0.762, 1.112) 0.939 (0.774, 1.134) 
Age at first birth ≥30 vs <30 years b 153/292 1.424 (0.859, 2.345) 1.418 (0.853, 2.341) 
Family history of breast cancer yes 
vs no 
191/356 1.751 (1.097, 2.789) 1.787 (1.115, 2.858) 
Previous breast biopsy yes vs no 191/356 1.607 (0.943, 2.727) 1.421 (0.823, 2.437) 
Number of alcohol drinks per month, 
per drink increase 
191/356 0.992 (0.972, 1.011) 0.990 (0.970, 1.009) 
Adjusted for age (continuous), current BMI (continuous), parity/age at first birth (nulliparous, parous age at first 
birth <30, parous age at first birth ≥30 years), previous biopsy (no, yes, other), and family history of breast cancer 
(no, yes), and alcoholic drinks per month (continuous) 
PMD was square-root transformed 
Nulliparous versus parous a: not adjusted for parity/age at first birth 
Parity per 1 child increase b: Among parous 
Age at first birth ≥30 versus <30 years b: Among parous 
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Table 5.4. Total, direct and indirect effects of exposure on risk of breast cancer, mediated by percent mammographic density 
(PMD), among postmenopausal women* 
 Natural Direct Effect (NDE) Natural Indirect Effect (NIE) Total Effect (TE) 
Proportion 
Mediated§ 
 OR 95%CI p-val OR 95%CI p-val OR 95%CI p-val  
Without exposure × PMD interaction           
 Full dataset†           
  BMI (continuous, kg/m2) 1.06 1.042, 1.093 <.001 0.97 0.956, 0.977 <.001 1.03 1.009, 1.046 0.004 < 
  BMI (continuous, kg/m2), current 1.06 1.038, 1.084 <.001 0.97 0.956, 0.977 <.001 1.02 1.005, 1.045 0.013 < 
  BMI (continuous, kg/m2), 5 years ago 1.04 1.014, 1.057 0.001 0.98 0.966, 0.986 <.001 1.01 0.991, 1.030 0.296 < 
  BMI (continuous, kg/m2), 10 years ago 1.05 1.022, 1.071 <.001 0.97 0.962, 0.983 <.001 1.02 0.996, 1.040 0.114 < 
  Age at menarche ≤10 vs 11-14 years 1.39 0.823, 2.337 0.219 1.01 0.895, 1.135 0.896 1.40 0.819, 2.388 0.220 ~ 
  Nulliparous vs parous* 0.81 0.577, 1.151 0.245 1.13 1.040, 1.218 0.003 0.92 0.646, 1.301 0.627 ~ 
  First degree family history of BC 1.47 1.140, 1.884 0.003 0.95 0.902, 1.011 0.170 1.40 1.082, 1.810 0.010 Not mediated 
  Breast biopsy/aspiration/lumpectomy 1.64 1.269, 2.120 <.001 1.09 1.025, 1.166 0.007 1.79 1.380, 2.330 < .001 18.7% 
  Age at menopause 1.13 1.012, 1.260 0.030 1.00 0.976, 1.021 0.877 1.13 1.008, 1.260 0.036 Not mediated 
  HRT current vs never/former use 0.93 0.718, 1.206 0.587 1.13 1.056, 1.201 <.001 1.05 0.807, 1.361 0.726 ~ 
  HRT current E vs never/former use 0.84 0.614, 1.144 0.265 1.11 1.032, 1.186 0.004 0.83 0.676, 1.270 0.637 ~ 
  HRT current E+P vs never/former use 1.65 1.026, 2.637 0.039 1.19 1.048, 1.340 0.007 1.95 1.203, 3.160 0.007 32.5% 
       Alcoholic drinks per month 1.01 0.999, 1.018 0.095 1.00 1.000, 1.004 0.096 1.01 1.000, 1.020 0.044 14.97% 
 Parous women only‡           
  Parity (continuous) 0.99 0.915, 1.077 0.864 0.99 0.970, 1.003 0.113 0.98 0.902, 1.064 0.623 ~ 
  Age at first live birth 30+ vs <30 years 1.18 0.782, 1.784 0.430 1.09 0.995, 1.199 0.064 1.29 0.846, 1.965 0.237 ~ 
With exposure × PMD interaction           
 Full dataset†           
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(cont.) 
Table 5.4. Total, direct and indirect effects of exposure on risk of breast cancer, mediated by percent mammographic density 
(PMD), among postmenopausal women* 
 Natural Direct Effect (NDE) Natural Indirect Effect (NIE) Total Effect (TE) 
Proportion 
Mediated§ 
 OR 95%CI p-val OR 95%CI p-val OR 95%CI p-val  
  Age at menarche ≤10 vs 11-14 years 1.34 0.776, 2.299 0.297 1.01 0.922, 1.098 0.897 1.34 0.773, 2.335 0.296 ~ 
  Nulliparous vs parous* 0.79 0.551, 1.143 0.214 1.18 1.032, 1.343 0.020 0.93 0.641, 1.361 0.724 ~ 
  First degree family history of BC 1.54 1.153, 2.068 0.004 0.94 0.863, 1.017 0.120 1.45 1.078, 1.943 0.014 Not mediated 
  Breast biopsy/aspiration/lumpectomy 1.64 1.269, 2.121 <.001 1.09 1.012, 1.178 0.023 1.79 1.375, 2.334 <.001 18.7% 
  Age at menopause 1.13 1.013, 1.263 0.029 1.00 0.981, 1.017 0.877 1.13 1.011, 1.262 0.031 Not mediated 
  HRT current vs never/former use 0.92 0.703, 1.197 0.526 1.15 1.049, 1.251 0.002 1.05 0.805, 1.374 0.714 ~ 
  HRT current E vs never/former use 0.83 0.604, 1.138 0.245 1.12 1.017, 1.243 0.022 0.93 0.676, 1.286 0.668 ~ 
  HRT current E+P vs never/former use 1.62 0.985, 2.667 0.057 1.20 0.968, 1.498 0.095 1.95 1.199, 3.177 0.007 34.3% 
       Alcoholic drinks per month 1.01 0.999, 1.019 0.086 1.00 1.000, 1.004 0.098 1.01 1.001, 1.021 0.040 14.99% 
 Parous women only‡           
  Number of live births (continuous) 1.01 0.920, 1.099 0.906 0.99 0.973, 1.004 0.138 0.99 0.907, 1.088 0.888 ~ 
  Age at first live birth 30+ vs <30 years 1.21 0.790, 1.840 0.385 1.05 0.957, 1.163 0.280 1.27 0.835, 1.937 0.262 ~ 
*Postmenopausal women at the time of mammogram. Mediation analysis using the SAS macro by Valeri, L., & VanderWeele, T. J. (2013) and the 95% CIs were estimated using the delta method; 
†Multivariate analyses adjusted for age (continuous), current BMI (continuous), parity/age at first birth (nulliparous, parous age at first birth <30, parous age at first birth >=30), previous biopsy (no, 
yes, unknown), family history of breast cancer (no, yes, unknown), any HT use (current vs past/never), and drinks per month (continuous); 
‡Multivariate analyses restricted to parous women. In addition to risk factors listed in footnote †, replaced number of live births (continuous) for parity/age at first birth and further adjusted for age at 
first live birth (continuous, years); 
Nulliparous versus parous *: not adjusted for parity/age at first birth; 
§Proportion mediated (PM) was calculated using the following formula if NIE is significant: PM = ORNDE (ORNIE - 1)/(ORNDE × ORNIE - 1); PM calculated to be < 0% and > 100% were denoted by “<” 
and “>” respectively; It was not calculated (notated using symbol ~) if the total effect is not significant; 
**Mediation analysis with exposure-mediator interaction for continuous BMI was not reported due to high multicollinearity detected for the interaction term; 
Abbreviations: CI, confidence interval; OR, odds ratio; NDE, natural direct effect; NIE, natural indirect effect; PM, proportion mediated. 
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Table 5.5. Total, direct and indirect effects of exposure on risk of breast cancer, mediated by percent mammographic density 
(PMD), among premenopausal women* 
 Natural Direct (NDE) Natural Indirect (NIE) Total 
Proportion 
Mediated§ 
 OR 95%CI p-val OR 95%CI p-val OR 95%CI p-val  
Without exposure × PMD interaction           
 Full dataset†           
  BMI (continuous, kg/m2)** 1.01 0.974, 1.041 0.689 0.98 0.956, 0.995 0.015 0.98 0.955, 1.009 0.192 ~ 
  Age at menarche ≤10 vs 11-14 years 2.69 0.932, 7.755 0.067 0.92 0.758, 1.129 0.443 2.49 0.848, 7.287 0.097 ~ 
  Nulliparous vs parous 1.05 0.615, 1.809 0.847 1.06 0.967, 1.157 0.224 1.11 0.647, 1.920 0.695 ~ 
  First degree family history of BC 1.75 1.090, 2.816 0.021 0.98 0.910, 1.062 0.664 1.72 1.065, 2.784 0.027 Not mediated 
  Breast biopsy/aspiration/lumpectomy 1.49 0.861, 2.568 0.154 1.07 0.966, 1.178 0.199 1.59 0.918, 2.742 0.098 ~ 
  Alcoholic drinks per month 0.99 0.968, 1.008 0.233 1.00 0.999, 1.005 0.202 0.99 0.970, 1.010 0.325 ~ 
 Parous women only‡           
  Parity (continuous) 0.94 0.778, 1.138 0.529 0.97 0.940, 1.007 0.119 0.92 0.756, 1.109 0.366 ~ 
  Age at first live birth 30+ vs <30 years 1.44 0.871, 2.380 0.155 1.00 0.929, 1.077 0.998 1.44 0.866, 2.393 0.160 ~ 
With exposure × PMD interaction           
 Full dataset†           
  Age at menarche ≤10 vs 11-14 years 5.78 0.599, 55.78 0.129 0.73 0.304, 1.738 0.474 4.20 0.509, 34.76 0.183 ~ 
  Nulliparous vs parous 1.04 0.603, 1.795 0.886 1.08 0.935, 1.245 0.298 1.12 0.645, 1.954 0.682 ~ 
  First degree family history of BC 1.72 1.072, 2.773 0.025 0.99 0.949, 1.037 0.718 1.71 1.061, 2.755 0.027 Not mediated 
  Breast biopsy/aspiration/lumpectomy 1.52 0.862, 2.677 0.148 1.13 0.928, 1.369 0.228 1.71 0.935, 3.136 0.082 ~ 
  Alcoholic drinks per month 0.99 0.969, 1.010 0.298 1.00 0.999, 1.006 0.197 0.99 0.971, 1.012 0.418 ~ 
 Parous women only‡           
  Number of live births (continuous) 0.98 0.795, 1.200 0.822 0.98 0.947, 1.024 0.427 0.96 0.776, 1.191 0.718 ~ 
110 
 
(cont.) 
Table 5.5. Total, direct and indirect effects of exposure on risk of breast cancer, mediated by percent mammographic density 
(PMD), among premenopausal women* 
 Natural Direct (NDE) Natural Indirect (NIE) Total 
Proportion 
Mediated§ 
 OR 95%CI p-val OR 95%CI p-val OR 95%CI p-val  
  Age at first live birth (continuous) 1.44 0.867, 2.380 0.160 1.00 0.924, 1.082 0.998 1.44 0.862, 2.395 0.165 ~ 
*Premenopausal women at enrollment. Mediation analysis using the SAS macro by Valeri, L., & VanderWeele, T. J. (2013) and the 95% CIs were estimated using the delta method; 
†Multivariate analyses adjusted for age (continuous), current BMI (continuous), parity/age at first birth (nulliparous, parous age at first birth <30, parous age at first birth >=30), previous biopsy (no, 
yes, unknown), family history of breast cancer (no, yes, unknown), and drinks per month (continuous); 
‡Multivariate analyses restricted to parous women. In addition to risk factors listed in footnote †, replaced number of live births (continuous) for parity/age at first birth and further adjusted for age at 
first live birth (continuous, years); 
Nulliparous versus parous *: not adjusted for parity/age at first birth; 
§Proportion mediated (PM) was calculated using the following formula if NIE is significant: PM = ORNDE (ORNIE - 1)/(ORNDE × ORNIE - 1); PM calculated to be < 0% and > 100% were denoted by “<” 
and “>” respectively; It was not calculated (notated using symbol ~) if the Total effect is not significant; 
**Mediation analysis with exposure-mediator interaction for continuous BMI was not reported due to high multicollinearity detected for the interaction term; 
Abbreviations: CI, confidence interval; OR, odds ratio; NDE, natural direct effect; NIE, natural indirect effect; PM, proportion mediated. 
 
 
 
111 
 
REFERENCES 
 
1. Boyd, N.F., et al., Mammographic breast density as an intermediate phenotype for breast cancer. 
The Lancet Oncology, 2005. 6(10): p. 798-808. 
2. Assi, V., et al., Clinical and epidemiological issues in mammographic density. Nature Reviews 
Clinical Oncology, 2011. 9(1): p. 33-40. 
3. Pettersson, A., et al., Mammographic density phenotypes and risk of breast cancer: A meta-
analysis. J Natl Cancer Inst, 2014. 106(5). 
4. McCormack, V.A. and I. dos Santos Silva, Breast density and parenchymal patterns as markers of 
breast cancer risk: A meta-analysis. Cancer Epidemiol Biomarkers Prev, 2006. 15(6): p. 1159-69. 
5. Boyd, N.F., Mammographic density and risk of breast cancer. American Society of Clinical 
Oncology Educational Book, 2013. p. 57-62. 
6. Chow, C.K., et al., Effect of tamoxifen on mammographic density. Cancer Epidemiology, 
Biomarkers & Prevention: A publication of the American Association for Cancer Research, 
cosponsored by the American Society of Preventive Oncology, 2000. 9(9): p. 917-921. 
7. Brisson, J., et al., Tamoxifen and mammographic breast densities. Cancer Epidemiology, 
Biomarkers & Prevention: A publication of the American Association for Cancer Research, 
cosponsored by the American Society of Preventive Oncology, 2000. 9(9): p. 911-915. 
8. Cuzick, J., et al., Tamoxifen and breast density in women at increased risk of breast cancer. Journal 
of the National Cancer Institute, 2004. 96(8): p. 621-628. 
9. Cuzick, J., et al., Tamoxifen-induced reduction in mammographic density and breast cancer risk 
reduction: A nested case-control study. J Natl Cancer Inst, 2011. 103(9): p. 744-52. 
10. Martin, L.J., et al., Family history, mammographic density, and risk of breast cancer. Cancer 
Epidemiology, Biomarkers & Prevention: A publication of the American Association for Cancer 
Research, cosponsored by the American Society of Preventive Oncology, 2010. 19(2): p. 456-463. 
11. Fejerman, L., et al., Genome-wide association study of breast cancer in Latinas identifies novel 
protective variants on 6q25. Nature Communications, 2014. 5: p. 5260. 
12. Woolcott, C.G., et al., Mammographic density, parity and age at first birth, and risk of breast 
cancer: An analysis of four case-control studies. Breast Cancer Res Treat, 2012. 132(3): p. 1163-
71. 
13. Rice, M.S., et al., Mammographic density and breast cancer risk: A mediation analysis. Breast 
Cancer Res, 2016. 18(1): p. 94. 
14. Rice, M.S., et al., Does mammographic density mediate risk factor associations with breast cancer? 
An analysis by tumor characteristics. Breast Cancer Res Treat, 2018. 170(1): p. 129-141. 
15. Azam, S., et al., Hormone replacement therapy, mammographic density, and breast cancer risk: A 
cohort study. Cancer Causes Control, 2018. 29(6): p. 495-505. 
16. Byrne, C., et al., Mammographic Density Change With Estrogen and Progestin Therapy and Breast 
Cancer Risk. J Natl Cancer Inst, 2017. 109(9). 
17. VanderWeele, T.J., H.O. Adami, and R.M. Tamimi, Mammographic density as a mediator for breast 
cancer risk: Analytic approaches. Breast Cancer Research: BCR, 2012. 14(4): p. 317. 
18. Olson, J.E., et al., The influence of mammogram acquisition on the mammographic density and 
breast cancer association in the Mayo Mammography Health Study cohort. Breast Cancer Res, 
2012. 14(6): p. R147. 
19. Vanderweele, T.J. and S. Vansteelandt, Odds ratios for mediation analysis for a dichotomous 
outcome. American Journal of Epidemiology, 2010. 172(12): p. 1339-1348. 
20. Valeri, L. and T.J. Vanderweele, Mediation analysis allowing for exposure-mediator interactions 
and causal interpretation: Theoretical assumptions and implementation with SAS and SPSS macros. 
Psychological Methods, 2013. 18(2): p. 137-150. 
112 
 
21. Tice, J.A., et al., Mammographic breast density and the Gail model for breast cancer risk prediction 
in a screening population. Breast Cancer Res Treat, 2005. 94(2): p. 115-22. 
22. Martin, L.J., S. Minkin, and N.F. Boyd, Hormone therapy, mammographic density, and breast 
cancer risk. Maturitas, 2009. 64(1): p. 20-26. 
23. Boyd, N.F., et al., Mammographic density as a surrogate marker for the effects of hormone therapy 
on risk of breast cancer. Cancer Epidemiol Biomarkers Prev, 2006. 15(5): p. 961-6. 
24. Boyd, N.F., et al., Mammographic features associated with interval breast cancers in screening 
programs. Breast Cancer Research, 2014. 16(4): p. 417. 
 
  
113 
 
CHAPTER 6: SUMMARY AND CONCLUSIONS 
 
6.1 SUMMARY 
6.1.1 Comparison of Study Findings 
 
This section aims to compare the results from the Seattle study and the Mayo study. While 
the subjects in the Seattle study were mainly premenopausal women, those in the Mayo studies 
were mostly postmenopausal. Although the characteristics of the subjects differ, both studies found 
similar conclusions regarding mediation for some of the breast cancer risk factors. This 
comparison is summarized in Table 6.1.  
 
The first breast cancer risk factor with consistent findings regarding mediation is a first-
degree family history of breast cancer. Both studies consistently found that the increased risk of 
breast cancer due to a history of breast cancer in the first-degree family member was not mediated 
by mammographic density, regardless of pre- or postmenopausal status. This indicates that a first-
degree family history of breast cancer may increase breast cancer risk through pathways 
independent of mammographic density. Therefore, for women who have an increased risk of breast 
cancer because of a first-degree family history of breast cancer, having a lower breast density 
would not decrease their breast cancer risk.  
 
The second breast cancer risk factor with a consistent finding regarding mediation is a 
history of breast biopsy. Both studies showed that a portion (18.7-83.1%) of the excess risk in 
relation to a history of breast biopsy was mediated by percent mammographic density. In the 
Seattle study, partial mediation was found for the increased risk associated with prior identification 
of breast calcifications. This suggests that breast lesions such as a history of breast biopsy and 
calcifications on mammograms may increase breast cancer risk through increasing breast density. 
However, the results must be interpreted with caution given that it is unknown whether breast 
lesions occur after an increase in breast density. We cannot rule out the possibility that it may 
occur before or just at the same time as the breast density changes.   
 
The third breast cancer risk factor with a consistent finding regarding mediation is BMI. 
Both studies observed inconsistent mediation or suppression for adult BMI. Suppression occurs 
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when there are multiple pathways with opposing directions between a risk factor and an outcome. 
On the one hand, increasing BMI has been found to be negatively associated with percent 
mammographic density [1-3], which in turn would reduce breast cancer risk. On the other hand, 
increasing BMI appeared to increase breast cancer risk through pathways independent of percent 
mammographic density. The overall total effect depends on these two opposing effects, which may 
seem to disappear when these two effects cancel out each other. This may be the reason why the 
total effects for BMI among pre-menopausal women were found to be not significant. However, 
the total effect for current BMI among postmenopausal women was found to be positive and 
significant. We observed that the direct effect among postmenopausal women independent of 
mammographic density appeared to be stronger than the direct effect via mammographic density. 
This observation supports the hypothesis that the increased risk of breast cancer associated with 
greater BMI in postmenopausal women is largely mediated through pathways independent of 
mammographic density such as those involving estrogen levels. This can also explain why BMI 
appeared to affect the risk of breast cancer for pre- and postmenopausal women differentially. 
  
Among the reproductive risk factors, nulliparity is the one most likely to be mediated by 
mammographic density. Although the total effect was not significant in the Mayo study, the NIE 
was found to be significant in both studies, indicating a potential mediation. As for postmenopausal 
hormone replacement therapy, current use of combined estrogen and progestin was found to be 
32.5% mediated by percent mammographic density in the Mayo data.  However, this factor was 
not considered in the Seattle data set because women in the Seattle study had their mammograms 
before age 50 years old and less than 10% of them used hormone replacement therapy, a majority 
of whom took the hormone replacement therapy after their mammographic density measures.  
 
6.1.2 Comparison of Study Findings to the Literature 
 
This section aims to compare the results based on the Seattle and Mayo datasets to the 
findings from the literature. Despite heterogeneous participant characteristics among studies, some 
of the findings regarding mediation were found to be consistent with other studies. The comparison 
is summarized in Table 6.2. 
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The findings from the Seattle and Mayo studies are in general consistent with the literature 
for some of the risk factors (Table 6.2). Percent mammographic density was found to partially 
mediate the associations between a history of a breast biopsy and current use of combined estrogen 
and progesterone hormone replacement therapy with risk of breast cancer, suggesting that these 
risk factors at least partially influence breast cancer risk through changes in breast tissue density. 
On the other hand, all studies consistently showed that percent mammographic density did not 
mediate the associations between family history of breast cancer and breast cancer risk in both pre- 
and postmenopausal women. Furthermore, inconsistent mediation or suppression was observed for 
adult BMI across all studies. For other risk factors, further studies are needed to determine the 
mediation effect of mammographic density given inconsistent results.   
 
6.2 CONCLUSIONS 
 
In conclusion, percent mammographic density partially mediated the associations between 
prior breast biopsy and breast cancer risk in both pre- and postmenopausal women as well as 
mediated the association with combined hormone replacement therapy use of estrogen and 
progesterone among postmenopausal women. However, the mediation results for prior breast 
biopsy must be interpreted with caution given that a causal relationship has not been established 
between breast lesions (reflected by a breast biopsy) and an increase in breast density (detected in 
a mammogram). We found that only 10-33% of the association between current use of combined 
HRT and breast cancer risk was mediated by percent mammographic density. While there might 
be a potential mediation for the association between ever parous and current use of HRT overall 
with the risk of breast cancer, further studies are needed to confirm the mediation effect. A 
suppression effect or inconsistent mediation was observed for adult BMI. For the rest of the risk 
factors, there appeared to be not much mediation. Particularly, the increased risk in relation to a 
family history of breast cancer and older age at menopause was found to be not mediated by 
percent mammographic density. This work suggests that the utility of percent mammographic as 
an intermediate marker of breast cancer risk may be limited. Additional research is necessary to 
confirm these observations as well as to explore the extent to which mammographic density 
mediates the associations with other established breast cancer risk factors. 
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TABLES 
 
Table 6.1. Comparison of causal mediation analysis results between the Seattle Data and the Mayo Data 
Risk Factor Seattle Study 
(Case-control) 
Mayo Study 
(Nested case-control) 
Conclusions 
 
Mostly Premenopausal Mostly Postmenopausal 
 
 
TE NIE PM TE NIE PM 
 
1st Degree family history of BC sig* ns Not mediated sig* ns Not mediated Not mediated 
Previous breast biopsy/lumpectomy sig sig* 83.1% sig* sig* 18.7% Partially mediated 
Breast calcifications classification sig* sig* 20.5% ~ ~ ~ Partially mediated 
Parous vs nulliparous sig* sig* 48.6% ns sig* Not calculated Partially mediated 
Parity per 1 child increase (parous only) ns sig* Not calculated ns ns Not calculated Not determined 
Age at 1st live birth (parous only) sig* ns Not mediated ns sig Not calculated Not mediated  
(premenopausal women) 
Age at menopause ~ ~ ~ sig* ns Not mediated Not mediated 
HRT, current vs never/former ~ ~ ~ ns sig* Not calculated Not determined 
HRT (E), current vs never/former ~ ~ ~ ns sig* Not calculated Not determined 
HRT (E+P), current vs never/former ~ ~ ~ sig* sig* 32.5% Partially mediated 
Smoking ever vs never sig ns Not mediated ~ ~ ~ Not mediated 
Alcoholic drinks per month ~ ~ ~ sig* sig 14.97% Partially mediated 
BMI (kg/m2), adult ns sig* Inconsistent 
mediation 
(NIE-, NDE+) 
~ ~ ~ 
Inconsistent mediation 
BMI (kg/m2), age 18 years ns sig* Inconsistent 
mediation 
(NIE-, NDE+) 
~ ~ ~ 
BMI (kg/m2), current ~ ~ ~ sig* 
(+) 
sig* Inconsistent 
mediation (NIE-, 
NDE+) 
BMI (kg/m2), 5 years ago ~ ~ ~ ns sig* Inconsistent 
mediation 
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(cont.) 
Table 6.1. Comparison of causal mediation analysis results between the Seattle Data and the Mayo Data 
Risk Factor Seattle Study 
(Case-control) 
Mayo Study 
(Nested case-control) 
Conclusions 
 
Mostly Premenopausal Mostly Postmenopausal 
 
 
TE NIE PM TE NIE PM 
 
(NIE-, NDE+) 
BMI (kg/m2), 10 years ago ~ ~ ~ ns sig* Inconsistent 
mediation 
(NIE-, NDE+) 
Abbreviations: BC: breast cancer; E: estrogen; E+P: estrogen plus progesterone; BBD: Benign breast disease; TE: total effect; NIE: 
natural indirect effect; NDE: natural direct effect; PM: proportion mediated; sig: significant (p-value <0.1, p-value <.05 if followed by 
an asterisk (*)), ns: not significant 
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Table 6.2. Comparison of our causal mediation analysis results to other studies 
Risk Factor Seattle & Mayo 
study results 
Literature 
Review 
(Chapter 2) 
 
Rice M. et al. 2016, 2018 [4, 5] Summary 
Premenopausal Postmenopausal 
1st Degree family 
history of BC 
Not mediated Small PE 
(≤14%) 
Not mediated Not mediated Not mediated 
Prior breast 
biopsy/BBD 
Partially mediated 
(PM = 18.7-83.1%) 
PE = 12-73% PE = 17%  PE = 24%-33% 
 
Partially Mediated 
Ever parous Partially mediated  
(PM = 48.6%, 
premenopausal) 
PE = 14-52% TE (ns), PE = 40-
52% (ns) 
Either not mediated or 
PE = 43-52%  
Further studies are 
needed 
Parity per child 
increase (parous 
only) 
Not determined Inconclusive Not mediated Not mediated Further studies are 
needed 
Age at 1st live birth 
(parous only) 
Not mediated 
(premenopausal 
women) 
PE = 16-17% Not mediated  PE = 13-16% Not mediated for 
premenopausal 
women 
Age at menopause Not mediated  ~ ~ Not mediated Likely not mediated 
HRT, current vs 
never/former 
 
Not determined PE = 10-37% ~ 
 
PE = 22-37% 
 
Further studies are 
needed 
HRT (E), current 
vs never/former 
Not determined Inconclusive ~ PE = 69% Further studies are 
needed 
HRT (E+P), 
current vs 
never/former 
Partially mediated 
(PM = 32.5%) 
PE = 10-26% ~ PE = 26% Partially mediated  
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(cont.) Table 6.2. Comparison of our causal mediation analysis results to other studies 
Risk Factor Seattle & Mayo 
study results 
Literature 
Review 
(Chapter 2) 
 
Rice M. et al. 2016, 2018 [4, 5] Summary 
Premenopausal Postmenopausal 
Smoking ever vs 
never 
Not mediated ~ ~ ~ Further studies are 
needed 
Alcoholic drinks 
per month 
Partially mediated 
(PM = 14.97%) 
~ Not mediated PE = 16-73% (ns) Further studies are 
needed 
Adult BMI Inconsistent 
Mediation 
All |PE| > 
100% 
TE (ns), IE (-) DE 
(+) 
TE (+), IE (-) DE (+) Inconsistent 
Mediation 
Abbreviations: BC: breast cancer; E: estrogen; E+P: estrogen plus progesterone; BBD: Benign breast disease; TE: total effect; IE: 
indirect effect; DE: direct effect; PM: proportion mediated; PE: proportion explained; sig: significant; ns: not significant 
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